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Sphingolipids are not only ubiquitous structural components of the plasma membrane they 
are also involved in many important cellular process such as cell signalling, signal 
transduction and the immune response. Serine palmitoyltransferase (SPT) catalyses the first 
and rate limiting step of sphingolipid biosynthesis; a decarboxylative, Claisen condensation 
of the amino acid L-serine and the long chain fatty acid palmitoyl CoA to produce the first 
sphingolipid precursor 3-ketosph ingan me (KDS). SPT is a membrane-associated 
heterodimer in eukaryotes making its isolation and characterisation challenging. However, a 
cytoplasmic, homodimeric homologue has been identified from the Gram-negative 
bacterium Sphingomonas paucimobilis. This organism has a unique outer membrane 
structure that contains glycosphingolipid (GSL) instead of lipopolysaccharide (LPS, 
endotoxin) as found in most other Gram-negative bacteria. As yet, no bacterial sphingolipid 
pathway has been characterised in detail, so we propose S. pauciniohilis as a model organism 
for the characterisation of sph ingol ipid biosynthesis. 
SPT belongs to the a-oxoainine syiithase family, which are a small group of pyridoxal 5'-
phosphate (PLP)-dependent enzymes. This thesis describes spectroscopic studies of 
recombinant SPT and reports high-resolution crystal structures of the PLP-, L-serine-
(substrate) and L-cycloserine- (inhibitor) bound forms of S. paucimobilis SPT (1.3, 1.5 and 
1 .45 A respectively). These structures are the first of an SPT from any organism and provide 
an insight into the mechanisms of catalysis and inhibition that take place at the active site of 
this important enzyme. 
Another interesting sphingolipid biosynthetic enzyme is Inositol Phosphory!ceraniide 
Synthase (IPCS; also known as AURIp) which, is encoded by the aw-1 gene and catalyses 
the transfer of phospho-i nosito I onto phytoceramide to produce i nositol phosphory Iceram ide 
(IPC). Deletion or mutation of this gene in S. cenevisiae was found to be lethal. therefore 




an attractive target for the development of novel anti-fungal agents. However, it is an 
integral membrane protein of the Golgi apparatus, with 6 predicted transmernbrane domains 
which means that to date, no structural information is available. Expression of a 
recombinant, soluble, affinity-tagged AURIp now paves the way for full characterisation of 
this important enzyme. 
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1.1 	Sphingolipid Structure 
During his studies in the field of brain chemistry in the 1800's, the German scientist J.L.W. 
Thudichum examined the presence of a mixture of substances within the matter of the brain. 
He showed that this mixture consisted of lecithins, cephalins and myelins and also correctly 
classified the latter two as phosphatides. Moreover, lie identified sphingomyelin, the 
sulphatides and the cerebrosides (1, 2). He characterised the molecule sphingosine, 7 
suggesting that the structure contained an amino acid and that it had basic properties. 
Following Thudichum's death, Levine and co-workers confirmed the structure of 
sphingosine as an unsaturated monoaminodihydroxyalcohol (3). Subsequently, Carter ci at. 
elucidated the structure of sphingine to be l-hydroxy-2-aminooctadecane and the 0-methyl 
esters of sphingosine to be 1-hydroxy-2-amino-3-methoxyoctadec-4-ene (4, 5). This early 
pioneering work, together with the development of various methodologies for the isolation 
and characterization of sphingolipids, has provided the basic structure upon which all 
sphingolipids are based (Fig. 1) (6). The basic sphingolipid structure consists of a sphingoid 
base (1, 3-dihydroxy-2-aniino-alkane and its derivatives) attached to a long chain fatty acid 
through an N-acyl linkage. 
Sphingoid base (D-erythro-sphingosine) 	 OH 
CH2OH 
NH 
Fatty acid (N-acylsphinganine) 
Figure 1: Basic Sphingolipid Structure 
The basic sphingolipid structure is derived from a sphingoid base joined by a N-acyl linkage to a long 
chain fatty acid (7). The addition of a polar head group onto the 1-hydroxy position gives the molecule 
distinctive properties e.g. addition of phosphate produces sphingosine-1-phosphate, a potent anti-
apoptotic molecule (8, 9). 
The sphingoid base moiety differs between species, for example in mammals, it is commonly 
D-erythro-sphingosine (a C18 hydroxylated alkene), in S. cerevisiae 4-hydroxysphinganine 
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(phytosphingosine, a linear CI 8 or C20 alkane) is the main sphingoid base whereas in plants 
this portion varies due to the synthesis of a diverse composition of unsaturated D-eryihro-
spli ingosine derivatives (10, 11). 
The moiety (R) attached to the 1-hydroxy position of the sphingoid base varies (Fig. 1), 
resulting in a high level of heterogeneity amongst sphingolipid molecules. For example, in 
mammals a phosphate may be added by sphingosine kinase to form sphingosine-1-phosphate 
or phospho-choline by sphingomyelin synthase to form sphingomyelin (12). In contrast, 
inositol-phosphate is attached to phytoceramide to produce inositol phosphorylceramide 
(IPC) in fungi, thus creating a difference between the eukaryotic sphingolipid pathways (/0). 
1.2 	The Sphingolipid Pathway 
Sphingolipid biosynthesis begins with the decarboxylative condensation of the amino acid L-
serine and the long chain fatty acid palmitoyl CoA. This step, which has been found to be 
rate limiting, produces the first sphingolipid precursor 3-ketosphinganine (KDS) and is 
catalysed by serine palmitoyltransferase (SPT) (13). KIDS is subsequently reduced to form 
dihydrosphinganine, 7 and it is at this stage where the two eukaryotic pathways diverge 
(Fig. 2). In mammals, phospho-choline is attached to ceramide to form sphingomyelin 
whereas in fungi, inositol-phosphate is added to phytoceramide forming inositol 
phosphorylceramide. These molecules are modified further by the addition of one or more 
carbohydrate moieties to produce the glycosphingolipids which include the cerebrosides and 
gangi iosides. 
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Figure 2: The Sphingolipid Pathway 
Sphingolipid biosynthesis commences with the decarboxylative, Claisen condensation of L-serine and palmitoyl-00A to produce the first sphingolipid precursor 3-
ketosphinganine (KDS). KDS is subsequently reduced to form dihydrosphinganine (DHS) and it is, at this point, that the pathway diverges amongst eukaryotes. In 
mammals the addition of phospho-choline onto ceramide forms sphingomyelin (see fig. 3 for structure) whereas in fungi, phospho-inositol is added to 
phytoceramide forming inositol phosphorylceramide (see fig. X for structure). Ceramide may also be glycosylated to form the glycosphingolipids, which can be 
further modified by the addition of more carbohydrate molecules. To date, no bacterial sphingolipid pathway has been identified however the studies discussed in 
this thesis suggest the existence of such a pathway. All structures are sourced from http://www.lipidmaps.org. 
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1.3 	Sphingolipid Metabolism 
Sphingolipids and their metabolites play important roles not only in cell signalling and signal 
transduction, but also in the immune response and in pathological conditions such as 
neurodegeneration and cancer. Sphingomyelin, for example, is an important lipid located in 
the plasma membrane of mammalian cells. Not only does it provide structural support within 
the membrane but it also takes part in the ubiquitous signalling system referred to as the 
"sphingomyelin cycle" (14, 15). Together with cholesterol, alterations in sphingomyelin 
levels have been associated with Alzheimer's disease. This occurs when amyloid beta 
peptide 42 activates sphingomyelinase (SMase) leading to the reduction of sphingomyelin 
levels (16). Extracellular inducers, such as tumour necrosis factor alpha (TNFa), have been 
shown to activate SMase in HL-60 human promyelocytic leukaemia cells causing hydrolysis 
of membrane sphingomyelin to produce phosphocholine and cerarnide (17). 
Cerarnide is another important cellular lipid and might be thought of as the central molecule 
in sphingolipid metabolism as it is the first biosynthetic precursor of all glyco- and phospho-
sphingolipids such as galactosylceramide and sphingomyelin. It has been proposed that a 
delicate and finely balanced equilibrium exists between ceramide and its metabolites in the 
control of cellular functions such as signal transduction (Fig. 3) (18). 
The implication of ceramide in programmed cell death has been discussed extensively and its 
involvement in pathological processes such as neurodegeneration and cancer have been 
highlighted (18-20). For example, by studying the conversion of ceramide to ceramide-1-
phosphate using diacylglycerol kinase and radiolabelled ATP, Riboni et al. showed that 
decreased levels of ceramide in association with human astrocytoma tissue in comparison 
with levels found in the surrounding peritumoural tissue. This suggests a reduction of the 
cellular ceramide levels in the progression of human astrocytomas which may be 
advantageous to the cancer cell as it may prevent apoptosis thereby allowing rapid tumour 
growth (21). 
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In contrast, Huang ci al. observed increased expression of acid ceramidase in Alzheimer's 
diseased brain (22). They noted an association of acid ceramidase with the pathological 
neurofibrillary tangles, however the relative levels of the substrate ceramide and the 
hydrolysis product sphingosine were not determined. Acid ceramidase catalyses the 
catabolism of ceramide to produce sphingosine, high levels of which are cytotoxic, hence the 
enzyme is maintained at low levels within the cell. Sphingosine has a direct effect on cellular 
sphingolipid content as this molecule can be N-acylated to form ceraniide or phosphorylated 
to produce sphingosine-i-phosphate. In contrast to ceraniide, sphingosine-1-phosphate 
(S-1-P) is an anti-apoptotic signalling molecule. It has been identified as a component of the 
intracellular second messenger system involved in calcium mobilisation and the regulation of 
sphingosine induced cell growth (8, 9). Olivera ci al. found that sphingosine kinase 
expression altered the balance of sphingolipid metabolites causing elevated levels of S-I-P 
with a concomitant decrease in the levels of sphingosine and ceramide (23, 24). Their results 
showed that sphingosine kinase expression in HEK293 and Jurkat T cells, as well as 3T3 
fibroblasts, suppressed serum deprived apoptosis which is known to result in elevated 
ceramide levels. 
As with all signalling molecules, cellular levels of S-i-P are tightly regulated and its 
production and degradation can be rapidly induced. For example, the expression of 
sphingosine kinase, to produce S-I-P in response to signal transduction pathways, is 
activated by the potent mitogens platelet derived growth factor and foetal calf serum and by 
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Figure 3: Ceramide Metabolism 
Ceraniide and its metabolites (sphingomyelin and sphingosine- l -phosphate, S- l -P) are important signalling molecules and exist in a tightly controlled equilibrium. 
Disruption of this equilibrium has been implicated in numerous pathological diseases such as neurodegeneration and cancer (/8-20). 
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1.4 Glycosphingolipids 
Glycosphingolipids form an extremely diverse group of complex sphingolipids and are 
exploited by many bacteria, viruses, parasites and microbial toxins when binding to host 
organisms (26). This diversity arises from variations in sugar type, number, linkage and 
modifications. For example, the most simple glycosphingolipids are the cerebrosides which 
consist of a ceramide moiety with a single sugar residue (glucose or galactose) attached at 
the 1-hydroxyl position. Two examples are galactosylceramide, 1 which, in mammals, is 
typically found in neural tissue and glucosylceramide, 2 which is common in most other 
tissues (Fig. 4). Galactosylceramides are restricted to animals and fungi whereas 
glucosylceramides are commonly found in plants, animals and fungi (27). 
Both of these molecules are important for cellular function as it has been shown that 
alterations to their concentrations lead to pathogenic disorders. For example, the 
accumulation of glucosylceramide, due to an autosomally inherited deficiency of 
glucocerebrosidase, causes the rare lysosornal storage disorder known as Gaudier disease 
(28). Autosomally recessive inherited mutations of the galactocerebrosidase gene cause an 
accumulation of galactosylceramide resulting in segmental demyelination of peripheral 
nerves. (29). This is followed by the onset of Krabbe's disease which is characterised by 
diffuse leukodystrohphy; the severe degeneration of mental and motor skills (30). 
In addition to the cerebrosides, there are more the complex glycosphingolipids known as 
gangliosides which were originally isolated and identified from brain tissue by Ernst Kienk 
in the 1940's, however the heterogeneity amongst brain gangliosides was not demonstrated 
until a decade later by Svennerholm (31). Although they are most abundant in neural tissue, 
gangliosides are also found at low levels in all animal tissues where they are concentrated, 
together with other glycosphingolipids, into lipid rafts. Structurally, they consist of ceramide, 
an oligosaccharide moiety and one or more sialic acid constituents. The structure of the 
prototypic ganglioside, GM I (monosialotetrahexosylganglioside, 3) is shown in figure 4. 
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Figure 4: Structures of the Cerebrosides GalCer and GluCer and the 
Ganglioside GMI The sugar group is attached in the a-anomeric position in the cerebrosides 
GalCer, I and GluCer, 2 to produce biologically active molecules. The prototypic ganglioside GM1 
(monosialotetrahexosylgangi ioside, 3) is a more complex tetrasaccharide. 
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1.5 The Role of Sphingolipids in Lipid Rafts and The 
Immune Response 
In addition to their involvement in neurodegeneration and cancer, sphingolipids also play a 
role in infectious disease, as they can be exploited by various pathogens in order to gain 
access into the host cell. The plasma membrane is a crucial element during host-pathogen 
interactions and contains primarily sph ingol ipids, cholesterol and phosphol ipids which 
interact within the membrane to form different domains. Sphingolipids and cholesterol 
preferentially associate to form mobile membrane inicrodomains known as lipid rafts". 
These rafts have been referred to as "detergent resistant" in comparison to phospholipids 
which are "detergent soluble" and their presence creates different environments within the 
membrane (32-34). It has been suggested that these rafts allow the attachment of specific 
proteins within the lipid bilayer and that the lipid niicrodomains are organized such that 
proteins can be selectively included or excluded. This allows the transport of selected 
membrane components and can potentially act as a platform for intracellular signalling (35). 
It has been proposed that viral entry through mucosal epithelial cells requires the presence of 
lipid rafts, in particular, the sphingolipid component of the raft. This has been studied for 
human immunodeficiency virus (HIV) where it has been shown that the treatment of virus-
producing cells or virus particles with raft-disrupting agents significantly impairs virus 
infectivity (36). In addition, it has been observed that C134-negative cell lines are still 
susceptible to infection with various HIV strains, therefore, although it is the major cellular 
receptor for HIV, CD4 appears not to be the only mode of infection. Studies by Harouse ci 
al. have shown that antibodies raised against galactosylceramide (GalCer) inhibited viral 
internalization and infection in two CD4-negative cell hues derived from the nervous system, 
U373-MG and SK-N-MC, suggesting that GaIC may play a role in HIV infection of neural 
cells (37). 
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In addition to viral recognition, their actions as agonists in the immune response have also 
been documented. Wu ci al. and Kinjo ci al. have described the ability of bacterial 
glycosphingolipids to activate human and murine Natural Killer T (NKT) cells (38, 39). 
Alpha-galactosyl ceramide ((x-GalCer) is a well known NKT cell agonist which acts by 
binding to CD  receptors which are antigen-presenting proteins that bind and display various 
lipids to T-lyrnphocytes. Wu ci at. found that microbial derived ct-GalCer from 
Sphingonionas wiiiichii activated NKT cells causing cytokine IFN-y and IL-4 release. By 
CD1d dimer/glycolipid staining of the NKT cell line they also showed NKT cell reactivity 
toward bacterial glycosphingol ipids (39). 
Krziwon ci al. compared the activation of monokine release by the common Gram-negative 
bacterial membrane constituent lipopolysaccharide (LPS) with glycosphingolipids from the 
Unusual LPS lacking Gram-negative bacterium Sphingoiiionas paucimobilis. Two forms of 
glycosphingolipid were isolated from S. paucimobilis by Kawahara ci al., the tetrasaccharide 
GSL-4A and the monosaccharide GSL-1 (40). Studies show that the tetrasaccharide GSL-4A 
activates monokine production whereas GSL-I does not. In comparison to LPS, a 10,000 
fold higher concentration of GSL-4A was required to induce the release of the cytokines 
TNF, IL-6 and IL-I (41). 
1.6 	Sphingomonas paucimobilis 
Sphingomonas pauciniobilis is an opportunistic pathogen that often causes nosocomial 
infections in immuno-comproinised individuals. It is often found in hospital environments 
and has been isolated from water systems and ventilation equipment (42, 43). This Gram-
negative bacterium was originally classed as a Flavobacieriurn in the 1970's. It later 
assumed the genus Pseudoinonas pauchnobilis, however the taxonomical genus was revised 
in 1990 to Sphingoinonas pauciinobi!is (type strain) in light of accumulating data suggesting 
features that distinguished this organism from other Pseudomonas species (44, 45). Early 
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work carried out on Flavobacterium devorans by Yamamoto ci al. showed that it produced a 
novel sphingoglycolipid containing glucuronic acid and a 2-hydroxy fatty acid (44, 45). 
Further work on the outer membrane of S. paucimobilis by Kawahara ci al. found that they 
could not isolate LPS using the common "hot-phenol" extraction method. Instead they 
isolated the lipids by chloroform/methanol extraction and found that they contained 2-
hydroxy myristic acid rather than the 3-hydroxylated fatty acids found in the Lipid A portion 
of LPS (46). This "Lipid A type" molecule was subsequently shown to be an equimolar 
mixture of two glycohipids. The structures of these were determined by Kawahara et al. and 







Figure 5: Structures of the Major Glycosphingolipids from S. paucimobilis 
Two distinct glycolipids have been identified from the outer membrane of S. paucimobilis. The 
monosaccharide GSL-I, 4 (glucuronic acid + fatty acid) and the tetrasaccharide GSL-4A, 5 (mannose 
(Man), galactose (Gal), glucosamine (GIcN), glucuronic acid (GIcA) + fatty acid) (40). 
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These glycosphingolipids were later designated as GSL-1, 4 and GSL-4A, 5 and were found 
to be localised in the outer leaflet of the outer membrane of S. paucimobilis as shown by 
biochemical and immuno-electron microscopic analyses (47). These analyses also showed 
that the outer membrane of this organism was less dense than that of E. coli. This is likely 
since the LPS constituent of E. coil outer membranes contains more fatty acid components 
compared with GSL, which contain only dihydrosphingosine and 2-hydroxy myristic acid. 
Models of the outer membranes of E. coil and S. paucimobilis (Fig. 6) highlight this distinct 
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Figure 6: Models of the Outer Membranes of E. coil and S. paucimobllls 
(a) Illustration of the outer membrane structure of E. coil highlighting the complexity of the LPS 
molecules (48). (b) Illustration of a proposed outer membrane structure of S. paucimobilis 
highlighting the less complex glycosphingolipids. Over all, the membrane of S. paucimobilis is less 
dense due to its less complex glycolipid composition compared with that of E. coil (47). 
The first step of (glyco-)sphingolipid biosynthesis in any organism commences with the 
condensation of the amino acid L-serine and the long chain fatty acid palmitoyl-CoA to 
produce the first sphingolipid precursor 3-ketosphinganine (KDS). This reaction is catalysed 
by the enzyme serine palmitoyltransferase (SPT). It is logical therefore to propose that S. 
paucimobilis contains SPT and indeed, a water soluble, homodimeric SPT has been 
characterised from this organism (49). Unsuccessful attempts at the crystallisation of S. 
paucimobilis SPT led Ikushiro et al. to look for alternative candidates in other sphingolipid-
containing bacteria (50). As a result, they have identified three novel SPT genes from 
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Sphingobacteriun and Bdellvibrio spp are unusual bacteria. Like Sphingoinonas, they lack 
Iipopolysaccharide and instead produce glycosphingolipids. Ikushiro et al. have successfully 
over-produced SPTs from both organisms, in E. co/i, and have shown that unlike SPT from 
S. paucimobi/is, they are peripheral membrane proteins (50). 
1.7 	Serine Palm itoyltra nsfe rase (SPT) 
To date, the genes encoding serine palmitoyltransferase (SPT) have been identified from an 
extremely wide variety of organisms. In addition to mammalian, murine and fungal sources, 
SPT has also been identified from bacteria, plants and a marine virus thus highlighting the 
ubiquitous nature of this enzyme and suggesting the importance of sphingolipid biosynthesis 
in a plethora of organisms (49, 51-55). 
1.7.1 Isolation and Characterisation of LCBI and LC132 
1.7.1.1 Human, Fungal and Murine Sources 
In work by Wells and Lester a mutant form of Saccharomyces cerevisiae was reported to be 
unable to synthesise phospho-inositol containing lipids in the absence of long chain bases. 
This mutant strain was viable and similar to wild type cells in the production of 
phospholipids when cultured in the presence of D-L-erythrodihydrosphingosine however, in 
the absence of exogenous long chain bases, cell growth was affected (56). This suggested an 
important role for one or more yeast sphingolipid(s) in cell viability. 
Eukaryotic SPT consists of two hetorologous sub-units encoded by the genes lcbl and /cb2. 
Early studies in this field identified mutant S. cerevisiae cells that exhibited decreased or 
even negligible SPT activity when either /cbl or /cb2 was absent, suggesting that both gene 
products are essential for SPT function. (52, 53, 57). In addition to yeast /cbl and /cb2, the 
complete cDNA sequences of genes encoding mammalian and murine SPT have now been 
identified and cloned (51). 
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The extensive work by Flanada et al., with mutagenised chinese hamster ovary (CHO) cells 
lacking the Icbl gene, showed that 110 SPT activity could be obtained unless both !cbl and 
lcb2 genes were expressed. Furthermore, the tagging of LCB I protein will a FLAG and His6 
tag confirmed that LCBI interacted with LCB2 since LCB2 could be co-purified and co-
immunoprecipitated with tagged LCBI (13). This also led them to propose that the 
stoicheometty of LCB I and LCB2 was 1: 1, again suggesting that they are two monomers 
which interact to form an active SPT heterodimer (13). Additionally, Yasuda ci al. 
demonstrated that LCB I is essential for the maintenace of LCB2 and that it is crucial for the 
formation of active SPT in mammalian cells (58). 
A novel 80 amino acid protein has been identified in association with LCBI and LCB2 from 
S. cerevisiae (59). This small protein, Tsc3p, does not influence the expression or membrane 
localisation of LCBI/2 however SPT activity decreases in mutant cells lacking Tsc3p, 
suggesting that this protein is required for optimal SPT activity. Tsc3p can also be 
solubilised from the microsoines in a similar fashion to LCBI and LCB2 suggesting that it is 
also membrane bound. Gable et al. showed that co-immunoprecipitation of Tsc3p with 
LCBI and/or LCB2 can be achieved at NaC1 concentrations up to 300 mM. However, above 
this concentration only LCBI and LCB2 co-immunoprecipitate together. This suggests that 
the interaction between Tsc3p and LCB 1/2 is weaker than that between the two monomers. 
To date however, no mammalian homologue of Tsc3p has been identified. Therefore it is not 
clear if an additional sub-unit is required for optimal SPT activity in mammals. 
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1.7.1.2 Viral and Plant Sources 
In the last decade the number of organisms known to express SPT has increased and now 
this includes a group of marine viruses of the genus Coccoliihovirus. The genome of this 
viral genus has recently been sequenced and was found to contain a cluster of sphingolipid 
biosynthetic genes, in particular, the single open reading frame ehv05O, which appears to 
encode a protein similar in sequence to eukaryotic LCBI and LC132. Further analysis has 
shown that this gene encodes two tandemly-repeated a-oxoamine synthase domains within a 
single polypeptide chain, with an N-terminal portion similar to LCB2 and a C-terminus 
similar to LCB1. When cloned into a S. cerevisiae double Alchl/ AIcb2 mutant, lacking 
endogenous SPT activity, viral SPT was able to rescue KIDS production suggesting it 
encodes an SPT (55, 60). 
One way in which viral SPT differs from eukaryotic SPT is in its substrate specificity. An 
increased proportion of longer C-16 sphingoid bases was observed in S. cerevisiae cells 
expressing viral SPT. This alteration in substrate specificity, for myristol-00A compared to 
palmitoyl-CoA, suggests that viral SPT may be capable of catalysing various condensation 
reactions of long chain fatty acids (55, 60). 
The significance of sphingolipid biosynthesis has also been demonstrated in plants, where 
sphingolipids contribute to growth and development. Work by Tamura et al. identified 
cDNA from Arabidopsis thaliana encoding a protein homologous to yeast and mammalian 
LCB2 (AtLCB2) and showed that expression of the gene encoding AILCB2 Aticb2)caused 
increased sphinganine production in mutant S. cerevisiae cells deficient in SPT activity (54, 
61). More recently, Chen et at. have identified a LCB I homologue from A. thaliana and also 
demonstrated that LCB auxotrophy could be rescued from mutant S. cerevisiae cells by co-
expression of AtIcbl with Ailcb2. Furthermore, partial RNA interference suppression of lcbl 
in A. thaliana leads to altered levels of saturated long chain bases which ultimatly, causes a 
decrease in plant size and altered leaf morphology (62). 
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1.7.1.3 Bacterial SPT 
As mentioned in section 1 .6, the Gram-negative bacterium Sphingornonas pauciinobi/is 
expresses a water soluble, homodimeric SPT, unlike the eukaryotic enzyme which is a 
membrane bound heterodimer. BLAST sequence alignment of S. paucimohilis SPT showed 
48% and 49% similarity to mouse LCB I and LCB2 respectively (49). Surprisingly however, 
S. pauciinobiiis SPT displayed higher similarity to the other enzymes of the a-oxoamine 
synthase family of which SPT is a member e.g. 56% similarity with 8-arnino-7-
oxononanoate synthase (AONS) of Bacillus sphaerious, 54% with 2-arnino-3 -ketobutyrate-
CoA ligase (KBL) of Bacillus sub/i/is, and 55% with 5-aminolevulinic acid synthase (ALAS) 
of Agrobacierium radiobacter ('49). 
Recombinant S. paucirnobilis SPT was over-expressed in E. coil and purified to homogeneity 
by Ikushiro ci al. and they demonstrated that it was active in the conversion of L-serine and 
palmitoyl-CoA to produce KDS (49). In their discussion Ikushiro and colleagues concluded 
that although their preparations of recombinant, untagged SPT were suitable for x-ray 
crystallography analysis. No structural data was deposited in the PDB between 2001 and 
2004. Since, unlike its eukaryotic counterparts, this protein is water soluble, a procedure for 
its characterisation and crystallisation was optimised and is the subject of this thesis (63). 
1.7.2 Identification of an Additional LCB Sub-unit (LCB3) 
As discussed earlier, the small 80 amino acid protein Tsc3p was identified by Gable ci al. as 
a requirement for optimal SPT activity in yeast. To date, no mammalian homologue has been 
identified. However, using a systematic screen of the genomic data base for sequences 
homologous to human /cbl (SPTLCI) and icb2 (SPTLC2) Hornemann et al. identified a 
short open reading frame encoding 134 amino acids that showed 86% similarity with the C-
terminus of LCB2. Further analysis revealed an open reading frame encoding a polypeptide 
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with an overall similarity of 84% to the LCB2 subunit of SPT. The similarity to LCBI was 
less at 45%. 
Based on its homology to LCB2, this new protein was named SPTLC3 and was proposed to 
be an isoform of SPTLC2 since it is located on a different chromosome (64). Further work 
showed that SPTLC3 co-immuno-precipitated with SPTLCI and SPTLC2 from human 
placenta extracts and human embryonic kidney (HEK) 293 cells. Non-denaturing PAGE and 
size exclusion chromatography suggests that all three protein sub-units interact to form a 
single SPT complex of approximately 480 kDa, suggesting that SPT is not a heterodimer but 
in fact a high molecular weight complex. The stoichiometry of SPTLC2 and SPTLC3 in the 
complex appears to be variable, suggesting a possible tissue specific mechanism of SPT 
activity which changes to suit the sphingolipid requirements of a particular cell type (65). 
1.7.3 Hereditary Sensory and Autonomic Neuropathy Type I 
Hereditary sensory and autonomic neuropathy type I (HSAN 1) is an autosomal dominant 
disorder which is the most common group of degenerative disorders of sensory neurons. The 
disease involves a progressive degeneration of dorsal root ganglion and motor neurons, 
leading to distal sensory loss and consequent distal muscle wasting. Sensory impairments 
include loss of sensation to pain and temperature. 
Nicholson ci al. showed that the gene responsible for HSAN I was located on chromosome 
9q22.1-q22.3 (66). Subsequently, the gene encoding SPT (SPTLCI) was mapped to this 
locus and mutational screening identified 3 three missense mutations resulting in a change to 
two amino acids within the protein structure (67, 68). Two of these mutations involve two 
different nucleotides in codon 133 which normally encodes a cysteine residue. The first, 
A398G, causes an amino acid change from cysteine to tyrosine and the second, G399T 
causes a change to tryptophan (67, 68). The third mutation T43 IA. within codon 144, causes 
a change of valine to aspartic acid (68). 
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In addition to identifying the mutations responsible for HSANI, Bejaoui ci at. have 
examined the effects of the C133 mutations on SPT function. They observed a 50% 
reduction of SPT activity in microsoinal preparations, obtained from the lymphoblasts of 
HSANI patients with C133 mutations, compared to preparations from healthy individuals. 
LCBI and LCB2 appeared to be present in similar concentrations in both preparations 
suggesting that the mutations do not affect the stability of the LCBI protein. They postulate 
that an alteration of LCBI may affect either; the formation of the active site upon 
dimerisation of LCB 1 with LC132, or the overall geometry of the active site (69). 
Sequence alignment of SPTLCI and S. paucirnobilis SPT maps residue C133 of SPTLCI to 
N 100 of the bacterial enzyme (Fig. 7). 
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Figure 7: Sequence Alignment of S. paucimobilis SPT with Human SPTI and 
SPT2 
Residues are coloured to indicate conservation and numbering refers to the S. paiicimobilis SPT 
sequence. "+" symbols denote important active site residues identified by examination of the SPT 
structure (see table 1, section 25.1). The secondary structure elements of S. paucirnobilis SPT are 
indicated above the sequence with red barrels representing an a-helix and the green arrow, 13-sheets. 
Regions considered to be relatively well aligned are boxed. Conserved residues (3/3) are highlighted 
in blue, 2/3 in yellow and regions considered to be relatively well aligned are boxed. 
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The crystal structure of S. paucirnobilis SPT was used as a model for the eukaryotic enzyme, 
and locates N100 within hydrogen bonding distance to the backbone carbonyl oxygen of the 
active site lysine residue (fig. 8, see section 2.5 for more detail). It is fair to suggest from 
this, that substitution of N 100 to a larger more hydrophobic residue (tryptophan or tyrosine) 






Figure 8: Active Site of S. paucimobilis SPT 
The distance between Nl00, monomer A (blue) and the backbone carbonyl oxygen from the active 
site lysine residue K265, monomer B (green) is highlighted. 
There have however, been cases of sensory neuropathy reported where there is no apparent 
mutation of SPTLCI. Analysis of patients carried out by Dawkins et al., where SPTLCI 
mutations have been excluded, did not show any alterations to the SPTLC2 sequence. This 
suggests that, in rare cases, other protein(s) may be involved in the onset ofHSAN1 (70). 
1.7.4 The a-oxoamine Synthase (AOS) Family 
The a-oxoamine synthase family is a group of pyridoxal-5'-phosphate (PLP)-dependent 
enzymes which commonly catalyse the decarboxylative condensation between an amino acid 
and a fatty acid thioester. These include 8-amino-7-oxononanoate Synthase (AONS) which 
catalyses the first step of biotin biosynthesis, 5-arninolevulinate synthase (ALAS) which 
catalyses the first step of tetrapyrrole biosynthesis. 2-arnino-3-ketobutyrate CoA Ligase 
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(KBL) which plays a role in threonine degradation, and serine palmitoyltransferase (SPT) 
which catalyses the first and rate limiting step of sphingolipid biosynthesis (71-73). 
Interestingly, two proteins involved in the biosynthesis of prodiginine antibiotics contain 
AOS-like domains in addition to acyl carrier protein domains. These are RedN and RedL 
from Sirepionlyces coelicolor and PigH from Serratia niarcescens (74, 75). 
Due to low sequence homology within the family of PLP-dependent enzymes, classification 
is difficult. Initially, this is normally based upon reaction specificity - which carbon (C-R) 
bond of the amino acid is targeted for cleavage (a f3 or y) (76). Reactions that occur at the u.-
carbon include transamination, decarboxylation, racemisation, condensation and elimination 
of a side group. Reactions that occur on the 1- or 7-carbons are less common and include the 
replacement of a side group and elimination. 
More recently, PLP-dependent enzymes have been divided into five groups based upon their 
three-dimensional fold-type: Fold type I, the aspartate amino transferase superfamily, which 
is sub-divided into a further 5 classes and contains enzymes previously classified under the c 
and y family as described by Alexander ci al. (76). Fold types Il-V are typified by enzymes 
of a specific fold. For example, fold type II is typified by tryptophan synthase, fold type Ill 
by alanine racernase, fold type IV by the D-alanine aminotransferase family and fold type V 
is based upon the lactate dehydrogenase fold superfamily (77, 78). 
There are two significant structural features within the sequences of the enzymes classified 
under fold type I. Firstly, the positioning of the conserved active site lysine residue which is 
located closer to the C-terminus directly following a hydrophobic n-strand and secondly, the 
positioning of the conserved aspartic acid residue that provides hydrogen bonding contact to 
the pyridoxal ring nitrogen, preceding the active site lysine residue by 20-50 amino acids. 
ALAS, AONS and SPT are classified under class II of the fold type I aspartate amino 
transferase family. 
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1.7.5 PLP-dependent Reaction Mechanism of the AOS Family 
A general reaction mechanism may be postulated for the AOS family, which constitutes 
class II (fold type I) within the PLP-dependent enzyme superfamily. The PLP co-factor is 
bound to these enzymes via a conserved, active site, lysine residue forming an internal 
aldimine/Schiff base. Generally, the initial steps of catalysis commence with a 
transaldimination reaction, where the internal aldimine complex is displaced by the incoming 
amino acid substrate, to form an external aldirnine (Fig. 9a(i)). The PLP exists in two 
tautomeric forms in the external aldimine: the enolimine and ketoenaniine. These tautomers 
have different absorbance maxima (336nm and 425nm respectively) which are responsible 
for the characteristic spectroscopic properties associated with PLP-dependent enzymes (Fig. 
9a (ii)) (79). 
External aldimine formation is followed by the heterolytic cleavage of a CR bond of the 
amino acid. Several studies indicate that the conserved active site lysine residue acts as the 
catalytic base during deprotonation in fold type I enzymes (80-82). Cleavage of the amino 
acid CR bond is postulated to generate a resonance-stabilized quinonoid intermediate (Fig. 
9b) which has been observed, spectroscopically, in the case of AONS (486nm), ALAS 
(SlOnm) and AAT (525 nm) (80, 83, 84). In addition, the formation of  quinonoid species in 
AONS was also demonstrated by deuterium exchange. Using 'H NMR, Ploux eta!, observed 
from the spectra of the AON product (formed from either L-[2-2 H]alanine in H20 or L-
alanine in D20) that the C2-H proton of alanine was lost during the reaction and that the C8-
H proton of 8-amino-7-oxononanoate was solvent derived (85). 
The quinonoid is consequently presumed to react with the other substrate, commonly a 
thioester (palmitoyl-00A in the case of SPT), in a Claisen-type condensation to form a 
putative f3-ketoacid aldiinine intermediate (Fig. 9c). Such an intermediate has been observed 
in the case of AONS, when incubated in the presence of alanine methyl ester and pimeloyl 
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CoA (86). Subsequently, the next step is presumed to be the decarboxylation and 
reprotonation of the resultant 13-ketoacid (Fig. 9d) to form the product external aldirnine. 
A further transaldimination reaction by the active site lysine allows product release and 
regeneration of the enzyme-PLP internal aldimine moiety (Fig. 9e). In ALAS the last steps, 
those of transainination and product release, are known to be rate determining. 
Intriguingly, unlike LC132, the LCB] sub-unit of eukaryotic SPT does not contain the active 
site lysine residue common to all other members of the AOS family. It is therefore suggested 
to play a regulatory role in the dimerisation with LCB2 facilitating the function of an active 
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Figure 9: PLP-dependent Reactions of Serine palmitoyltransferase (SPT) 
(a) L-serine External Aldimine Formation: (i) A transaldimation reaction occurs between the alpha amino group of L-serine and the imine bond of the Lys-PLP 
internal aldimine to form the PLP-L-serine external aldimine. (ii) The PLP moiety exists in two tautomeric forms (enolimine and ketoenamine) which give the 
enzyme characteristic absorbance maxima at 336 and 425 nm respectively. (b) Deprotonation and Quinoiioid Formation: Deprotonation occurs to form a 
resonance stabilized (quinonoid) intermediate. It is postulated that the active site lysine acts as the catalytic base during deprotonation. Quinonoid intermediates 
observed to date have characteristic absorbance maxima between 480-530 nm. (c) Product External Aldimine Formation: The incoming palmitoyl-CoA substrate 
undergoes nucleophilic attack by the quinonoid intermediate, causing CoA release and the formation of a condensation intermediate. (d) Decarboxylation and 
Reprotonation: Decarboxylation is then thought to take place to form the product quinonoid. This is subsequently reprotonated, possibly by the active site lysine, 
to form the 3-ketosphinganine (KDS) product external aldimine. (e) Product Release and Internal Aldimine Regeneration: The active site lysine residue initiates 
a transaldirnination reaction to release KIDS and regenerate the Lys-PLP internal aldimine. 
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1.8 	Inositol Phosphorylceramide Synthase 
Inositol phosphorylceramide synthase (IPC synthase, IPCS), also known as Aureobasidin 
resistance protein (Aurl p), catalyses the transfer of inyo-phosphoinositol from phosphatidyl 
inositol (P1) onto phytoceramide to yield inositol phosphorylcerarnide (IPC) and 
diacylglycerol (DAG) (87). This reaction is shown in figure 10 below. To date, IPC synthase 
and its orthologues have been identified from a wide variety of sources from protozoan 
parasites and pathogenic fungi to bean plant microsornes (88-90). Down-regulation of C. 
neofornians IPC synthase activity in J774.16 murine macrophage-like cells, significantly 
decreased the intracellular growth of this pathogenic fungus indicating that inhibition of 
Aurip activity could be a strategy for fungicidal action (91). Aurlp is not present in 
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Figure 10: IPC synthase Catalysed Transfer of Inositol-phosphate 
IPC synthase catalyses the transfer of inositol phosphate onto phytoceramide to produce inositol 
phosphorylceramide (IPC). 
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1.8.1 IPC synthase Homologues 
Using a combination of bioinforrnatic and functional genetic approaches Denny el al. 
identified a functional AURJ orthologue from the protozoan parasite Leishmania major. 
Despite having the same function as fungal IPC synthase and having the ability to rescue 
Aurl p null mutants, it shares more sequence similarity with its human orthologue 
sphingomyelin synthase. This suggests the presence of a novel class of protozoan IPC 
synthases and since there is no functional equivalent in mammalian cells, it offers a potential 
target for the development of anti-protozoan inhibitors. Such compounds could help combat 
a number of human diseases such as leishmanaises, Chagas disease and African sleeping 
sickness (88). 
Bromley ci al. have examined IPC synthase activity from the microsomes of a variety of 
plant tissues by monitoring the incorporation of [3H]-inositolphosphate. From the seven 
tissue samples analysed it was found that the highest IPC synthase activity came from bean 
leaf and hypocotyl samples. Bean microsomal IPC synthase is also inhibited by aureobasidin 
A and rustrnicin, which are two known inhibitors of the fungal IPC synthase (90). 
Homologues of S. cerevisiae AUR] have also been identified from a number of human 
pathogenic fungi including Candida glabrata and Crypiococcits neojbrmans. Sequence 
alignment of the proteins encoded by these genes with other homologues from Candida 
albicans, Aspergillus fuinigatus, Aspergillus nidulans, Saccharoniyces cerevisiae and 
Schizosaccharoniyces pombe showed a high degree of homology within the central 250 
amino acids. Two domains within this region are highly conserved suggesting that they may 
play a role in transferase activity (89). 
The mammalian contrapart of IPC synthase is sphingornyelin synthase (SM synthase) which 
catalyses the transfer of phosphocholine onto ceramide to produce sphingomyelin (SM), a 
major component of the mammalian plasma membrane (Fig.3). Two forms of human SM 
synthase have been identified by Huitema ci al. as integral membrane proteins located in the 
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Golgi lumen (SMSI) and the plasma membrane (SMS2) (12). VS-tagged versions of SMSI 
and SMS2 were transfected into HeLa cells and monitored by iimuno-flourescence 
microscopy. SMSI co-localised with sialyltransferase, a trans Golgi marker protein, whereas 
SMS2 was associated mainly with the plasma membrane. Additionally, protease protection 
analysis showed that the C-terrnini of both enzymes were located on the cytosolic side of the 
membrane with the active site facing the exoplasmic leaflet, which is where SM synthesis 
takes place (12, 92). 
1.8.2 Inositol; An Essential Growth Factor 
It was discovered as early as 1928 by Eastcott that a substance essential for yeast growth and 
survival (originally termed "bios") was in fact inositol (93). Later, in the 1940's and 50's it 
became apparent that inositol was an essential growth requirement for both bacterial and 
eukaryotic cells. Pennington et at. investigated the growth requirements of S. cerevisiae for 
inositol and noted that the rate of growth of inositol-deficient cultures was less than the rate 
of growth of cells in a medium containing excess inositol (5 jig/ml) (94). Similarly Ghosh et 
at. demonstrated that inositol deficiency in the yeast Saccharomyces carishergensis resulted 
in the formation of abnormal cell walls leading to failure of separation of daughter cells from 
parent cells causing the formation of large cellular aggregates (95). Myo-inositol was shown 
by Eagle et at. to be an essential growth factor for a variety of normal and malignant human 
cells: as growth of cell lines in inositol-deficient media was lethal and only a few myo-
inositol analogues such as inositol monophosphate were capable of sustaining cell growth 
and survival (96). 
Inositol containing lipids and glycolipids have also been isolated from S. cerevisiue by 
Steiner et at. who have shown that the major inositol containing lipid is mannosyl di-
inositoiphosphate ceramide. This lipid can also incorporate deoxyglucose to form a 
glycolipid with identical chromatographic properties as the previously identified inositol- 
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phospholipids (97, 98). Inositol containing sphingolipids ((IP)2 ceraniide) and glycolipids 
(tetrahexoside sphingolipid) have also been identified from the fungus Neurospora crassa 
(99). 
18.3 Characterisation of AURI 
Work by three independent groups identified a gene responsible for the resistance of S. 
cerevisiae to the antifungal agent aureobasidin A (AbA, 18) (100-102). Originally named 
ABRI by Heidler and Radding, this gene is now commonly known as aurl. In S. cerevisiae, 
AbA resistant mutants are characterised by single base alterations in AL/RI resulting in the 
amino acid substitutions L137F, H157Y and F158Y (103, 104). In AbA sensitive yeast and 
fungi there are a number of reported cases where single amino acid mutations have rendered 
the Aurl protein (Aurl p) resistant to AbA. As these mutations occur within close proximity 
to one another, this region must be important for AbA binding and it has been argued that 
either; the mutations cause a change in the binding site of Aurl p or that AbA still binds but 
the protein maintains its function. 
It was demonstrated by Heidler and Radding that the partial deletion of the AURJ ABR1) 
locus affects S. cerevisiae cell growth and division. A more detailed study by Hashida-
Okado et al. showed that the dominant S. cerevisiae mutants were resistant to AbA 
concentrations greater than 25 j.tg/mL and analysis of the nucleotide sequence of AURJ 
predicted that the polypeptide is a hydrophobic protein, 401 amino acids in length, 
containing several possible transrnernbrane domains. Furthermore, they demonstrated that 
wild-type Aurip is also a target for AbA, as cells containing a disrupted AURJ locus 
expressed morphological changes including the disappearance of microtubules and 
degradation of tubuliri. This abnormality in microtubule organisation is similar to that 
observed in cells treated with AbA. This also suggests a possible role for Aurip in 
microtubule organisation and stabilisation (103, 104). 
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In addition, mutations ofAURJ resulting in an amino acid substitution have been observed in 
other fungi and also result in the production of an AbA resistant phenotype e.g. G240C in S. 
ponthe and G275V in A. nidulans (corresponds to G240 in S. ponibe) (105, 106). Moreover, 
Hash ida-Okado ci al. have also carried out a three base pair mutation in S. cerevisiae AURJ 
causing the amino acid substitution A240C. This mutant is named AURI-C and has been 
manipulated for use as a selection marker, in combination with AbA, for use in a new 
transformation system not only with standard lab strains of S. cerevisiae but also with the 
industrial strain S. carlsbergensis (107). Hansen ci a!, have used this AURI-C mutant, in 
addition to a lacZ reporter gene, to develop the pYC plasmid series thus expanding the 
possibilities available as alternatives to G418 resistance (108). 
1.8.4 Location of Aurl p and IPC Synthase Activity 
It was demonstrated by Hechtberger ci al. (and subsequently by Leber ci al.) that 
inositoiphosphorylceramide (IPC) is highly enriched in the Golgi and vacuolar membranes 
of S. cerevisiae whereas most of the more complex mannosylated sphingolipids are located 
in the plasma membrane (109, 110). Hechtberger and Daum also showed that treatment of S. 
cerevisiae cells with the drugs cycloheximidine and nocodazole, which affect the ER to 
Golgi transport of IPC, have no effect on IPC biosynthesis. However, treatment with 
brefeldin A, which is known to cause disassembly of the Golgi in yeast, caused a decrease in 
IPC formation. Both studies hinted at the sub-cellular localisation of IPC synthase to the 
Golgi apparatus (111). 
In addition to these early studies, the location of Aurl p and IPC synthase activity has been 
examined in an extensive series of experiments by Levine etal. (112). The incorporation of 
three copies of an HA epitope at the C-terminus of A UR] by homologous recombination was 
used to monitor the localisation of Aurl p in vivo. In a manner similar to that used in the 
identification of human SM synthase (section 1.8.1) imniunofluorescence was used to 
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compare the localisation of HA tagged Aurl p with other membrane proteins of the Golgi. 
Anti-HA staining of Aurlp expressing cells showed co-localisation of the protein with 
mannosyltransferase, a medial Golgi marker. Membranes form Aurip-HA expressing cells 
were fractionated using a velocity gradient and fractions assayed for IPC synthase activity. 
There was close correlation between fractions containing Aurip-HA and those exhibiting 
IPC synthase activity. 
Furthermore, an Aurl p-Protein A fusion was used to determine the cellular sub-location of 
the C-terminus. Cleavage of the protein A tag occurred in the absence of detergent, in 
comparison to Vanip-Protein A, a lumenal, type II Golgi enzyme, where detergent was 
required to cleave the protein A tag. From these studies it seems that the C-terminus of IPC 
synthase may reside on the cytoplasm face of the golgi membrane whereas the active site 
residues are located in the lumen. This is consistent with the location of the flourescently 
labelled ceramide (C6-NBD-ceramide) product, which remains within the Golgi of live yeast 
cells rather than in the cytosol. 
1.8.5 IPC synthase Solubilisation and Activity 
There is at present, no structural information available for IPC synthase only predicted 
topologies. Based on the predicted molecular mass of the protein encoded by AURI and the 
predicted topologies, the presence of 6/7 transmembrane domains is inferred suggesting that 
IPC synthase is an integral membrane protein. This makes its isolation, solublisation and 
characterisation very challenging. 
Initially, Ko ci' al. showed that IPC synthase activity could be released from S. cerevisiae 
crude membrane extracts in the presence of the non-ionic detergent Triton X-lOO and that 
IPC synthase activity was dependent upon surface concentrations of the substrates P1 and 
ceramide in a Triton-X mixed micelle (113). 
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In an extensive study, Aeed ci al. examined the effects of 26 membrane-perturbing agents on 
IPC synthase activity from C. albicans and found that CHAPS (zwitterionic detergent) 
treated membranes had significantly improved activity compared to crude membrane 
extracts. In this study Triton X-100 extracts were shown by size exclusion chromatography, 
to be large aggregates or complexes of between 1 .5-20 x 106  Da. They were unable to 
determine whether these aggregates were comprised of discrete complexes formed by several 
enzyme molecules or a result of unspecific aggregation of enzyme and membrane lipids. The 
requirement for the addition of high concentrations of P1 in the extraction buffer also makes 
this method of extraction unattractive. Aeed ci al. also developed an assay which is almost 
completely dependent upon substrate concentration and were able to determine appropriate 
K1 values for C6-NBD ceramide and P1 which were 3.3 LM and 138[LM respectively (114). 
Since it appears that C. albicans IPC synthase contains two potential protein-protein 
interaction motifs, consisting of nine consecutive glutamic and aspartic acid residues towards 
the C-terininus and a cluster of 6 positively charged amino acids at the N-terminus, it may be 
that these sequences are responsible for the aggregation of IPC synthase molecules into large 
protein complexes (115-117). 
1.9 Novel Antifungal Targets 
There are a host of potential targets for the development of fungicidal agents for example, 
cell wall biosynthesis, plasma membrane biosynthesis, DNA and protein synthesis and signal 
transduction pathways (118). Under the umbrella of plasma membrane biosynthesis, 
extensive studies by Nagiec ci al. have identified the sphingolipid pathway as a viable target 
for the development of novel anti-fungal agents (119, 120). However, enzymes early in the 
sphingolipid pathway, such as SPT, have mammalian homologues and are therefore less 
attractive targets in comparison to IPC synthase, for example, which is essential to fungi 
(and some fungal pathogens such as Botrytis cinerea, section 1 .9.3) but absent in mammals 
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(121). Secondary metabolites, produced from many micro-organisms, provide a rich source 
of lead compounds for the development of novel anti-microbial agents (/22, 123). However, 
most naturally occurring anti-fungal compounds possess a broad spectrum of activity and 
over decades of use have become less effective. This increased resistance to commonplace 
antiungal agents, such as the azoles (fiuconazole and itraconazole) requires the development 
of novel compounds with high efficacies and specific modes of action (124). It has been 
suggested that efficient inhibitors of IPC synthase would fit these criteria. 
1.9.1 Natural Product Inhibitors of SPT 
Several natural product inhibitors of SPT have been isolated froni various sources. These 
include  the sph ingofungi ii s from the thermo-tolerant fungi Aspergillus Ilirnigatus and 
Paeciiomyces variotii, lipoxamycin from Streptomyces virginiae and myriocin from the 
fungus Jsaria sinclairii (125-127). Although their mechanism of action remains unsolved 
their structures resemble that of sphingosine, 7. This structural similarity suggests that their 
mode of action may be similar. Each group of antibiotics have broad-spectrum anti-fungal 
activity. However, since SPT is also present within mammalian cells, it does not provide a 
useful target for the development of new anti-fungal agents. 
1.9.1.1 Myriocin 
During a screening program for the identification of novel antifungal agents, antifungal 
activity was detected from the fermentation broth of the thermophillic fungus Myriococcuni 
alboniyces. Analysis of the broth revealed an active compound which was isolated and its 
structure determined, this antibiotic was named myriocin, 6 (128). Independently, the potent 
immunosuppressive compound ISP-I was isolated from a culture of the fungus Isalia 
sinclairli and shown to be identical to that of myriocin (129). 






Subsequently, myriocin/ISPI was shown by Miyake et al. to inhibit the proliferation of a 
murine IL-2 dependent cytotoxic T cell line (CTLL-2), with all IC50 of 15 nM. This growth 
inhibition could only be abolished by the addition of exogenous sphingosines. As a result 
they identified the primary target of myriocin as SPT and found that it inhibited the enzyme 
in a non-competitive manner with an apparent inhibition constant of 0.28 nM (126). Using a 
myriocin-containing affinity matrix, Chen ci al. isolated LCB1 and LCB2 from the lysate of 
CTLL-2 cells (130). 
Hanada ci al. subsequently showed that 95 % inhibition of de novo sphingolipid 
biosynthesis, in CHO cells (L-YB/cLCBI), occurred in the presence of myriocin. Since 
growth inhibition could be rescued by the addition of exogenous sphingosine, this reinforces 
the suggestion that myriocin inhibits sphingolipid biosynthesis via inactivation of SPT (131). 
Myriocin was shown to competitively inhibit L-serine binding to S. pauciniobilis SPT with a 
Kd 	of 1.3 jiM, a 1 fold higher affinity, than the natural substrate L-serine (132). Since the 
structure of myriocin appears to mimic that of the condensation intermediate formed 
between L-serine and palmitoyl-CoA (Fig. 9c) it is possible to see why it binds so strongly to 
the enzyme. 
1.9.1.2 The Sphingofungins 
During screening tests for anti-fungal compounds from fungal sources, VanMiddlesworth et 
al. isolated and characterised four related compounds from cultures ofAspergi!lusfumigatus. 
These novel compunds were named sphingofungin A, B, C and D (Fig. 11, 8-11). 
Sphingofungins A-C exhibited a potent antifungal effect on Cryptococcus neoformans, 
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Saccharornyces cerevisiae and various Candida species with MIC values in the ig/mL 
range. Sphingofungin D exhibited less potent activity (127). 
More detailed studies into the biological activity of sphingofungin B, 9 and C, 10 were 
carried out by Zweerink c/ al. in which the MIC values for Saccharomyces cerevisiae were 
determined to be 2 and 12 ig/mL respectively (133). Both compounds were observed to be 
lethal to growing cultures of S. cerevisiae with 99% lethality after 24 hours. In contrast, the 
antibiotics aculeacin and nystatin, which target cell wall/membrane biosynthesis, exhibited 
fungicidal activity afterjust 30 minutes. Since neither sphingofungin B or C had an effect on 
cell morphology and reversal of sphingofungin growth inhibition could be rescued by the 
addition of exogenous KDS, it was suggested that SPT is the target. Indeed, SPT activity 
from crude S. cerevisiae membrane extracts was inhibited by nanomolar levels of 
sphingofungin B and C, with sphingofungin B having a lower IC50 (20 nM) compared to 
sphingofungin C (100 nM) (133). 
Horn ci al. have identified two further sphingofungin compounds, sphingofungins E 12 and 
F 13 (Fig. 11) from Paecilomyces variotii, which share close structural resemblance, to 
myriocin. Their in vitro activity against SPT from crude S. cerevisiae membrane extracts was 
tested and compared to that of sphingofungin B (134). The IC50 values obtained are in the 
nanomolar range (7.2 and 57 nM respectively) however these were less potent than 
sphingofungin B. Sphingofungin F, 13 in which the CH7OH at C2 is changed to CH3 is 
distictively less potent than sphingofungin D, 11. 
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Figure 11: Structures of the Sphingofungins and Related Long Chain Bases 
The sphingofungins (A-F. 8-13) are sphingosine, 7 related molecules and bear a very close 
resemblance to myriocin, 6 therefore it is not surprising that they are able to bind to, and inhibit, SPT 
activity. 
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1.91.3 Sulfamisterin and Lipoxamycin 
Recently, the novel inhibitor sulfamisterin, 14 has been identified from the fungus 
Pycinidiella strain AB5366. It is a naturally occurring cit-substituted ri-amino acid derivative 
possessing a sulfonated hydroxy function. An IC50 of 3 nM has been reported for this 
compound using a CHO cell-free lysate (135). To confirm that sulfamisterin inhibits 
sphingolipid biosynthesis by the inhibition of SPT. Yamaji-Hasegawa et al. monitored the 
incorporation of 4C-serine and [3H]-sph ingosine/[3H]-dihydrosphingosine into complex 
sphingolipids. In a cell-free system 100 nM sulfamisterin was required for the complete 
inhibition of SPT although a higher dose (10 tiM) was required for the complete inhibition of 





The total synthesis of sulfamisterin and a number of analogues was achieved by Sato ci al. 
and these compounds were tested for their biological activity as described above. 
Interestingly, sulfonation of the hydroxyl group at position C3 is not essential for inhibition 
as desulfonated sulfarnisterin also inhibits SPT activity (136). In addition, their studies show 
that the stereochemistry of this molecule at the C2 and C3 positions is vital for potent 
inhibitory activity. For example, the 2R compounds are ten-fold more active SPT inhibitors 
in vitro than the 2S compounds. Sphingolipid synthesis in vivo was also inhibited more 
significantly by the 2R compounds. 
Lipoxamycin, 15 was originally isolated from Streptoinyces virginiae var. lipoxae UC 5108. 
It was active against a range of fungi and yeast; the complete inhibition of Candida a! bicans 
and Cryptococcus neoformans growth was achieved at 10 and I Lg/mL, respectively, but it 
proved less effective against bacteria with MIC values above 250 tg/mL. It was also found 
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to be intolerable to mice at concentrations above 10 mg/mL and was also ineffective against 
infections with C. ablicans and C neofhr,nans and some other pathogens in mice (137). 
0 	 OH NH2 
0 	15 
The structure of lipoxamycin was later determined by NMR and mass spectrometry (138). 
Although its structure contains a long alkyl chain and an amino containing polar head group, 
it does not resemble the sphingoid bases as closely as the sphingofungins. It does however 
exhibit comparable potency to the sphingofungins with an 1050 value of 21 nM in vitro 
against S. cerevisiae SPT. Its antifungal activity was also comparable with sphingofungin B 
against Cryptococcus neoforinans, Candida albicans and Aspergillus jiirnigatus. Since the 
inhibition of lipoxamycin can be reversed by the addition of exogenous sphingolipid 
intermediates it was concluded that its mode of action is inhibition of SPT (125). 
1.9.1.4 Cycloserine 
Cycloserine, 16 (4-amino-3-isoxazolidinone, Seromycin) is a broad spectrum antibiotic used 
in combination with other antibiotics to treat tuberculosis. D-cycloserine is a natural product 
produced by Slreploniyces lavendulae and Streploniyces garvphalus and acts on the PLP 
dependent enzymes alanine racemase and D-amino acid aminotransferase resulting in 
disruption of peptidoglycan biosynthesis (139, 140). In contrast, the L-isorner, originally 
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Studies have shown that the antibiotic L-cycloserine (LCS) has a potent inhibitory effect on 
SPT activity and hence sphingolipid production. Williams c/ al. have shown that KDS 
production in rabbit aorta was significantly inhibited by LCS; 50 % inhibition was obtained 
with 5 tM LCS and 50 tg of microsomal SPT protein (144). Additionally, Sundararn and 
Lev showed that growth of the anaerobic bacterium Bacieroides levii was significantly 
impaired in the presence of LCS. In particular, the activity of KDS synthetase was inhibited 
by 70% after one hour with 100 jig/mL LCS. Synthesis of phosphorylceramide containing 
lipids was also inhibited significantly as shown by the reduction of [32 P] incorporation (142). 
In a comparative inhibition study using mouse brain microsomes and SPT from Bacieroides 
Ievii they also demonstrated that LCS was the most potent inhibitor of KDS production (0.04 
M caused a 50 % inhibition of SPT activity) (145). 
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1.9.2 Inhibitors of IPC synthase 
1.9.2.1 Aureobasidin A 
The natural product Aureobasidin A (AbA, 17) is the major aureobasidin isolated from 
Aureobasidium pullulans R106 (Fig. 12). It is a cyclic depsipeptide with potent, broad 
spectrum, antifungal activity targeted towards the inhibition of IPC synthase activity (102, 
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Figure 12: Structure of Aureobasidin A 
Aureobasidin A, 17 is a cyclic depsipeptide, natural product inhibitor, isolated from Aureohasidium 
pullulans R106. Abbreviations; D-Hmp; 2(R)-hydroxy-3(R)-methylpentanoic acid, MeVal; N-methyl-
L-valine, Phe; L-phenylalanine, MePhe; N-methyl-L-phenylalanine, Pro; L-proline, Leu; L-leucine, 
alle; L-allo-isoleucine, HOMeVal; 3-hydroxy-N-methyl-L-val me. 
AbA has been shown to exhibit potent antifungal activity against S. cerevisiae and is thought 
to affect the organisation of bud growth and the integrity of the cell membrane (149). In 
addition, AbA has been shown to inhibit the parasitic organisms Leishmania Major and 
Toxoplasma gondii. Studies by Denny ci al. have shown that 20 jiM AbA inhibited 90 % 
growth of L. major cultures (although the parasites remained viable) and pre-treatment cells 
with AbA significantly delayed infectivity (88). Sonda ci al. showed that AbA blocked T 
gondii replication without affecting host cell metabolism (150). 
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The pathogenic fungal species Candida and Aspergillus are also susceptible to AbA 
treatment although there may be a naturally resistant phenotype of Aspergillus furnigaius 
(151). The growth of all species tested from both genera of fungi were inhibited with IC50 
values in the nanoniolar range (2-6 ng/rnL) however, tests with the Aspergillus strains 
showed variable MIC values from 0.8 to >50 jtg/mL. This difference in resistance to AbA 
was investigated further by Zhong ci al. in order to determine the cause. MIC values 
measured in the presence of verapamul, a mammalian multi-drug resistance (MDR) 
modulator, showed that a concentration of 200 tg/mL verapamil reduced the MIC value for 
A. fimniigatus to 3 tg/mL, suggesting that the increased resistance observed is due to 
increased efflux of AbA through some form of transporter (147). 
MDR transporters belong to the superfamily of ATP Binding Cassette (ABC) transporters of 
which the CFTR sub-group are also members. Both subgroups of transporters are often 
involved in the increased resistance to chemotherapeutic agents (152). ABC transporters are 
also present in S. cerevisiae where the mutant strain aur3' contains a recessive mutation in 
the pleotropic drug resistance gene PDRJ. PDRJ is a transcriptional regulator of two ABC 
transporter genes YORJ, a member of the CFTR subgroup and PDR5 which belongs to the 
MDR group of transporters. AbA resistant phenotypes are produced when functional YORI 
and mutated PDRJ are both present, suggesting a potential interaction for AbA with multi-
drug resistance transporters. 
1.9.2.2 Rustmicin 
Rustmicin, 18 also known as galbonolide A, is a 14-membered macrolide isolated from 
Microinonospora sp. which was discovered due to its potent antifungal activity against 
phytopathogenic fungi (153). It is a reversible inhibitor of sphingolipid biosynthesis and acts 
upon IPC synthase, resulting in the accumulation of ceramide and consequent loss of 
complex sphingolipid formation. 
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Rustrnicin displays exceptional activity against Cryptococcus neofornias. Growth inhibition 
was achieved by Mandala ci al. at concentrations below I ng/mL and IPC synthase was 
inhibited with an IC50 value of 70 pM (154). Its limitations for use as an antifungal agent lie 
mainly in its stability as it has been found to be less potent in vivo than expected from results 
achieved in vitro. This reduction in potency arises from a rearrangement of the structure in 
solution to produce the inactive y-lactone derivative, 19. An additional factor in reducing 
rustmicin's efficiency in vivo is that it is a good substrate for the MDR transporter PDR5 
mentioned previously (section 1.9.2. 1 ). 
1.9.2.3 Khafrefungin 
Khafrefungin, 20 is a linear C22-polyketide acid esterified with an aldonic acid. Like AbA 
and rustmicin, khafrefungin is active against C. albicans, C. neofornians and S. cerevisiae 
with MIC values of 2.0, 2.0 and 15.6 .tg/mL respectively. Growth inhibition has been shown 
to result from the inhibition of sphingolipid biosynthesis, as khafrefungin is a potent 
inhibitor of IPC synthase (155). 
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Inhibition of IPC synthase was shown, as in the case of rustmicin, to cause ceramide 
accumulation in vivo resulting in induced apoptosis of S. cerevisiae cells. In the same study 
by Mandala et al., IC50 values of 0.09, 0.5 and 0.35 jig/mL were also obtained for the 
inhibition of IPC synthase from these organisms (155). 
Wakabayashi el cii. have shown that the stereochemistry of the hydroxyl groups of the 
aldonic acid moiety of khafrefungin is critical for antifungal activity as only the 2R, 3R, 4S 
compound, 20 exhibits antifungal activity. Their results have suggested that the mode of 
inhibition is mediated by the polar head group, which may mimic phosphoinositol (156). 
1.9.2.4 The Pleofungins 
The most recently discovered group of novel antifungal agents which are active against IPC 
synthase are the pleofungins, a group of depsipeptides isolated from a Phoina sp. fungus. 
Growth inhibition of C. a/b icans, C. neojbrmans and A. fuinigatus by pleofungin A showed 
MIC values of 2.0, 0.3 and 0.5 ug/mL respectively. This molecule inhibited IPC synthase 
from S. cerevisiae and A.fuinigatus with IC50 values of 16 and I ng/rnL respectively (157). 
1.9.3 Fungal Infections in Plants 
In agriculture, the control of fungal infections is of great importance as fungal plant diseases 
are estimated to destroy approximately 20% of major food and cash crops worldwide (158). 
The plant pathogen Botrytis cinerea (grey mould) is one example as it causes serious pre-
and post-harvest disease in economically important crops. It is a necrotrophic pathogen 
which affects plant cell viability by secreting toxins and host-degrading enzymes. In contrast 
to more specialised species, B. cinerea is indiscriminate in its phytopathogenicity and will 
therefore infect a range of plants and plant parts (159). This pathogen favours cool, moist 
conditions and is a weak parasite often found on injured or senescent plant tissue. The plants 
it can infect vary greatly in their biochemical defence mechanisms (160). B. cinerea infects 
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tissues by coordinating the expression of pathogenic enzymes, thus degrading the plant 
chemical defence systems and protective cell coatings (161). 
In contrast to the agricultural problems it causes as a pathogen, under certain conditions B. 
cinerea infections can be beneficial. It is the causative organism of noble rot' which dries 
berries and causes the sugar and flavour to concentrate without affecting the acidity. This is 
exploited in the manufacture of dessert wines. 
Studies by Ippolito et al. have shown that the yeast-like fungus Aureobasidiurn pullulans 
controls apple wound decay caused by B. cinerea (grey mould) and Penicilliurn expansuin 
(blue mould). Typically, at the end of storage periods, A. pullulans had reduced decay from 
grey and blue mould by 89% and 67% respectively, compared to a water treated control 
(162). A. pullulans is thought to weaken the pathogen by out competing it for space and 
nutrients thus increasing their vulnerability to host secreted lytic enzymes and antibiotics. 
Since the antifungal agent aLireobasidin A was originally isolated from the fermentation 
broth of A. pullulans, it is possible that A. pullulans suppresses the pathogenicity of B. 
cinerea through the action of AbA on IPC synthase. Furthermore, the IPC synthase inhibitor 
galbonolide A (rustmicin), isolated from Sireptoinyces ga/bus culture broth, possesses potent 
activity against B. cinerea amongst other pathogens (163, 164). The above studies indicate 
that B. cinerea may be a potential "model target" for further studies into IPC synthase 
inhibition. 
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1.10 Aims 
Before the research described here was carried out, there was no structural information 
available for any enzyme involved in sphingolipid biosynthesis although enzyme isolation 
and biochemical characterisation studies were abundant. Since SPT catalyses the first and 
rate-limiting step of sphingolipid biosynthesis, it is an interesting target for structural studies. 
Since the structures of three members of the a-oxoamine synthase family of enzymes have 
been solved, comparative studies with SPT would be of significant interest (71-73). 
Unfortunately, eukaryotic SPT is a membrane bound heterodimer and is extremely insoluble 
posing major technical difficulties for its isolation and characterisation. Fortunately however, 
a water soluble, bacterial honiologue from Sphingonionas paucinwhilis had been identified 
prior to this work providing a platform for structural studies (49). 
The first aim in this research was the over-production, purification and crystallisation of 
wild-type S. pauciinobilis SPT (Sp SPT). Naturally, if this could be crystallised in a form 
suitable for X-ray diffraction, it was hoped to solve the structure and to examine Sp SPT with 
substrates and/or inhibitors bound at the active site. It was expected that this structural 
information would provide an insight into the SPT mechanism. 
Despite its importance as a target for antifungal agents, IPC synthase remains poorly 
characterised and therefore further studies into its isolation, over-production and biochemical 
characterisation need to be carried out. To date, no method for the over-production of IPC 
synthase has been reported and current wild-type IPC synthase isolation procedures are long 
and complicated processes these two areas need to be addressed (113). The second aim of 
this research therefore, was to optimise the over-production and purification of soluble IPC 
synthase from S. cerevisiae. 
Although it would be relevant to agrochemical research to study IPC synthase from 
phytopathogenic fungi such as Boirytis cinerea, this fungus is more difficult to culture and 
manipulate compared to yeast. It seemed reasonable, therefore, to develop methods for IPC 
Beverley Yard 	 Sphingolipid Biosynthesis 	 48 
synthase over-production and purification using the yeast enzyme. Isolation and 
characterisation of pure, soluble IPC synthase from either source should allow for further 
enzymatic studies and the availability of fungal IPC synthase for high-throughput screening 
would allow the identification of potentially useful inhibitors. 
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Chapter 2: Serine Palm itoyltransferase (SPT) 
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2.1 	Cloning and Over Expression of the Gene Encoding S. 
paucimobilis Serine palm itoyltransferase (SPT) in E. coil 
2.1.1 Production of N-terminal Histidine-Tagged SPT; pET6HSPT 
Previous work has been reported on wild type and recombinant serine pal mitoyltransferase 
(SPT) from Sphingonionas pauciinobi/is (1). Ikushiro et al. have isolated and purified both 
native SPT from S. pauciniobilis, and a recombinant version from E. co/i (131-2I (DE3) 
pLysS) cells. It is unclear in their paper whether their recombinant SPT protein contained a 
6-histidine tag as purification using nickel-affinity chromatography was not reported. 
Despite concerns that the over-production of SPT, and hence an increase in the production of 
3-ketosphinganine, could be toxic to E. co/i, this was proven not to be the case. 
Prior to the studies discussed in this thesis, the full length spi gene was amplified by PCR 
from S. paucimobilis strain 13361 using chromosomal DNA as a template and PCR forward 
and reverse primers based on the spt sequence deposited in the NCBI database by Ikushiro et 
al. (accession number A13055142). This DNA sequence was modified by insertion of the 
restriction endonuclease sites BspHl (5') and BainfIl (3'), which allowed the gene to be 
inserted into the expression plasmid pET16b. Over-expression of pET16bspi produced 
untagged recombinant SPT protein however the isolation of untagged SPT was time-
consuming, involving numerous chromatographic steps. In light of this, the gene encoding 
SPT was modified, by PCR, in an attempt to produce a N-terminal 6-histidine tagged protein. 
To do this, primers were designed to incorporate a Ncol restriction endonuclease site at the 
5'- end of the spt gene allowing it to be excised from pET 16b (NcoI/BainHI) and inserted 
into pET6H (an Edinburgh lab constructed plasmid). 
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Expression trials of pET6l-lspt were carried out, varying the following parameters: E. co/i 
strain; HMS 174 (DE3) and 131_2I (DE3), temperature; 30°C and 37°C, induction time; 3, 4, 
5, 6 hours and concentration of IPTG; 0.1, 0.25, 0.5 and 1 mM. Optimal expression was 
obtained from HMS 174 (DE3) cells grown at 30°C and induced for 6 hours with 0.1 mM 
IPTG. While efficient over-production of pET6HSPT could routinely be obtained, 
purification proved more difficult as the protein bound very weakly to a His-TrapTM column 
(GE Healthcare) and as a result could be eluted with only 50mM imidazole. 
To investigate this further, anion exchange chromatography was carried out as the untagged 
protein had also been purified in this way. Unfortunately, SPT did not bind to the anion 
exchange resin. As a result, it is feasible to suggest that over-production of SPT with a N-
terminal tag had either; interfered with the correct folding of the protein or that the tag was 
inaccessible for purification. Initial crystallisation screens (Hampton Research) were set up 
with pET6HSPT however, no crystals could be obtained for structural studies. 
The gene encoding SPT was also cloned into the plasmid pHISTEV ((lab constructed strain 
gifted by Dr. H. Liu, SSPF, St. Andrews) to produce recombinant SPT with a cleavable N-
terminal histidine tag. However, again, the protein bound very weakly to a HisTrapTM 
column. Both results imply that tagging SPT at the N-terminus leads to an ineffective 
purification strategy. 
2.1.2 Production of C-Terminal Histidine Tagged SPT; SPT-His6 
In light of the problems encountered with N-terminal tagged SPT, primers were designed to 
incorporate, by PCR, the restriction sites BspHl and Xhol at the 5' and 3' ends of the spt 
gene respectively. As a result, spt was cloned (by PCR) from pET6H with the restriction 
sites BspHl/Xhol which enabled the gene to be inserted into pET28a using the restriction 
sites NcoI/Xhol (Fig. 13). As NcoI and BspHI are complementary sequences. the N-terminal 
restriction site on the spt gene is lost upon insertion into pET28a. 
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Figure 13: Expression Plasmid pET28aspt 
The S. pauci,nohi/is spi gene was inserted into pET28a using the BspHl and Xhol restriction sites. The 
resulting construct encodes a C-terminal 6-histidine (His6)-tagged SPT protein. 
Expression trials of pET28as'pt were carried out as mentioned previously for pET6HSPT. 
The optimal conditions were similar, with the exception of time as it was found that similar 
levels of protein could be obtained after five, rather than six hours, of induction. 
2.2 	Purification and Characterisation of Recombinant 
SPT-His6 
Single step purification of SPT-His6 was successful using a HisTrapTM column (GE 
Healthcare) and the protein was eluted with approximately 200mM imidazole. SPT-HiS6 was 
subsequently purified by size exclusion chromatography and was eluted with 110-130 mL of 
size exclusion buffer. Using a standard curve, obtained from known molecular weight 
standards (GE Healthcare), the elution volume was used to calculate the approximate 
molecular weight of SPT- His6 as 90-100 kDa. This suggests that SPT-His6 was purified as a 
dimer in solution. This was confirmed by native gel PAGE of the elution fractions 12, 13 and 
14 (Fig. 14). 
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Figure 14: Size Exclusion and Native PAGE Analysis of SPT-His6 
Size exclusion purificationand native gel PAGE analysis both suggest the presence of SPT-His6 as a 
dimmer in solution with an approximate molecular weight of 90 kDa. 
Electrospray ionisation mass spectrometry (ESI-MS) analysis of the purified protein 
indicated a monomer molecular weight of 45,969.64 + 4.93 Da. This is consistent with the 
predicted mass of recombinant SPT (46,104 Da) from the gene sequence taking into account 
loss of the N-terminal methionine residue and the addition of the C-terminal 6-histidine 
affinity tag. 
On average, purification yielded approximately 10 mg of protein per litre of cell culture. 
Although this yield was sufficient for biochemical and structural analyses, purification was 
optimised to give a higher yield of protein. This was accomplished by replacing the 
commercial pre-packed HiPrepTM column with Ni-NTA agarose (Invitrogen) to allow longer 
contact between the cell free extract and the chromatography media. Elution with 100 mM 
imidazole resulted in protein of a similar degree of purity and this protocol was optimised to 
yield 20 mg of protein per litre of cell culture (a two-fold increase compared with the pre- 
packed column method). 
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2.3 SPT Activity 
2.3.1 Spectroscopic Analysis of holo-SPT 
Since PLP is bound via Lys265, in holo-SPT, it gives the enzyme characteristic UV-visible 
absorptions (Fig. 15). Typically in PLP-dependent enzymes, the PLP moiety can exist in 
two tautomeric forms, an enolimine, 21 and ketoenamine, 22 which have different 
absorbance maxima at 336 and 425 nm respectively. These peaks represent the two different 
protonated states of PLP; the enolimine is formed when the oxygen is protonated and the 
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Figure 15: UV Visible Spectrum of holo-SPT 
UV-visible spectrum of holo-SPT showing the characteristic peak of the enolimine, 21 (336 nm) and 
ketoenamine, 22 (425 nm) forms of the PLP. 
2.3.2 Kinetic Analysis of L-serine Binding 
Upon binding of L-serine to form the external aldimine complex, 23 (Fig. 16), there is a 
decrease in absorption at 336 nm with a concomitant increase at 425 nm. This is almost 
certainly due to the displacement of PLP from Lys265 by L-serine. The UV-visible spectra 
of SPT (20 1.tM) were measured in the presence of various L-serine concentrations (Fig. 16). 
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Figure 16: UV-visible Profile of L-serine External Aldimine Formation 
The bold line represents holo-SPT and the dotted lines show the formation of the external aldimine, 23 
upon incubation with increasing concentrations of L-serine. Assays were carried out in 20mM KPhos 
pH 7.5, 150 mM NaCl, 1mM EDTA with 20 LM SPT and increasing L-serine concentrations of 5, 10, 
20, 30, 40 mM. 
The spectral changes observed during L-serine binding showed a hyperbolic dependency on 
the concentration of L-serine (Fig. 17a). From this graph (of L-serine against the change in 
absorbance at 425 nm) the steady state apparent dissociation constant for external aldiniine 
formation (K2) was estimated as 1.65 ± 0.22 mM. This is comparable with the value of 1.40 
mM reported by Ikushiro et al. for wild type SPT (3). 
Pre-steady state measurements were performed and rate constants k0hs  for the formation of 
the L-serine external aldimine were determined by monitoring the absorbance increase at 
425 nm over time (Fig. 17b). The resultant traces (average of 4) were fitted to single 
exponential functions. Since the apparent rate constants (kapp) for changes in absorbance 
indicate saturation kinetics, it was assumed that the reaction followed scheme 1 (E; SPT, S; 
L-serine, ES, and ES-, SPT-L-serine complex species, K1; L-serine binding to SPT, K2; 
external aldimine formation). 
K2 
K1 	k+2 
E+S4 ES, 4k-2 ES2 (1) 
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Figure 17: Kinetic Analysis of L-serine Binding 
(a) The change in absorbance at 425 nrn shows a hyperbolic dependency on L-serine concentration 
therefore L-serine concentration (0.5, 1, 2, 5, 10, 20, 40) was plotted against the change in absorbance 
at 425 nrn and K7 for external aldimine formation was estimated as 1.65 mM. (b) Rate constants for 
the formation of the external aldimine at increasing concentrations of L-serine (0. 1, 0.5, 1, 2, 5, 10, 15, 
25, 50 mM). All assays were carried out in 20mM KPhos pH 7.5. 150 mM NaCl, 1mM EDTA with 
20iM SPT. 
Kinetic parameters for L-serine binding were obtained by fitting the stopped flow data (Fig. 
17b) to equation 2: K I = 33.30 ± 4.48 mM, k = 220.70 ± 14.01 see1, k7 = 8.92 ± 1.71 
sec* These parameters differ from the published results by Ikushiro et al.: K1 = 53.9 ± 8.7 
mM, k7 = 1016.6 ± 68.2 s, k 2 = 32.6 + 11.251 (3). 
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k = IS] k+2 +k 2 	K2= 	K1  
app 	K1  +[S] 	 (2) 	 k+2+k2 	(3) 
K2 was calculated as 1.30 mM using equation 3 and is comparable with the experimental 
value (1.65 mM) obtained from steady-state spectroscopic analyses (Fig. 17a) and with that 
obtained by Ikushiro etal. (1.40 mM). 
The rate of external aldimine formation (k2) for, recombinant SPT-His6 is approximately 5-
fold slower (220.70 ± 14.01 sec-) than the untagged, recombinant enzyme isolated by 
Ikushiro etal. (1016.6 ± 68.2 s1), 
2.3.3 Confirmation of Product Identity 
To confirm that purified SPT was active in the production of 3-ketod1hydrosphingosine 
(KDS), a radioactive assay was developed. Purified holo-SPT was incubated with U-14C 
labelled L-serine and Paliitoyl-CoA. After incubation for 20 minutes at 37 °C, the lipids 
were extracted using chloroform: methanol (2:1, v/v). The aqueous (a) and organic (b) phases 
were separated and analysed by TLC, using a storage phosphor screen to detect radioactivity. 
14C labelled KDS was present in the organic phase (2) and absent, as expected, in the 
aqueous phase (1) (Fig. 18). 
Control experiments were also carried out as follows; SPT and palmitoyl-00A, SPT and L-
[U-14C] serine, L-[U-'4C] serine and palmitoyl-CoA (no SPT). In each experiment, no 
radioactivity was detected, by TLC, in the organic layer. 
To confirm that the radioactive product was KDS, a non-radioactive standard (Matreya) was 
also analysed by TLC (as described in Fig. 18) and detected with ninhydrin. The Rf was 
measured as 0.61 for the non-radioactive standard and 0.64 for 
14C_  labelled product 
suggesting that this radioactive spot corresponds to '4C-KDS. 
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Figure 18: TLC Analysis of KDS Formation 
(a) Autoradiographs showing that SPT (20 tiM) is active in the conversion of L-[U-'4C] serine (2mM, 
I85kBq/mL) and palmitoyl-00A (0.86mM) to KDS. 1: aqueous phase, 2: organic phase. (b) TLC of 
KDS standard (4 mM). KDS was detected with ninhydrin. Both TLCs were eluted with 
CHCI3:CH30H:NH40H (40:10:1). 
In an attempt to observe any turnover of the 14C-KDS product, the assay mixture from figure 
18a was incubated with a concentrated cell free extract from S. paucimobilis. The spot, 
suggested to be 14C-KDS (Fig. 19a), is no longer present after incubation with S. 
paucimobilis cell free extract. Instead, at least four new radioactive spots are observed (Fig. 
19b). The appearance of these new radioactive spots suggest that there are soluble enzymes, 
and perhaps additional substrates present, in the S. paucimobilis extract, which are capable of 
modifying KDS into new lipids. 
In addition to '4C-KDS formation (Fig. 19a), a radioactive spot is observed at the top of the 
TLC plate. This spot moves with the solvent front and, as yet, remains unidentified. 
Preliminary mass spectrometry analysis of this spot (carried out by Marine Raman) suggests 
that it may correspond to the KDS-PLP product external aldimine. As radioactivity from this 
spot is occasionally more intense than that for KDS, it is feasible to suggest that KDS-
product release may be a rate-limiting factor in the SPT reaction. 
The faint radioactive spot below KDS is currently uncharacterised however it has been 
observed during radioactivity assays carried out by Ikushiro et al. although no speculation 
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Figure 19: S. Paucimobilis Cell Free Extract Assay 
(a) A standard assay is carried out to obtain 14C-KDS (indicated by red box). 20 tM SPT, 2 mM L-[U-
"4c] serine 9250 Bq/0.250p.Ci and 1.6 mM palmitoyl CoA were incubated for 1 hour at 37 °C before 
the addition of concentrated S. paucimobilis cell free extract. (b) The assay mixture was incubated for 
a further hour, at 37 °C, with S. paucimobilis cell free extract. The lipids were extracted and analysed 
as mentioned previously (Fig. 18). 
2.4 Structural Biology of holo-SPT 
All crystallographic analyses and discussion in this thesis were carried out in collaboration 
with Dr L Carter, Dr K Johnson and Prof J Naismith at the SSPF facility, University of St. 
Andrews. The bioinformatic data, discussed in section 2.5, were processed by Dr I Overton 
and Prof G Barton (University of Dundee) as part of the SSPF collaboration (4). 
2.41 PLP-Internal Aldimine (holo-SPT) 
Since SPT was active in the production of KDS, structural studies were carried out in an 
attempt to gain information about enzyme mechanism. Firstly, crystals of the apo-form of 
SPT were obtained from co-crystallisation experiments with myriocin, however they were of 
poor diffractive quality, with the 'best" (highest diffracting) crystal only diffracting to 3.0 A. 
In light of this, conditions were optimized to obtain the holo-forni of the enzyme. SPT was 
crystallised in the presence of excess PLP and yellow crystals of holo-SPT were obtained, 
which diffracted to 1.30 A. Using a homology model generated from the 2-amino-3- 
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ketobutyrate CoA ligase (KBL) monomer structure (PDB code: 1FC4), molecular 
replacement was used to solve the holo-SPT structure. 
The first twenty N-terminal amino acids and the last nine C-terminal residues, including the 
histidine tag of SPT, are not visible in the electron density map hence the final model 
contains 391 of the 427 amino acids, from Arg22 to lle419 inclusive. The rest of the 1.30 A 
map is of a high quality and the PLP cofactor is clearly defined (Fig. 20). 
Figure 20: Density Maps of holo-SPT (1.30 A) 
(a) A 2fo-fc map is shown for Tyr123 at 1.0 sigma. (b) The internal aldimine bond between PLP and 
Lys265 is shown. The red density surrounding the PLP-Lys265 atoms is a 2fo-fc unbiased map 
contoured at 2 sigma and the blue density shows the 2fo-fc map of the refined structure contoured at I 
sigma. 
2.4.2 Structural Comparison of the AOS Family 
In common with the other members of the PLP-dependent enzyme superfamily, bacterial 
SPT is an intimate interlocked dimer. Both monomers of holo-SPT consist of three domains; 
N-terminal, central catalytic and C-terminal (Fig. 21). The N-terminal domain, of 
approximately 80 residues, is comprised of an a-helix followed by a three-stranded 
antiparallel 13-sheet. This is linked to a larger central catalytic domain composed of a seven-
stranded, mainly parallel, 13-sheet domain of approximately 200 residues where the active 
site lysine (Lys265) resides. The C-terminal domain is comprised of approximately 100 
amino acid residues which, make many interactions with residues from the N-terminal 
domain. 
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Figure 21: Overall Structure of the holo-SPT Homodimer 
One monomer is coloured with the N-terminal domain shown in red, the central catalytic domain in 
green, and the C-terminal domain in yellow. The second subunit is shown in blue. PLP in each 
monomer is shown purple. Magnesium ions are shown in orange and are thought to be buffer derived. 
The overall topology of SPT closely resembles that observed for structures of other members 
of the AOS family e.g. ALAS, KBL and AONS (Fig. 22). All of the structures have the same 
relative orientation of domains with the most obvious differences being observed in the 
orientation of the N-terminal helix and the position of loops connecting secondary structural 
elements remote from the active site (Fig. 23b). 
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AONS ALAS 
SPT 
Figure 22: Crystal Structures of the AOS Family 
The overall topology of AONS (PBD code: I DJE), ALAS (213WN), KBL (I FC4) and SPT (2JG2) are similar as each enzyme has the same 
relative orientation of domains. 







Figure 23: Structural Alignment of the AOS Family 
(a) Overlay of key conserved residues involved in cofactor binding: His234, His159, A1a160, SerI6I 
and Lys265 (S. paucirnobi/is SPT numbering). The SPT structure is shown in green, the AONS in 
orange, ALAS in purple and KBL in blue. (b) An overall alignment of the monomers (same colouring 
scheme as (a). 
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Figure 24: Sequence Based Structure Alignment of the AOS family. 
The structure-based sequence alignment of SPT. ALAS. KBL and AUNS. The conserved (His, Ala, Ser) motif is shown in pink, the conserved Asp residue which 
interacts with NI of PLP in turquoise, the conserved His involved in PLP binding is highlighted in green and the conserved active site Lys residue is shown in red. 
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2.4.3 The Co-factor Binding Site 
The co-factor binding site is composed of residues from both monomers. For example, the 
side-chain of Asn 100 from monomer B is located in close proximity to the backbone of 
Lys265 from monomer A providing further evidence of the inherent dimeric nature of SPT 
as a requirement for catalysis. Within the active site of SPT, PLP makes polar contacts with 
the side-chains of Asn138, Asp231, His234 and Thr262 and with the main chain residues 
Gly134 and Tyr135 (Fig. 25). Another important residue, His159, stacks above one face of 
the PLP ring. This residue is located at the beginning of a three-residue motif (HisI 59, 
Ala 1 60, Ser 161) that is strictly conserved throughout the -oxoamine synthase family (Fig. 
24). 
Other residues interact with the cofactor; the pyridinium nitrogen atom (N 1) and the oxygen 
atom ofAsp23l are 2.8 A apart, suggesting that this carboxylic acid group may stabilise the 
protonated pyridinium form of the PLP by salt bridge formation. This acidic residue is also 
conserved throughout the family (Fig. 24) and a similar interaction has been observed 
between the NI of PLP and the Asp204 residue of E. co/i AONS, the Asp214 of 
Rhodobacter capsulatus ALAS and the Asp2l 0 of E. co/i KBL (5-7). 
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Figure 25: Ligplot Representation of the PLP Binding Site 
This illustration shows the constellation of residues involved in cofactor binding. Llp265 refers to the 
PLP cofactor, covalently bound to the active site residue Lys265. (A) represents residues from 
monomer A. 
2.4.4 Palmitoyl-CoA Binding Site 
A complex of SPT with palm itoyl CoA could not be obtained during these studies, however 
the structure of the R. capsulat us holo-ALAS/succinyl-CoA complex (PDB code: 213WO) 
was used to predict potential binding sites for palmitoyl CoA (6). 
In the ALAS structure the density corresponding to the adenine part of the succinyl CoA is 
well defined. The base is bound within a hydrophobic pocket formed by a group of 
isoleucine residues on the surface of the enzyme. The adenine also makes a number of H-
bond contacts with serine side-chains and the 3'-phosphoribose moiety interacts with a lysine 
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residue. Density for the phosphopantethene arm of CoA was not observed in the ALAS 
structure but the carboxylate of the succinate makes contact with an arginine residue 
(Arg2l). A similar interaction has been observed in the AONS/AON-external aldimine 
structure where the carboxylate of the product also interacts directly with an arginine residue 
(Arg2 1) (8). 
Figure 26: Analysis of Coenzyme-A Thioester Binding 
(a) In purple, the space-fill structure of ALAS from R. capsulatus (213WO) with the succinyl-CoA 
substrate shown as a ball and stick. (b) In blue, a space-fill for the S. paucirnobilis SPT structure 
aligned to the ALAS structure (RMSD 2.2A), showing where the succinyl-CoA is positioned after the 
structural alignment. Black arrows highlight the two putative channels where the additional carbons of 
palmitoyl-00A may bind. (c) Shows an overlay of the ALAS and SPT space-fills, displaying how the 
first putative channel is foreshortened in the ALAS structure, possibly leading to specificity for 
succinyl-CoA. This specificity is mainly achieved by a rearrangement of the first helix, as shown 
circled by the dashed line, in (d). 
These interactions were used to superimpose the holo-SPT structure onto the ALAS structure 
in an attempt to define a palmitoyl-CoA binding site. Two long hydrophobic channels where 
the C6 chain of palmitoyl-00A could reside are illustrated in figure 26b. Since palmitoyl-
CoA lacks a terminal carboxylate, SPT is devoid of a salt-bridge anchor, which delineates 
the end of the channel in ALAS. 
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2.5 	Modelling of HSANI Mutations 
2.51 Sequence Analysis of Bacterial and Human SPT 
An update of the protein nomenclature arising from the sequencing of the human genorne 
has meant that LCBI is also known as SPTI and LC132 is known as SPT2. SPTland SPT2 
have been adopted for the analysis in this section. The S. paucimobilis SPT sequence 
(PubMed accession number AB055 142) can be aligned reasonably well to the human SPTI 
and SPT2 sequences (UniProt Primary accession numbers: 015269 and 015270 
respectively). This includes the putative transmenibrane sections of human SPTI/SPT2 
(residues 16-36 and 67-87, respectively) and the first ct-helix and first two 13 -strands of the 
bacterial structure. 
Mapping of the putative S. paucimohilis SPT active site residues to SPTI and SPT2 is shown 
in table 1 below. It is notable that many of the SPTI active site residues are markedly 
different to the bacterial and SPT2 residues. This suggests that substantial degradation of the 
ancestral active site may have taken place within the SPTI subunit. 
SPT SPTI SPT2 Suggested function 
Y73 F106 Y176 Hydrophobic interactions with K265 
G134 G167 G238 Interacts with phosphate of PLP 
Y135 F168 F239 Interacts with phosphate of PLP 
1-1159 Cl 92 H263 Stacks above pyridinium ring of PLP 
S161 A194 S265 Part of strictly conserved HAS motif 
D231 E274 D344 Makes polar contacts to NI of pyridinium ring 
A233 S276 A346 Hydrophobic interactions with PLP 
H234 L277 H347 Hydrogen bond to oxygen of pyridinium ring 
T262 N306 T376 Interacts with phosphate of PLP 
K265 N309 K379 Forms internal aldirnine with PLP 
G268 A3 12 G382 Hydrogen bond to backbone oxygen of Lys265 
T294 S338 A408 Interacts with phosphate of PLP 
A295 A339 A409 Interacts with phosphate of PUP 
Table 1: Potential Functions of Active Site Residues 
Active site residues were identified from the S. paucirnobilis SPT structure and the homology model 
for the wild-type human SPTI/SPT2 heterodimer. 
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Analysis of a number ofHSANI patients has revealed several mutations of the SPTI subunit 
e.g. C 133W, C133Y and V144D. These mutations cause alterations to SPT activity, resulting 
in a reduction of sphingolipid biosynthesis (9, 10). Currently, the role played by these 
mutations in HSANI remains unclear. 
The S. pauciniobilis SPT structure was used to make a homology model of the human 
SPT1/SPT2 heterodimer in order to examine the possible structural impacts of the HSAN I 
mutations. The alignment of SPTI and S. paucirnobilis SPT maps residues Cys133 and 
Val 144 of SPT 1 to residues Asn 100 and Asp 111 of S. pauciinobilis SPT (see fig. 7, section 
1.7.3 for alignment). Homology models for the human SPTI/SPT2 heterodimer, 
incorporating the C133W (SPTI) and V144D (SPTI) mutations, were built using the 
structure of the S. paucinobths holo-SPT as a template. 
2.5.2 Structural Impact of HSANI Mutations in S. paucimobilis 
Residue AsnlOO in the bacterial sequence maps to human SPTI residue Cys133 and is 
located in the S. pauciinobiiis holo-SPT structure at the dimer interface. More importantly, it 
is found in close proximity to the active site (Fig. 27). The amino group of the Asn 100 side-
chain (monomer B) is within 2.63 A of the backbone oxygen from the active site lysine 
residue (Lys265) of monomer A. Thus, it is reasonable to suggest that substitution of 
asparagine 100 by tryptophan or tyrosine will affect the active site geometry and perturb 
enzyme activity. Figure 27 shows the N 100W and NI OOY mutant models of S. paucimobilis 
SPT where the side chain of tryptophan is within 0.52 A and tyrosine 2.22 A of the backbone 
oxygen of Lys265. 





Figure 27: HSANI Models of S. paucimobilis SPT 
(a) The distance of  100 (monomer B) to the backbone carbonyl oxygen of Lys265 (monomer A) is 
2.63 A. (b) The N 100W mutant model highlights the close proximity of the tryptophan residue to the 
backbone of Lys265 (0.52 A). (c) The N I OOY mutant model shows tyrosine to be situated closer (2.22 
A) to Lys265 in comparison to the wild type asparagine residue (2.63 A). Monomer A is represented 
in green and monomer B in cyan. 
2.5.3 Structural Impact of Human HSANI Mutations 
Figure 28 shows homology models of the human C 133W and V144D mutations. These 
models provide insights into how mutations in the non-catalytic SPT1 subunit could affect 
the catalytically active SPT2 subunit and reduce SPT activity. The model for the C 133W 
mutant (Fig. 28b) shows a steric clash between W133 and the backbone carbonyl oxygen of 
Lys265, which is not observed in the 'wild-type" model (Fig. 28a). This suggests that the 
C 133W mutation directly perturbs the active site geometry, which could consequently affect 
enzyme activity. In addition, the mutant model suggests that W133 contacts residue T378 of 
the SPT2 active site and may also affect Y 176 via contact with N 177. 
Beverley Yard 	 Serine palmitoyltransferase 	 81 
The "wild-type" model reveals that V144 in cL-helix3 (1-13), packs together with several 
hydrophobic residues in cL-helix9 (H9) (Fig. 28d). It could be postulated that V144 is 
important in stabilising the packing of H3 and H9. Indeed, the models predict that the N-
terminal portion of H9 is composed of hydrophobic residues and interpretation of the V 144 
mutant model suggests that alterations to the H3-H9 packing may cause shifts in the 
neighbouring structure (Fig. 28c). The opposite face of 1-19 is seen to contact the C-terminal 
portion of a-helix 2 (1-12), which is predicted to be adjacent in space to the region of the 
active site containing SPT2 residues S380 and G382. Furthermore, the H2-H3 loop (SPTI 
residues 129-149) appears close to the cofactor and is the location of the pathogenic Cys 133 
mutations. It seems reasonable to suggest that movement of the H2 C-terminal region is 
likely to disturb the H2—l-13 loop thus affecting the active site. 
Figures 28c and 28d show that, despite being remote from the active site, the V144D 
mutation could conceivably disrupt the hydrogen bonding network and disturb the active site 
geometry by inducing rearrangements of H9, H3, H2, and the I-12-H3 loop. 
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In all panels the PLP cofactor is shown in orange. u-helix 2 (H2) in purple, u-helix 3 (H3) in cyan, and the H2—H3 loop in magenta. Unless otherwise specified, 
residue numberings refer to SPTI. (a) The "wild-type" model with C133 (red) close to, but not contacting the cofactor. The S atom of the C133 side-chain is 
closest to the phosphate oxygen of the PLP cofactor (van der Waals distance of 0.73 A to the PLP 02P). (b) The C 133W mutant model; the W133 (red) C3 and N 
atoms clash with the backbone carbonyl oxygen of Lys265 which binds the PLP cofactor. The W133 C3 has 0.65 A van der Waals overlap with the Lys265 
carbonyl oxygen. (c) The V144D mutant model; the Asp144 mutation appears to destabilise the H3-l-19 packing and is likely to cause shifts in the neighbouring 
structure. Pro343 (blue) is highlighted at the N terminus of H9 as disturbance of this, and other residues, by perturbations of the H3—H9---H2 interactions is 
Postulated to affect the H2—H3 loop (magenta). The C13  atom of the D144 side-chain is closest to the PLP cofactor (van der Waals distance of 14.1 A from the PLP 
02P). (d) The "wild type" model; Val 144 (red) packing with 11e350. Ala346 and A1a347 (all shown in yellow). These residues form part of u-helix 9 (1-19), shown 
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2.6 	Crystal Structure of the L-serine External Aldimine 
To obtain the SPT-L-serine external aldimine, holo-SPT crystals were soaked for in buffer 
containing L-serine. The highest diffractive quality crystal obtained, produced a dataset to 
1.5 A resolution. In the structure, the first twenty N-terminal amino acids and the last eight 
C-terminal residues, including the histidine tag, are not visible hence, the final model 
contains 392 of the 427 amino acids from Arg22 to G1y420 inclusive. Examination of the 
active site shows, as expected, that Lys265 has been displaced (3.87 A) from PLP by L-
serine to form the external aldimine. Since it is no longer bound to PLP. Lys265 is free and 
makes hydrogen bond contacts (2.95 A) with the hydroxyl of the L-serine side chain. 
Overall, there are no dramatic alterations to the dinieric structure of SPT. The main 
difference between the internal and external aldimine structures is the shift of a loop region 
within the C-terminal domain, by 5.37 A. This causes new hydrogen bond interactions to 
occur between Arg378 and the carboxylate group of L-serine (Fig. 29). This arginine is from 
the same monomer as the active site lysine residue. 
Figure 29: Structural Comparison of the Internal and External Aldimine 
A large shift (5.37 A) of a loop region within the C-terminal domain occurs during L-serine binding. 
This results in the formation of new hydrogen bond interactions between Arg378 and the carboxylate 
side group of L-serine. The internal aldimine is shown in red and the external in green/pink. 
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There do not appear to be any other significant movements among the constellation of 
residues within the active site. For example, the conserved histidine residues, His 159 and 
His234, remain in the similar positions. However, the orientation of the plane of the PLP 
ring has changed slightly; the N 1 nitrogen has moved by 1.09 A towards Lys265 (Fig. 30). 
I 
Figure 30: Overlay of the Internal and External Aldimine Active Sites 
The orientation of the pyridinium ring of PLP differs between the internal and external aldiniine 
structures by 1.09 A. Internal aldimine structure is shown in green and the external in red. 
It is interesting to note, that Arg378 of S. paucirnobilis SPT does not align with an arginine 
residue in SPT1 or SPT2. However, it does align with Arg349 of AONS from E. co/i and is 
located before the conserved PXXP motif found in the SPT and AONS sequences (PATP; 
SPT and PTVP; AONS). It has been noted by Webster and colleagues, that this motif forms 
a flexible loop in the AONS structure which moves by 5.5 A toward the C-terminal catalytic 
domain upon substrate binding. In particular, the threonine residue (Thr352) of this loop is 
mobile, providing contacts with the AON product (8). 
The PATP motif is conserved between S. pauciinobi/is SPT and human SPT2 however it is 
completely lost in the human SPT1 sequence, being replaced by the residues RSIA. Again, 
this highlights the dramatic differences between SPTI and SPT2, which result in the 
SPTI/SPT2 dimer having a single active site. It is also interesting to note that mutations in 
the SPT2 "PATP" motif destroy SPTI/SPT2 activity (Prof. Teresa Dunn, personal 
communication). 
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2.7 	Inhibition by Cycloserine 
2.7.1 Mechanisms of Inhibition 
The natural products, L-cycloserine (LCS) and D-cycloserine (DCS) are enantiomers of an 
interesting drug molecule that it used to treat MycohacIeriuin tuberculosis. The mechanisms 
of cycloserine inhibition of PLP-dependent enzymes (Fig. 31 and 32) have been studied 
previously (11-15). The first step involves displacement of the internal aldimine lysine 
residue, from the bob-enzyme, by cycloserine. The resultant external aldirnine commonly 
undergoes deprotonation to form a resonance stabilised ketimine adduct, 24 (see Fig. 31a). 
HN-O 
The structure of this non-covalently bound adduct has been determined by the crystallisation 
of cycloserine with the PLP-dependent enzymes ArnB aminotransferase and dialkylglycine 
decarboxylase, amongst others, and has been observed with both enantiomers of cycloserine 
(12, 14). 
Breakdown of the PLP-cycloserine ii-nine appears to occur by two distinct routes. The 
simplest is hydrolysis of the imine to give pyridoxamine 5'-phosphate (PMP. 26) and a 
ketoacid, 27 (pathway (a), Fig. 31) whereas the second involves participation of an enzyme 
derived nucleophile within the active site (pathway (b), Fig. 31). 
The second mechanism has been suggested by Rando as a result of his studies on alanine 
racemase (16). Isomerisation of the Schiff base occurs to form a ketimine intermediate, 25 as 
before, which is then followed by the nucleophilic attack of the cycloserine amide bond, 
possibly by an active site residue, to form a covalently bound adduct. Subsequent hydrolysis 
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yields PMP, 26 and an acylated enzyme adduct and further hydrolysis of the acyl-adduct 
may also occur to release a 3-ketoacid, from the enzyme. However, liquid chromatography-
mass spectrometry analysis of SPT after incubation with L-cycloserine showed that the 
molecular mass of the enzyme was unchanged, suggesting that if an enzyme bound adduct 
had formed it was easily hydrolysed. 
Another mechanism for the inhibition of SPT by L-cycloserine has been suggested by 
Ikushiro ci' al. and is shown in figure 32a (3). In comparison to the formation of the non-
covalent adduct, 25 discussed above, it has been suggested that after external aldimine 
formation, the L-cycloserine ring is hydrolysed to form a ring-opened intermediate, 28. It is 
suggested that this intermediate then rearranges via rapid ring closure and reopening to form 
an oxime intermediate, 29. In addition, the ring-opened species, 28 can undergo 1,3-proton 
transfer to form an unstable mime that is hydrolysed to form PMP, 26 and 3-
oxyaminopyruvate, 27. While these mechanistic theories are attractive, it is noteworthy that 
to date, no structural information has been published on L-cycloserine inhibition of SPT and 
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Figure 31: Hydrolysis Mechanisms for Cycloserine Inhibition: (a) Amino acid conversion proceeds via a ketimine intermediate, 25 which is 
subsequently hydrolysed to the corresponding 3-keto acid, and PMP, 26. (b) Cycloserine inhibition of alanine racemase (as proposed by Rando) involves an 
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Figure 32: Proposed Mechanisms of SPT Inhibition by L-cycloserine (3) 
L-cycloserine (LCS, 16) binds to SPT to form an external aldimine where the LCS ring remains intact. Subsequent hydrolysis, possibly enzyme catalysed due to the 
speed of the reaction, produces a species which absorbs at 328 nm. This species is postulated to be the ring opened intermediate, 28. This intermediate rearranges to 
form an oxime species. 29 with a Xlfla. of 380 nm. (a) The ring open intermediate can undergo 1,3-proton transfer to form an unstable imine that is susceptible to 
hydrolysis. The final step suggested by Ikushiro ci al. involves the slow hydrolysis of the unstable imine to form PMP 26, which can be observed spectroscopically 
at 332 nm and -oxyaminopyruvate, 27. (b) In contrast, the ring open intermediate may undergo decarboxylation before hydrolysis occurs, releasing PMP. 26 and 
3-oxyaminoacetaldehyde, 30. 
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2.7.2 Inhibition of SPT Activity by L-cycloserine 
Studies by Sundaram and Lev, and Williams ci al. have shown that L-cycloserine inhibits 
SPT activity. Radioactive assays were used to investigate the inhibition; Sundaram and Lev 
monitored the incorporation of DL-[3-'4C]serine into 3-ketosphinganine (KDS) by TLC and 
autoradiography and Williams el al. monitored the incorporation of water soluble 
[3  H]-serine
into chloroform soluble KDS (17, 18). In light of these studies, a radioactive assay was also 
used to observe L-cycloserine inhibition of S. pauciniobi!is SPT. The assay was carried out 
as previously described for holo-SPT (section 2.3.2) however, prior to incubation with L-[U- 
14C-]serine, SPT was incubated with L-cycloserine (1 mM). Figure 33 shows that KDS 
production is significantly decreased when SPT is pre-incubated with L-cycloserine. 
(a) 	 (b) 
Figure 33: Inhibition of KDS Production by L-cycloserine 
(a) Control assay: SPT (20 1iM), palmitoyl-00A (1.6 mM) and L-[U-14C-} serine (10 mM) were 
incubated for 1 hour at 37 OC. (b) Inhibition by L-cycloserine: SPT (20 PM), palmitoyl-00A (1.6 
mM) and 1 mM L-cycloserine were incubated for 1 hour at 37 OC after which L4U-14C-j serine (10 
mM) was added and incubated for a further hour. Arrows indicate the presence of KDS. 
It is relevant to note, that a large radioactive spot is observed at the top of the TLC plate as 
seen in previously in figure 19. In addition to the inhibition of KDS formation, this spot is 
also missing from the post-inhibition TLC. This would make it feasible to suggest that 
formation of the unidentified radioactive spot is SPT-dependent. 
It is also relevant that S. pauciniobi!is growth was inhibited in a dose-dependent manner 
when incubated with L-cycloserine (Fig. 34). It seems likely that interruption of sphingohipid 
biosynthesis, by inhibition of SPT, has an adverse effect on cell growth. Sphingohipids have 
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been shown to be essential components of the eukaryotic plasma membrane and, although 
they are not present in most bacteria, may be important in stabilisation of the membrane 
structure in S. paucimobilis (19, 20). It should be noted that cycloserine may also inhibit 
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Figure 34: L-cycloserine Inhibition of S. paucimobilis Growth 
S. paucimohilis were grown overnight at 37°C in LB broth before being diluted to an OD(,QQ of 0.4 in 
LB containing L-cycloserine (0.5, 1, 5 and 10 mM). Cells were incubated at 37 °C for a further 4 
hours and the 0D600  recorded. It was observed that the cell density decreased as the concentration of 
L-cycloserine increased. 
2.7.3 Spectroscopic and Crystallographic Analyses of L-cycloserine 
Inhibition 
Manohar and co-workers have shown that, upon binding of D-cycloserine to serine 
hydroxymethyl transferase, there is an immediate decrease in absorbance at 425 nm with the 
appearance of a shoulder at 330 rim. This reaction appears to proceed via a transient 
intermediate which absorbs at 340 n -n. It has been suggested that this is the tetrahedral 
intermediate adduct between the internal and external aldimines (21). L-cycloserine 
inhibition of ArnB amino transferase results in loss of the internal aldimine peak at 430 nm 
and the appearance of a new species at 334 nm (14). Reaction of D-cycloserine with this 
enzyme is extremely rapid and irreversible. 
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Spectroscopic analysis of L-cycioserine binding to SPT shows complex changes in the UV 
visible spectra (Fig. 35). Approximately 20 seconds after the addition of L-cycloserine, there 
is a decrease in absorbance at 425 nm and consequently, the characteristic yellow appearance 
of SPT is lost. It is reasonable to imply that this decrease at 425 nm results from the loss of 
conjugation within the PLP molecule. It might also be suggested that disappearance of the 
internal aldiniine and formation of two new species absorbing at 328 and 380 nm 
respectively, could be responsible for the loss in colour. Over approximately 24 hours, both 
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Figure 35: UV visible Spectral Analysis of SPT Inhibition by L-cycloserine 
Blue; holo-SPT (20 1iM), magenta; 5 seconds after addition of LCS (1 mM) there is rapid 
disappearance of the internal aldimine, can; 10 seconds after addition, 	; 20 seconds after 
addition, iHe; 30 seconds - 30 minutes after incubation there is formation of two species which have 
absorbance maxima of 328 and 380 nm, green; 20 hours after addition of LCS there is formation of a 
new species which absorbs at 332 nm. The assay was carried out in 20 mM KPhos pH 7.5, 150 mM 
NaCl, ImMEDTA. 
Since D-cycloserine (DCS) is a rigid analogue of D-alanine, it is known to target a/.alline 
racernase. In the crystal structure of the DCS-inhibited enzyme the density at the active site 
is consistent with a planar cycloserine ring and a saturated, hybridised C4' of PLP. in the 
structure of tile L-cycioserine inhibited enzyme, it is unclear from the density whether the 
ring is planar, however it has been suggested that an aromatic 3-hydroxyisoxazole-PMP 
adduct (tautomer of 24) may be formed (22). It is also worthy to note that in tile crystal 
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structure of DCS inhibited D-arnino acid amino transferase there are no covalent interactions 
between the DCS and the enzyme. Instead, the intact cycloserine ring tautomerises to form a 
stable, cyclic adduct with PLP. As there are no covalent interactions between the enzyme 
and PLP-inhibitor adduct, D-amino acid amino transferase could be reactivated slowly by 
dialysis against PLP (15). 
SPT displayed similar behaviour after incubation with L-cycloserine, as Liquid 
chromatography-mass spectrometry (LC-MS) analysis of SPT after dialysis against PLP 
suggested no covalent modifications had taken place within the enzyme. 
Holo-SPT, obtained from the dialysis experiment, was re-incubated with L-cycloserine and 
UV-visible spectra were recorded (Fig. 36). The characteristic decrease at 425 nm, upon 
addition of L-cycloserine and concomitant increases in absorbance at 380 and 330 nm 
0 
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Figure 36: UV Visible Spectrum After Incubation of "Re-loaded" SPT with L- 
cycloserine 
SPT (20 jiM) was incubated with L-cycloserine (1 mM) and the UV-visible spectra recorded over 15 
minutes. The characteristic decrease in absorbance at 425 nm is observed together with the appearance 
of two new peaks at 330 and 380 nm. The magenta line represents reloaded SPT (20 jiM). 
The UV-visible spectra of SPT, before incubation with L-cycloserine, and after dialysis 
against PLP, were overlaid (Fig. 37). Even after incubation with L-cycloserine, gel filtration 
and dialysis, SPT still exhibited the same spectroscopic properties as the original purified 
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Figure 37: UV-Visible Spectra of SPT Before and After Inhibition With L- 
cycloserine 
Overlay of holo-SPT (20 tM) before incubation with L-cycloserine (bold line) and holo-SPT (10 ttM) 
after gel filtration and dialysis against PLP (dotted line). 
2.7.4 Breakdown of L-cycloserine 
In an attempt to identify the intermediate(s) formed during the breakdown of L-cycloserine 
(LCS), SPT (after incubation with LCS) was denatured with urea and the UV-visible spectra 
of the solution were recorded over a four hour period (Fig. 38). Initially, a shift in 
absorbance is observed from 425 to 400 nrn. This could result from the presence of the LCS 
external aldimine where the LCS ring is still intact. In addition, there is the appearance of a 
new species with an absorbance maximum at 328 n -n. The appearance of this peak is 
accompanied by a decrease in absorbance at 400 nm. It is reasonable to suggest that the 
decrease at 400 nm results from hydrolysis of the LCS ring to form a ring-opened L-
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Figure 38: UV-Visible Spectra of a Solution Containing L-cycloserine After 
Denaturation of SPT 
SPT (20 jtM) was incubated with L-cycloserine (1 mM) and the protein denatured with Urea 
(final concentration 4 M). UV visible spectra were recorded 15, 20, 30, 40, 60, 120 and 240 
minutes after denaturation. A new species was detected in solution at 328 nrn. Bold line: 
holo-SPT, dotted lines: formation of a species which absorbs at 328 urn. 
SPT was also incubated with O-methyl-DL-serine, a structural analogue of the hydrolysed L-
cycloserine-PLP intermediate. After denaturation of SPT, the UV-visible spectra were 
recorded. As no visible changes were observed after 10 minutes the solution was incubated 
further and the UV-visible spectrum was recorded after 24 hours. During this time a new 
species, which could be the O-methyl—DL-serine-PIP external aldimine 31, was observed 
with an absorbance maximum at 328 nrn (Fig. 39). 
Figure 39: UV-Visible Profile of Solution Containing O-methyl-DL-serine After 
Denaturation of SPT 
SPT (20 tM) was incubated with O-Me-DL-serine (10 mM) and the UV visible spectra recorded after 
5, 60. 300, 600 seconds and 24 hours. The species remaining in solution after denaturation of SPT also 
absorbs at 328 urn. The bold line represents holo-SPT and the dotted lines the formation of the 0-Me-
DL-serine-PLP external aldimine, 31. 
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2.7.5 Crystal Structure of SPT and L-cycloserine 
In an attempt to obtain the structure of L-cycloserine inhibited SPT, the protein was co-
crystallised in the presence of 1 mM L-cycloserine. Colourless crystals were obtained and 
data was collected on the highest diffractive quality crystal to 1.45 A resolution. Refinement 
of the data showed that two L-cycloserine hydrolysis products were bound at the active site 
(Fig. 40a). The electron density of one of these products was sufficiently defined to identify 
it as pyridoxamine 5'-phosphate, PMP. It is apparent that the active site lysine (Lys265) is 
retracted away from the pyridine ring of PMP in a manner similar to that seen in the L-serine 
external aldimine structure. 
The highly conserved residue Hisl59, which forms part of the HAS motif conserved 
amongst the AOS family, remains stacked above the pyridine ring of PMP as seen in the 
holo-SPT and L-serine external aldimine structures (Fig. 40b). As with holo-SPT (see table 
1, section 2.5.1) Thr262 (monomer A), Ser264 (monomer A) and T111-294 (monomer B) 
provide hydrogen bond contacts to the phosphate of PMP and His234 also remains in a 
similar position, providing hydrogen bond contacts to the oxygen of PMP. 
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Figure 40: Electron Density Showing the L-cycloserine Hydrolysis Products 
Within the Active Site of SPT 
(a) Two hydrolysis products were observed at the active site of SPT after co-crystallisation with L-
cycloserine (1 mM). One of these products has been identified as PMP. The active site lysine 
(Lys265) is retracted away from the pyridine ring of PMP. (b) The highly conserved histidine residue 
(His 159) remains stacked above the pyridine ring of PMP. In addition, Thr262(A), Ser264(A) and 
Thr294(B) provide hydrogen bond contacts to the phosphate of PMP, as seen in the holo-SPT and L-
serine external aldimine structures. 
The density representing the additional LCS-hydrolysis product shown in figure 40, 
orthogonal to the plane of the PMP ring, is ambiguous and it is difficult to ascertain what this 
density represents. It appears to be too short to be 3-oxyarninopyruvate and therefore may 
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correspond to a truncated species. It is feasible to suggest that this truncated species is the 
decarboxylated 13-ketoacid derivative f3-oxyaminoacetaldeliyde, 30 as SPT is a 
decarboxylating enzyme (Fig. 32b, section 2.7.1). In fact, Ser264 is located at one end of this 
density suggesting that it may be providing hydrogen bond contacts, possibly with an amino 
group, of the small molecule. In contrast, His159 is located at the opposite end of the 
electron density and it could be suggested that this may provide a docking site for the 
carboxylate (aldehyde) group of the small molecule. 
2.8 Conclusions 
The holo-SPT and L-serine external aldimine structures are the first to be solved of a SPT 
from any organism. In addition to the crystal structures, bioinformatic analysis of bacterial 
and human SPT has not only provided insight into enzyme function but also how mutations 
may affect enzyme behaviour e.g. mutations associated with hereditary sensory and 
autonomic neuropathy type I (HSAN 1). The crystal structure of L-cycloserine inhibited SPT 
has opened a gateway for the analysis of inhibition and although the mechanism for 
cycloserine inhibition of PLP-dependent enzymes is hypothesised in many publications, a 
specific mechanism for the inhibition of SPT remains unclear (15-18, 24, 25). Many 
experiments are therefore required in order to confirm the identity of reaction intermediates 
and hence solve the mechanism of L-cycloserine inhibition. 
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Chapter 3: Inositol Phosphorylceramide Synthase 
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31 	Production of Recombinant Aurl p 
Previous attempts to obtain soluble, active Inositol Phosphorylceramide Synthase (Aurlp) 
were carried out by Dr. Rachel Breen (2005, PhD Thesis, University of Edinburgh). These 
included cloning AURJ with 6-hisitidine and GST tags for expression and purification in E. 
coil. In summary, both methods were unsuccessful due to the toxicity of AURI to E. coil. 
Hence, insoluble inclusion bodies were formed. Isolation and refolding of insoluble Aurip 
was not attempted and since E. coil also lack the appropriate post-translational modification 
machinery found in eukaryotic organisms, this expression system was not optimised further. 
Instead, the eukaryotic host Pichia pasloris and the expression vector pPlCZctA were used. 
This produced a His6 tagged Aurlp with a c-myc tag for Western blot detection and an ct-
signal sequence for secretion into the media (Fig. 41). 
6His 
Figure 41: Recombinant AURI gene constructed in pPICZaA 
AURJ was cloned into the expression vector pPICZuA. This produced a C-terminally tagged Aurip 
construct which contained an a-signal sequence for secretion into the media. 
Positive P. pastoris transformants were selected using the antibiotic zeocin (100 tgImL) 
however this is a relatively expensive method of selection in comparison to ampicillin and 
kanamycin used for the selection of bacterial transformants. Induction of recombinant A URJ 
expression was carried out using methanol due to the presence of the AOXJ promoter. Since 
AOXJ is tightly regulated at the transcriptional level, the presence of glucose represses 
transcription even in the presence of methanol. As a result, P. pasloris cells had to be grown 
in glucose-free media. Induction of pPICZaAAUR1 expression was a lengthy procedure 
lasting four days and required the addition of methanol every 24 hours to compensate for 
metabolism and evaporation. Limited information was obtained from analysis of the media 
as both the cells containing pPICZaAAURJ and the controls appeared to exhibit Aurip 
activity. As a result, an extensive library of constructs was created in an attempt to obtain 
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over-expression of AURJ. These clones included truncated and full-length forms of AUR] 
from S. cerevisiae and B. cinerea. The clone taken forward as the best candidate for further 
investigation in this thesis (by personal communication with Dr Breen) was 
pPICZA URlScKozak. 
Ni-NTA purification of Aurlp-His6 was carried out from the cell free extract of P. pasloris 
containing pPICZAURIScKozak. SDS-PAGE analysis of the Ni-NTA elution fraction 
produced 4 bands consistent with previous purifications carried out by Dr Breen (Fig. 42). 
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Figure 42: SDS Analysis After Ni-NTA Purification of Aurl p-His6 
(a) Ni-NTA elutions of Aurip constructs, carried out by Dr Breen. The Ni-NTA elution of 
pplCZaurlScKozak is highlighted (b) SDS analysis of Ni-NTA purification carried out during these 
studies. 1; flow through from load onto Ni-NTA column, 2; wash (5 mM irnidazole), 3; elution (500 
mM iniidazole). The Ni-NTA elution is highlighted. SeeBlue plus2 pre-stained marker (lnvitrogeii) 
was used for both gels. 
The bands highlighted in figure 42b were subjected to proteolytic digest with trypsin and the 
fragments analysed by Matrix Associated Laser Desorption lonisation Time of Flight 
(MALDI-ToF) mass spectrometry in an attempt to identify Aurip. Unfortunately, no 
conclusive data was obtained from this experiment. As it remained unclear if these bands 
corresponded to Aurl p and its aggregates/degradation products, an alternative expression 
strategy was required to obtain Aurip for structural studies. 
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3.2 	TAP-tagged Aurl p from S. cerevisiae 
32.1 Cloning of pKW804AURI 
This approach involved tagging AURIp with a Tandem Affinity Purification (TAP) tag 
using homologous recombination, which allowed the insertion of a gene encoding tagged 
Aurl p into the chromosome of S. cerevisiae thus replacing the wild type gene. For this to 
occur, the C-terminus (3' end) ofAURI had to be cloned to include DNA encoding the TAP 
tag. This was carried out using the pKW804 binding cassette which is identical to the 
pFA6a-GFP-kanMX6 cassette developed by Longtine et al. except for the GFP moiety, 
which has been replaced by the ZZ-TEV-S tandem affinity tag via the restriction sites 
Paci/Asci (Fig. 43) (1). 
(




Figure 43: pKW804 Binding Cassette 
The ZZ-TEV-S region encodes an affinity tag that is comprised of a ZZ domain containing 
two IgG binding domains from Staphylococcus aureus, a TEV protease cleavage site and an 
S peptide. The tag also confers resistance to the arninoglycoside anti-biotic G418. 
Once the ZZ-TEV-S sequence had been incorporated onto the 3'-end ofAURJ, the DNA was 
used to transform the S. cerevisiae strain J13811 (the genetically modified JB8I I cells were 
renamed JB8I IBY). This strain was selected as it is protease deficient thus it was hoped 
that the degradation of Aurip during purification would be prevented. The presence of G418 
resistance provided a cheaper method of selection in comparison to zeocin resistance as 
discussed above. However, the over-expression of AURJ-ZZ-TEV-S was unattainable due to 
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the lack of an inducible promoter sequence. Identification of positive transformants was 
achieved by PCR using transformed S. cerevisiae JB8I 1_BY genomic DNA as a template 
and primers specific forAURl-ZZ-TEV-S (section 4.2.1.2). The forward primer (AUR1 TAP 
for) was designed to bind to the N-terminus of wild type A URJ as no modifications had been 
made to the 5' -end of the gene. In contrast, the reverse primer (AURI TAP rev) was specific 
to the ZZ-TEV-S tag-encoding region and consequently only bound to the 3 -end of 
recombinant A UR]. A single band of 3573 bp, corresponding to A URI-ZZ-TEV-S (Fig. 44). 
Figure 44: PCR of S. cerevisiae (JB8I 1_BY) Genomic Preparation 
Lane 1; negative control, 2; AUR/-ZZ-TEV--S, M; Hyperladder 1 (New England Biolabs). A band is 
observed in lane 2 at approximately 3.5 kbp which corresponds to the ALJRI-ZZ-TEV-S PCR product. 
3.2.2 Purification of Recombinant TAP-tagged Aurip 
A small-scale preparation (1 litre) was achieved using JB811BY cells containing AUR1-ZZ-
TEV-S. An IgG "pull down" with IgG sepharose (Amersharn) was used in the first 
purification step of Aurlp-ZZ-TEV-S from the JB811BY cell free extract. Samples were 
collected at each step of purification for analysis by SDS-PAGE (Fig. 45a) and Western blot 
(Fig. 45b) using peroxidase anti-peroxidase (PAP) antibodies which bind specifically to the 
ZZ region of the affinity tag. Similar to the results obtained by Ni-NTA purification of His-
tagged Aurip, four bands were observed by SDS-PAGE and Western blot after IgG 
sepharose purification (lanes 6 and 7, Fig. 45). These bands were analysed by MALDI-ToF 
mass spectrometry however, again, no conclusive evidence was obtained which allowed 
them to be assigned as Aurip and/or its aggregation/degradation products. 
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Figure 45: SOS-PAGE and Western Blot Analysis of IgG Sepharose 
Purification 
(a) SDS PAGE analysis of lgG purification. Lane 1; negative control (JB8I I CFE), 2; cell free extract 
before incubation with lgG, 3; supernatant (sin) after centrifugation, 4; s/n after wash, 5; lgG 
sepahrose after wash, 6; s/n after incubation with TEV protease, 7; lgG sepharose after incubation 
with TEV protease. (b) Western Blot using peroxidase anti-peroxidase (PAP) antibodies. Lanes are 
the same as (a). M; SeeBlue plus2 pre-stained marker (Invitrogen). 
The predicted molecular weight of AurlpZZ-TEV-S is 61,502 Da. A band below 64 kDa is 
observed in lanes 6 and 7 (Fig. 45a and 45b) and may correspond to AurlpZZ-TEV-S. 
However, there are additional bands with higher and lower molecular weights suggesting the 
presence of modified/degraded forms of Aurl p-ZZ-TEV-S. This evidence suggests that 
although a protease deficient strain and protease inhibitors were used during purification, 
Aurl p-ZZ-TEV-S has still become truncated in some way. Since no mass spectrometry data 
could be obtained, it is difficult to assign the identity of the proteins in these bands. In 
addition, the bands obtained after lgG purification do not correlate to previous purification of 
pPICZcLAAurI p by Ni-NTA chromatography thus highlighting the difficulties of purifying 
Aurip to homogeneity (Fig. 46). In light of this, another method was required to obtain pure, 
recombinant Aurlp. 
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Figure 46: Comparison of pPlCZaAAurlp and AURI-ZZ-TEV-S Purifications 
(a) Ni-NTA purification of pPlCZaAAurlp. Lane 1; Ni-NTA elution. (b) IgG sepharose purification 
of Aurlp-ZZ-TEV-S. Lane 7; lgG sepharose after TEV protease cleavage. M SeeBlue plus2 pre-
stained marker (lnvitrogen). 
3.3 	Production of a C-Terminal H1s6-tagged Aurl p from 
S. cerevisiae 
3.3.1 Manipulation of pAURI23 
In contrast to ZZ-TEV-S (TAP) tagged Aurlp, attempts were made to obtain a histidine 
tagged Aurip (Aurlp-1-liso) in S. cerevisiae. Although this had failed previously in E. co/i, S. 
cerevisiae was used with the rationale that this would be a more suitable host since it already 
contains a copy of wild-type AURJ. Initially, AURI-C was cloned, by PCR, from the 
pAURI23 expression vector and inserted into pGEM. The pAURI23 expression vector is a 
non-integrating episomal plasmid that can be used to transform both E. co/i and S. cerevisiae 
(Fig. 47). Sequencing of the AURI-C gene in pGEM identified two point mutations, FI58Y 
and A240C which are responsible for resistance to aureobasidin A (AbA). To confirm this, 
pAURI23 was used to transform the S. cerevisiae strains W303 and JB8I 1, which were 
subsequently tested, together with wild type cells, on YPD agar containing AbA. Wild type 
JB8I I and W303 cells did not grow in the presence of AbA however the growth of those 
cells transformed with pAUR 123 was not affected. 
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Although there is an effective selection procedure for pAURI23, the over-expression of 
A URI-C is not possible, nor are there any specific methods for the purification and detection 
of AurI-C protein. In light of this, attempts were made to tag Aurl-C protein with a histidine 
tag however, after extensive amounts of cloning, codons encoding only three histidine 
residues were added successfully onto the 3'-end of AURI-C and this method was not 
optirn ised further. 
71. 




Figure 47: pAURI23 Expression Vector 
aur-C; AbA resistance gene in S. cerevisiae, ARS; replication origin in S. cerevisiae, CEN; 
centromere in S. cerevisiae, AmpR; selective marker in E. co/i, Ori replication origin in E. 
co/i, PADHI; promoter of ADI-ll gene. 
3.3.2 Cloning of AURI-C-His6 using pYES2ICTILacZ 
As numerous attempts to obtain histidine-tagged AURI-C were unsuccessful, AURJ-C was 
cloned with a 3'- XhoI restriction site to allow the gene to be excised from the pAURI23 
plasmid. The AURJ-C gene was excised from pAURI23 (HindllltXhol) and subsequently 
cloned into pGEM. Sequencing of pGEMAURJ-C confirmed the presence of the point 
mutations F158Y and A240C therefore the gene could still be selected for using AbA. After 
sequencing, AUR]-C was excised from pGEM (HindlIl/XhoI) and ligated into 
pYES2/CT/LacZ to produce pYES2/CT/A URI-C (Fig. 48). 
The pYESTM vector (Invitrogen) has similar properties to the pAUR 123 vector (Takara) as it 
is a shuttle vector which allows cloning in E. co/i and expression in yeast. However, pYES 
contains the GALl promoter for protein over-expression in S. cerevisiae and also encodes a 
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C-terminal 6-histidine tag, followed by a V5-epitope, to allow purification by Ni-NTA 
chromatography and detection with anti-V5 antibodies. It also contains the URA3 selection 
marker for selection of positive transformants with —uracil minimal media. 
INVSc 1 cells (S. cerevisiae auxotrophic for uracil) were used for the transformation with 
pYES2ICT/A URJ-C and positive transformants were selected for on —uracil minimal media 
agar. Galactose was added to the agar to induce expression of AURJ-C and the resistance 
conferred by Aurip to AbA, provided an additional selection procedure for the identification 
of positive traiisforinants 
HindIII (502) 
( 	 _________________________________ 	 / 	Born HI (679) a _____________ / 
5881 bp 	
EcQRI (948) 
1227 bp pYES2/C17AIJRI -C 	- XhoI (1729) 
Figure 48: Cloning of pYES2ICTIAURI-C 
(a) Restriction digest of 1: pYES2/CT/LacZ and I. pGEMaurJ-C with Hi,uIIII and XIioI produced 
bands corresponding to the pYES2/CT plasiiud (5881 bp) and aurl-( (1227 bp). (b) The digested 
A URI-C gene was ligated into pYES2/CT using the Him/lULl/wi restriction sites to give 
pYES2/CTL1 (Ri-C. 
3.3.3 Selection for Aurl -C-His6 With Aureobasidin A 
S. cerevisiae INVSc1 cells, were tested for their sensitivity to AbA and were killed at a 
concentration of 1 .tg/mL. These cells were transformed with pYES2/CT/LacZ (negative 
control) and pYES2/CT/AURJ-C before being spread onto —uracil minimal agar containing 
2% galactose and 1 g/mL AbA. Cells transformed with pYES2ICT/AURJ-C grew in the 
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Figure 49: Selection for Aurl -C His6 Using Aureobasidin A 
S. cerevisiae containing pYES2/CT/LacZ did not grow on minimal agar containing Aureobasidin 
A (AbA). However cells containing pYES2ICTIA URI-C were stable in the presence of 1 jtg/mL AbA. 
Microtitre plates containing ten fold dilutions of transformed S. cerevisiae overnight cultures were 
spotted onto minimal agar containing 2% galactose with and without AbA. The cells expressing aurl-
C grew in the presence of AbA. 
Small-scale induction of pYES2/CTIAURJ-C expression was carried out over a 12 hour 
period using 2% galactose and samples were taken at 2 hour intervals for analysis by 
Western blot. Expression of Aur 1-C-His6 was observed after 2-4 hours of induction however 
significant expression was obtained after 8-12 hours. Since the level of Aurl-C-His6 
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expression after 12 hours was not significantly more than after 8, an induction time of 8 
hours was chosen (Fig. 50). 
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Figure 50: Galactose Induction of pYES2ICTIAURI-C 
(a) Detection of Aurl-C-His6 with anti-V5 antibodies. (b) Detection of Aurl-C His6 with anti-C- 
terminal 6 His antibodies. Samples were taken after 8, 10 and 12 hours of induction at 30°C. T0 
before induction, Tm after induction. 
3.3.4 Detection of Aurl -C-His6 by Western Blot 
Detection of Aurl -C-His6  expression was carried out using anti-V5 (1:1000) and anti-C-
terminal 6His (1:5000) antibodies. Both antibodies detected a band at approximately 40 kDa, 
however the predicted molecular weight of Aurl-C-His6 is 48,694 Da suggesting that post-
translational modification could have taken place e.g. the cleavage of an N-terminal signal 
sequence. An additional band at approximately 75 kDa is observed by anti-VS detection 
(Fig. 50a). The smear observed above 75 kDa is indicative of glycosylation, often observed 
during analysis of eukaryotic proteins. To test the specificity of the anti-VS antibody the 
LacZ protein (expressed from the pYES2/CT/LacZ plasmid) was used as a control. Analysis 
of an INVScI cell free extract detected a band between 75 and 160 kDa (Fig. 51) and 
corresponds to the predicted molecular weight of the LacZ protein (119,678 Da). 
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Figure 51: Detection of Aurl -C-His6 From a S. cerevisiae Cell Free Extract 
Anti-VS detection ofpYES2/CT/ALJR/-C and pYES2/CT/LacZ from an INVScI cell free extract after 
8, 10 and 12 hours of induction. 
3.3.5 Isolation and Purification of Aurl-C-His6 
As Aurl p is an integral membrane protein of the Golgi apparatus, isolation of soluble 
microsomal protein has previously been problematic. Encouraged by the expression 
observed from the pYES2ICT/AURJ-C construct it was decided to increase the scale of 
induction from I to 10 litres and attempt to isolate soluble, recombinant Aurl p. After 
mechanical disruption of INVScI cells expressing pYES2ICT/AURI-C, the cell free extract 
was centrifuged as described by Ko et al. (2). Firstly, the rnitochondrial fraction was 
removed and secondly the microsomal fraction was obtained. The microsomal fraction was 
subsequently solubilised using the non-ionic detergent Triton X-100 as this had been shown 
by Aced et al. to retain Inositol Phosphoiylceramide Synthase activity (3). The solubilsed 
fraction was incubated with Ni-NTA agarose and soluble, recombinant Aurip was eluted 
using imidazole (300 mM). 
All wash and elution fractions from the purification were analysed by SDS-PAGE and 
Western blot using anti-VS antibodies (Fig. 52). A single band was observed at 
approximately 40 kDa in both the solubilised microsomal fraction (lane 6) and the Ni-NTA 
elution fractions (lanes 10-13). 
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Although this result is promising, it can be seen from figure 52 (lanes 2-5) that most of the 
recombinant Aurl p protein remained in the insoluble, membrane fractions suggesting that 
further optimisation of the solubilisation procedure is required. Furthermore, recombinant 
Aurl p could not be detected by Coornassie staining suggesting that the isolated yield was 
very low. 
1 2 3 4 5 6 789 10 11 12 13 14 
Figure 52: Detection of Aurl -C-His6 After Ni-NTA Purification 
Anti-VS Western blot detection of Aurl-C-His6 after Ni-NTA purification. Lane 1; marker, 2; blank, 
3; cell debris, 4; cell free extract, 5; insoluble fraction, 6; solubilised microsornes, 7; 5 mM irnidazole 
wash, 8; 20 mM imidazole wash, 9-14; 300 mM imidazole elutions. The marker is indicated by the 
green lines and represents the following molecular weights, in descending order, from the top of the 
gel; 250, 160, 105, 75, 50, 35, 30, 25 kDa. 
3.4 Conclusions 
After numerous attempts to obtain recombinantly tagged Aurip protein (N-terminal 
6HisAurlp, TAP-tagged Aurip, C-terminal AurIpHisa), pure, soluble protein was acheived 
using the pYES2/CT expression vector. This allowed the galactose induced over-expression 
of a C-terminal His6  tagged Aurip which could be purified, in one step, by Ni-NTA 
chromatography. The presence of a V5-epitope, located before the His6 tag, allowed the 
detection of Aurl-C-His6  by Western blot. Optimisation of the Western blot procedure for 
detection of Aurl-C-His6  was beneficial as the low yields of protein, obtained from Ni-NTA 
purification, were not visible by Coomassie staining. Both aims outlined in section 1 .10 have 
been successfully achieved and will now allow future work to focus on methods to increase 
the yield of protein to facilitate biochemical and structural studies. 
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Chapter 4: Materials and Methods 
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4.1 MATERIALS 
All reagents, chemicals and media were purchased from either Sigma, Aldrich, Fisher, 
Biorad, Pharmacia or Oxoid unless otherwise stated and all primers were purchased from 
Sigma Genosys. All competent cells and pET plasmids were purchased from Novagen and 
all chromatography columns were from GE Healthcare unless otherwise indicated. The 
pETI 6bSPT plasmid was constructed in the lab, prior to this work, by Dr Rachel Breen. The 
pAURI23 plasmid was purchased from TaKaRa Bio. Inc. via Cambrex Bioscience 
Wokingham Ltd., the pYES2/CT/LacZ plasmid and lNVScl strain were purchased from 
Invitrogen and the pKW804 and pFA6a-TRPI-pGALI plasmids, together with the S. 
cerevisiae strains W303 and J138I I were gifted by Dr Kevin Hardwick, Wellcome Trust 
Centre for Cell Biology, University of Edinburgh. 
4.1.1 Competent E. coil Cell Lines 
Table 2 
Species Cell line Genotype Application 
E. co/i 131-2 I DE3 F ompT hsdS B  (FB ma) gal dcm Transformation, 
(Novagen) (DE3) expression host. 
E. co/i DH5aTM F p80d/acZAM 15 A(/ac2YA- Transformation, plasmid 
(Invitrogen) argF) U169 recAl endAl hsdRl7 storage. 
(rK , mK)  phoA supE442 thi- I 
gyrA96 re/Al 
E. co/i HMS 174 DU F recAl hsdR (rK12, rnK2) Transformation, 
(Novagen) (DE3) (RIFR) expression host. 
E. co/i One Shot 	Top F rncrA A(mrr-hsdRMS-mcrBC) Transformation of 
10 980/acZAMI5 A/acx74 recAl ligations, plasmid 
(Invitrogen) araA 139 A(ara-ieu)7697 ga/U storage. 
ga/K rpsL (StrR)  endA 1 nupG 
E. co/i JM 109 endA 1, 	recA 1, 	gyrA96. 	thi. Transformation of 
(Prornega) hsdRI7 (rk , mc),  re/Al, supE44. ligations. plasmid 
A( 	lac-proAB), 	[F' 	traD36, storage. 
proAB, /aqiZAM  15]. 
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4.1.2 Saccharomyces cerevisiae Cell Stocks 
The S. cerevisiae strains W303, JB8I I and INVScI were plated onto YPD agar and grown 
for 2 days at 30°C. A single colony was used to inoculate YPD (5 rnL) under sterile 
conditions since the broth contained no antibiotic at this stage. The inoculant was grown for 
at least 24 hours at 30°C with agitation. Glycerol was added to a final concentration of 30% 
and allowed to equilibrate into the membrane for 20 minutes. The cell stock was 
subsequently flash frozen in liquid nitrogen prior to storage at -80°C. 
4.1.3 Growth Media 
All media were dissolved in distilled water and the p1-1 adjusted to 7.5 where required. All 
were autoclaved for 20 minutes at 120°C, 15 psi before use unless otherwise stated and if 
required to be stored, were kept at 4°C. 
2YT: Bacto-tryptone (16 g/L), bacto-yeast extract (10 g/L), sodium chloride (5 g/L). 
Luria Bertani (LB): Bacto-tryptone (10 gIL), bacto-yeast extract (5 g/L), sodium 
chloride (10 g/L). 
Minimal Glycerol Medium, MGM: Yeast Nitrogen Base without amino acids (13.4% 
w/v), glycerol (10% w/v) and biotin (0.02% w/v) were added to autoclaved, sterile water. 
Minimal Methanol Medium, MM: Yeast Nitrogen Base (13.4% w/v), methanol (1 %) 
and biotin (0.02%) were added to autoclaved, sterile water. 
SOC: Bacto-tryptone (20 g/L), bacto-yeast extract (5 g/L), sodium chloride (10 mM), 
potassium chloride (2.5 mM), magnesium chloride (10 mM), magnesium sulfate (10 mM). 
glucose (2 % w/v). 
YPD: Bacto-tryptone (20 g/L) and bacto-yeast extract (10 g/L) were dissolved in sterile 
water and autoclaved. Glucose (20%, 0.2 im filtered) was added to a final concentration of 
2% on cooling. 
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4.1.4 Agar 
LB: Bacto-agar (15 g/L) was added to LB media and autoclaved for 20 minutes at 120 °C, 
1 5 psi. Antibiotic was added on cooling (approximately 50°C) to the required concentration. 
Plates were allowed to dry before being stored at 4 °C with a shelf life of 1-2 months, 
however those containing antibiotic generally have a shorter shelf life of a few weeks. 
YPD: Bacto agar (20gIL) was added to YPD media and autoclaved for 20 minutes at 120 
°C, IS psi. Antibiotic was added on cooling (approximately 50°C) to the required 
concentration. Plates were allowed to dry before being stored at 4°C with a shelf life of 2-3 
months, however those containing antibiotic generally have a shorter shelf life of 
approximately I month. 
Sc Minimal Selection: Bacto agar (20g/L), Yeast Nitrogen Base (7g/L) and -Ura drop 
out mix (0.77g/L) were added to sterile water and autoclaved for 20 minutes at 120 °C, 15 
psi. Glucose was added to a final concentration of 2% on cooling. 
Sc Minimal Induction: Bacto agar (20g/L), Yeast Nitrogen Base (7g/L) and -Ura 
drop out mix (0.77g/L) were added to sterile water and autoclaved for 20 minutes at 
120 °C, 15 psi. Galactose was added to a final concentration of 2% on cooling. 
4.1.5 Antibiotic Stock Solutions 
All antibiotic stocks were sterile filtered (0.2 Lm) and stored at 4°C. 
Ampicillin: A 100 mg/mL stock solution was made and the required volume added to 
media to give a final concentration of 100 ig/mL. 
Aureobasidin A: A S mg/mL stock solution was made and the required volume added to 
media to a final concentration of 1 or 5 tg/mL. (S. cerevisiae cells were tested for their 
sensitivity to AbA on YPD agar containing I and 5 ig/mL AbA. Those that did not grow in 
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the presence of I jtg/rnL were consequently classed as AbA sensitive and were used for 
future transformation procedures.) 
G418: A 100 mg/L solution was made and the required volume added to media to give a 
final concentration of 200 tg/mL. 
Kanamycin: A 30 mg/mL stock solution was made and the required volume added to 
media to give a final concentration of 30 tg/rnL. 
Zeocin': A 100 mg/mL stock solution was made and the required volume added to media 
to a final concentration of 100 jig/mL. 
4.1.6 Solutions and Buffers 
Each buffer was made by dissolving the components described below in sterile 
water. All buffers were 0.2 tm  filtered and degassed prior to chromatography. All 
buffer stocks were stored at 4°C. 
0.5 M Potassium Phosphate, KPhos pH7.5: Dibasic potassium phosphate, 
K7HPO4  (0.470 moles/L), monobasic potassium phosphate, KH2PO4 (0.0299 rnoles/L). 
IPC synthase Binding Buffer: 20 mM Tris-HCI pH 7.4, 10% glycerol, 0.5 M NaCI, 
5 mM 3-mercaptoethanol, 0.05% Triton X-100, 5 mM imidazole. 
IPC synthase Elution Buffer: 20 mM TrisHCl pH 7.4, 10% glycerol, 0.5 M NaCl, 
5 	m 3-mercaptoethanol, 0.05% Triton X-100, 500 mM imidazole. 
IPC synthase Lysis buffer: 50 mM Tris-1-ICI pH 7.0, 0.3 M sucrose, 10 mM 13-
mercaptoethanol, 1 mM EDTA, 1 mini protease tablet per 50 mL. 
IPC synthase Solubilisation Buffer: 50 mM Bis-Tris-CI pH 6.0, 10% glycerol, 
5 mM 3-mercaptoethano1, 1 mM manganese chloride. 1% Triton X-100. I mini protease 
tablet per 20 mL of buffer. 
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Lithium Acetate Mix: 100 mM LiOAc, 10 mM Tris pH 7.4, 1 mM EDTA were made up 
to the required volume using distilled water. 
PEG Mix: 40% PEG (2800), 100 mM LiOAc, 10 mM Tris pH 7.4, 1 mM EDTA were 
made tip to the required volume using distilled water. 
Ni-NTA Binding buffer: 20 mM KPhos pH 7.5, 25 tM PLP, 10 mM imidazole, 
150 mM NaCl, I protease inhibitor cocktail tablet per 50 mL of buffer. 
Ni-NTA Elution buffer: 20 mM KPhos pH 7.5, 25 i.LM PLP, 100 mM imidazole, 
150 mM NaCl. 
Size Exclusion Chromatography Buffer: 20 mM KPhos pH 7.5, 25 jtM PLP. 
2mM EDTA, 150 mM NaCl. 
SPT Assay Buffer: 50 mM KPhos pH 7.5, 150 mM NaCl, 0.1 mM EDTA. 
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4.2 METHODS 
4.2.1 DNA Manipulation 
4.2.1.1 Cloning and Expression Plasmids 
Plasmid Cloning! Expression Application 
pCR2.1 -TO PO Provides stock of DNA available for 
(Invitrogen) Cloning in E. co/i manipulation into various expression 
vectors. 
pGEM®-T Easy Provides stock of DNA available for 
(Promega) Cloning in E. co/i manipulation into various expression 
vectors. 
pET-16b Expression in E. co/i Expression of an untagged protein. 
pET-28a Expression in E. co/i Expression of a C-terminal His6-tagged 
protein. 
pET-6H Expression in E. co/i Expression of a N-terminal 6His-tagged 
protein. 
pHISTEV30a Expression in E. co/i Expression of a cleavable N-terminal 
611is-tagged protein. 
pAUR 123 (Takara) Cloning in E. co/i and Allows cloning of target gene in E. co/i 
expression in S. cerevisiae and expression of an untagged protein 
in S. cerevisiae. 
pYES2/CT/LacZ Cloning in E. co/i and Allows cloning of target gene in E. co/i 
(Invitrogen) expression in S. cerevisiae and expression of a C-terminal His6- 
tagged protein in S. cerevisiae. 
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4.2.1.2 Oligonucleotide Primers 
Table 4 
Primer Sequence (5'- 31) 
3HisAU RI 23 for AATCATTCCTTTGCGTATGGCACACCACCACAACCCT 
TTTTCGAGATGG 
3H isAURI 23 rev CCATCTCGAAAAAGGGTTGTGGTGGTGTGCCATACG 
CAAAGGAATGATT 
CCTTCGTTATTTGATGGATCTACTTCTGTTTCTCGTTC 
AU RI TAP for GTCCGCCACGTCTATAACGTCACTAGGTGTAAAGAG 
GGCTCGGATCCCCGGGTTAAT 
TATAAAATTCTAAAGATAATCAGTGGTATGTGATTAA 
AU RI TAP rev ATAAACTACATGTATATTATGCTAAACGACAATCCTG 
ACTAAGGAATTCGAGCTCGTTTAAAC 
pAURI23 seq for GTTGCGGTTTTCATA 
pAURI23 seq rev TATCCGTAATTGCA 
pAURI23 Xhol rev CTCGAGAGCCCTCTTTACACCT 
pYES2ICTIAURI-C for seq ACTACTAGCAGCTGTAATAC 
pYES2ICTIAURI-C rev seq GTAAGCGTGACATAACTAAT 
GGACACCGTCATGACCGAAGCC 
SPT BspHl for  
GATCCTCGAGGCCGATGACGCCGACCGCGCGGC 
SPT Xhol rev 
4.2.1.3 Transformation of Competent E. coil 
Plasmid DNA (1 tl-) was added to competent E. co/i cells (20 [LL) and incubated for 
30 minutes on ice. The cells were then heat shocked for 30 seconds at 42°C before being 
incubated on ice for a further 2 minutes. Soc medium (80 tL) was added and the cells were 
agitated (250 rpm) for 1 hour at 37 °c. cells (50 11L) were spread onto LB agar containing 
the appropriate antibiotic and incubated overnight at 37°C. Subsequently, I colony was used 
to inoculate 2YT broth (10 mL) containing antibiotic and grown overnight at 37°C with 
shaking (250 rpm). 
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4.2.1.4 Transformation of Saccharomyces cerevisiae: Lithium Acetate 
Method 
Cells (from glycerol stock) were streaked onto YPD agar and incubated at 30°C for 2-3 days. 
One colony was used to inoculate YPD broth (5 rnL) and was grown overnight at 30°C with 
shaking (250 rpm). This inoculant (2 ml-) was diluted into YPD (50 ml-) and grown to an 
0D66() of approximately 0.5 before the cells were harvested by centrifugation (1 500 rpm for 3 
minutes). Tile cells were washed with lithium acetate mix (LiOAc, I mL) and transferred to 
a 1.5 mL epindorf. They were subsequently centrifuged for 10 seconds using a bench top 
centrifuge and the supernatant removed. This wash step was repeated using 0.5 JilL LiOAc. 
Carrier DNA (15 itL, 10 mg/mL single stranded salmon sperm DNA) was mixed with the 
DNA to be transformed (1-5 big) in a separate 1.5 mL epindorf to which 100 LL of cells in 
L1OAc (containing 700 LL of PEG mix) were added. The mixture was incubated at room 
temperature for 30 minutes before being heat shocked at 42°C for 15 minutes. The cells were 
harvested using a bench top centrifuge and resuspended in YPD (200 tL) before being 
spread onto YPD agar and incubated for 2 days at 30°C. The colonies obtained were replica 
plated onto YPD agar containing the appropriate selection agent and incubated for a further 2 
days at 30°C. 
4.2.1.5 Polymerase Chain Reaction (PCR): Taq Polymerase Beads (GE 
Healthcare) 
Generally, each PCR reaction contained; template DNA (5 [LL), forward primer (5 LL), 
reverse primer (5 [LL) and puRe Taq Ready-To-Go PCR beads (x2, GE Healthcare). Each 
PCR bead was reconstituted to a final volume of 25 ttL to yield the following concentration 
of reactants; dNTPs (200 liM in 10 mM Tris-HCL, pH 9 at room temperature), potassium 
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chloride (50 mM) and magnesium chloride (1.5 mM). The final reaction volume (50 ti-) was 
made with sterile water and subsequently covered with a layer of mineral oil. 
A general PCR reaction consisted of 30 temperature cycles; denaturation (94°C, 60 seconds), 
annealing (54°C, 30 seconds), elongation (72°C, 90 seconds) followed by an additional 
extension period (72°C, 10 minutes). The reaction was terminated by the addition of DNA 
loading dye (6x, Novagen) and the mixture was separated by electrophoresis. 
The purified PCR product could then be cloned using the pCR2.1-TOPO' vector 
(Invitrogen) or pGEM-Teasy (Promega) according to manufacturers instructions. All cloned 
DNA was transformed into ToplO competent cells (25 jiL) and cultures were grown on S-
Gal agar plates containing ampicillin (100 tg/mL) thus providing blue/white screening for 
the identification of viable clones. 
4.2.1.6 Polymerase Chain Reaction: Expand Polymerase (Roche) 
Generally each reaction contained, forward primer (300 mM), reverse primer (300 mM), 
dNTP (350 [LM), Buffer 1 (5 LL, I Ox), template DNA (1.75 mM) and Expand long template 
enzyme mix (0.75 jtL). The reaction was made up to 50 tL with sterile water. The general 
thermal cycling procedure consisted of the following steps: stepi, initial denaturation (94°C, 
2 minutes), steps 2-31, denaturation (94°C, 15 seconds), annealing (45-65°C, 30 seconds) 
and elongation (72°C, 2 minutes). This was followed by a final extension step for 10 minutes 
at 72°C. 
4.2.1.7 Polymerase Chain Reaction: QuickChange® Site-Directed 
Mutagenesis (Stratagene). 
Generally, each reaction contained forward primer (125 ng), reverse primer (125 ng), dNTP 
(1[LL), reaction buffer (5 tL, I Ox), double stranded template DNA (5-50 ng) and PfuTurbo 
DNA polymerase (1tL). The reaction was made up to 50[LL with sterile water. 
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The general thermal cycling procedure consisted of the following steps; step 1, initial 
denaturation (95°C, 30 seconds), steps 2-19, denaturation (95°C, 30 seconds), step 20, 
annealing (55°C, 1 minute) and elongation (68°C, 1 rninute/kbp). 
Following thermal cycling, the reaction mixture was cooled to 37°C before adding the 
restriction endonulease DpnI (1 jiL) to remove any darn methylated/parental DNA. This 
solution was mixed using a pipette and centrifuged for 1 minute at 13,000 rpm before being 
incubated for 1 hour at 37°C. After digestion with Dpnl, the DNA mixture (2 tL) was 
transformed into TOPIO competent cells as mentioned in section 4.2.1.3. 
4.2.1.8 Ligation Into An Expression Vector 
Ligations were carried out using the gene of interest (3 tL), the restricted plasmid (14 tL), 
T4 ligase (I jiL, 1x106 ligations/unit, New England Bio-labs) T4 ligase buffer (2 tL, lOx, 
New England Bio-labs). The ligation was incubated overnight at room temperature and 
subsequently, 2 pLL was transformed into TOP 10 competent cells (25 PiL) as described in 
section 4.2.1.3. 
4.2.1.9 Cloning Using pFA6a-ZZ-TEV-S-kanMX6 
The binding cassette pKW804 was used for this procedure. It is identical to pFA6a-GFP-
kanMX6 used by Longtine et al. except for the GFP moiety (1). The GFP part has been 
replaced by the S-TEV-ZZ (S peptide; binds S protein, TEV; TEV protease cleavage site, 
ZZ; 2x IgG binding domains from Stapholococcus aureus) tandem affinity tag using the 
restriction sites Paci/Asci. 
The forward primer (AURI TAP for) contained 80 bp homologous to the 5'-end of the 
AURI gene followed by the F2 C-terminal tagging sequence acquired from Longtine et al. 
(1). The reverse primer (AURI TAP rev) contained 80 bp homologous to part of 
chromosome XI (downstream of the AURI gene) followed by the RI Deletion/C-terminal 
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tagging sequence acquired from Longtine ci al. (1). These primers were used for PCR in 
combination with Expand DNA polymerase and the PKW804 cassette according to section 
4.2.1.6. The PCR was analysed by electrophoresis and where successful, a product of 
approximately 2.5 kbp was obtained. The reaction was scaled up to 500 pL (10 x 50 iL 
reactions) after which, all reactions were pooled and extracted using 
phenol:chloroforrn:isoamyl alcohol (25:24:1, v/v) see section 4.2.1 .10. 
4.2.1.10 Solvent Extraction of sTAP DNA 
All PCR reactions were pooled and to them was added an equal volume of 
phenol :chloroform : isoarnyl alcohol (25:24:1, v/v). The mixture was vortexed vigorously 
before being centrifuged for 5 minutes at 13,000 rpm. The upper aqueous layer was removed 
and the DNA precipitated using 2.5 volumes of ethanol (ice cold). The mixture was 
centrifuged again, as before, and the ethanol removed by evaporation at room temperature 
overnight. The precipitated DNA was resuspended in sterile water (10-20 tL) and 
transformed into JB81I cells using the lithium acetate method described in section 4.2.1.4. 
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4.2.2 DNA PURIFICATION 
4.2.2.1 Mini-Prep: QiAprep® Spin Miniprep Kit (QIAGEN) 
This procedure was carried out according to the manufacturers instructions, provided with 
the kit and is summarised below. 
An overnight culture (1.5 mL) was transferred to a sterile epindorf (1.5 mb) and centrifuged 
(13,000 rpm, 2 minutes) using a bench-top centrifuge. The supernatant was discarded and the 
procedure repeated with a further 1.5 mL of culture. The pellet was resuspended in P1 buffer 
(250 jtL) and to this, P2 buffer (250 pL) was added. This was followed by immediate 
invertion of the epindorf 4-6 times. Subsequently, N3 buffer (350 tL) was added and the 
mixture inverted immediately (4-6 times). The resultant cloudy mixture was centrifuged 
(13,000rpm, 10 minutes) after which, the supernatant was transferred to a QiAprep spin 
column and centrifuged (13,000rpm, 1 minute). The flow through was discarded and the spin 
column washed with PB buffer (500 LL) and centrifuged (13,000rpm, 1 minute). The column 
was washed further with PB buffer (750 [LL) and centrifuged (13,000rpm, 1 minute). The 
column was centrifuged for a further minute to remove any residual wash buffer before the 
purified DNA was eluted with sterile water (100 1iL) and stored at -20°C until required. 
4.2.2.2 Gel Extraction —QlAquick ® Gel Extraction Kit (QIAGEN) 
DNA was excised from an agarose gel (1%) and purified according to the manufacturers 
instructions, which are summarised below. 
Agarose containing the DNA, was covered in sufficient QG buffer (600 111_ - 1 mL) and 
incubated at 50°C until the agarose had completely dissolved. This solution was transferred 
to a spin column and centrifuged (13,000 rpm, 1 minute). The supernatant was discarded and 
QG buffer (500 L) was added to the column and centrifuged (13,000 rpm, 1 minute). The 
supernatant was discarded and PE buffer (750 L) added to the column and incubated for 2- 
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5 minutes. The column was centrifuged (13,000 rpm, 1 minute), the supernatant discarded, 
and the column centrifuged again to remove any residual buffer. The purified DNA was 
eluted with sterile water (30 tL) and stored at -20°C until required. 
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4.2.3 DNA ANALYSIS 
4.2.3.1 Digestion by Restriction Endonuclease 
Generally, a single restriction digest contained the following; template DNA (8 tl-), 
restriction buffer (I iL, lOx, New England Biolabs) and restriction endo11uclease(1 tL, New 
England Bio-labs). This mixture was incubated at 37°C for 3 hours and the reaction was 
terminated by the addition of DNA loading dye (2 iL, 6x, Novagen). The digestion mixture 
was loaded onto an agarose gel (1%) and separated by electrophoresis (section 4.2.3.2). 
4.2.3.2 Electrophoresis 
Agarose (1.0 g) was added to TAE buffer (100 ml-, Bio-Rad) and boiled until the agarose 
had completely dissolved. On cooling, to approximately 50°C, ethidiurn bromide was added 
to a final concentration of 0.5 tg/mL and the solution swirled to ensure complete mixing. 
The molten agarose solution was transferred to the casting mould and allowed to set at room 
temperature. DNA loading dye (6x, Novagen) was added to the DNA samples (2 j.iL to small 
samples of approximately 10 1iL and 10[LL to larger samples of approximately 50 pt). The 
gel was immersed in TAE buffer and run at a constant voltage of 100 volts until good 
separation between bands was observed. 
4.2.3.3 Sequencing PCR 
To prepare a DNA sample for sequencing the DNA source (5 [LL) was added to sequencing 
buffer (2 j.tL, 5x, Applied Bioscience) containing Big Dye version 3.1 (2 j.tL) and sequencing 
primer (1 jiL forward or reverse). Primers (table 5) were provided as 100 ng/tL stocks 
however, 3.2 pM/p.L stocks were made as 3.2 pM was required for each sequencing reaction. 
Only one primer, forward or reverse, was required for each sequencing reaction. The general 
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sequencing program consisted of 25 cycles of the following steps; 95°C for 30 seconds, 50°C 
for 20 seconds and 60°C for 4 minutes. 
Primer Plasmid Sequence 
pCR2.1 M13 Rev (forward primer) pCR2.1 5' CAGCAAACAGCTATGAC 3' 
pCR2.1 	M31 	For (reverse primer) pCR2.1 5' GTAAAACGACGGCCAG 3' 
pGem T7 For (forward primer) pGem 5' TAATACGACTCACTATAGGG 3' 
pGem T7 Rev (reverse primer) pGem 5' ATTTAGGTGACACTATAGAA 3' 
Table 5: Sequencing Primers 
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4.2.4 PROTEIN PRODUCTION AND ISOLATION 
4.2.4.1 Large Scale Over-expression in E. coil 
One colony was used to inoculate 2YT broth (500 rnL) containing the appropriate antibiotic 
and was grown overnight at 37 °C with shaking (250 rpm). This inoculant was sub-cultured 
into 2YT broth (4 litres containing antibiotic) and grown to an OD oo of 0.6, at 37 °C before 
being induced with IPTG (0.1 mM). Induction was carried out at 30 °C for 5 hours. 
4.2.4.2 Expression of pPICZaAAURISc in Pichia pastoris 
Cells were streaked onto YPD-agar containing Zeocin (100 ig/ml) and incubated for 2 days 
at 30°C. A single colony was used to inoculate MGM broth (10 nil-) containing zeocin (100 
t(Y/rnL) and was incubated at 30°C, with shaking (250 rpm), until an 0D60() of 2-6 had been 
reached. This culture was then used to inoculate MGM broth (1 .5 litres) and was grown at 
30°C to an 0D600  2-6 before the cells were harvested by centrifugation (3000 rpm, 10 
minutes, 4°C). The cell pellet was resuspended in MM (500 mL) to an ODc,00 of 20-40 and 
agitated (250 rpm) for 4 days at 30°C. To compensate for metabolism and evaporation, 
methanol was added to a final concentration of 1% (v/v) every 24 hours. The cells were 
harvested by centrifugation (3000 rpm, 4°C, 10 minutes) and flash frozen in liquid nitrogen 
before being stored at -80°C. 
4.2.4.3 Cell Lysis by Sonication 
All steps were performed on ice. The cell pellet was resuspended in resuspension buffer (40 
mL, 4:1 v/w) containing I protease inhibitor cocktail tablet (Roche) and sonicated for 15 
cycles (30 seconds on, 30 seconds off) using a soniprep 150. The cell debris was harvested 
by centrifugation (15,000 rpm, 20 minutes, 4°C) and the supernatant retained for 
purification.was 
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4.2.4.4 Cell Lysis by Mechanical Disruption: Bead Beater 
The outer chamber of the bead beater (Biospec Products Inc.) was filled to 3/4  of its capacity 
with ice which, was subsequently immersed in a solution of ethanol:water (50:50 v/v). The 
inner chamber was filled to approximately 50% with acid washed glass beads (Sigma) to 
which, the thawed cell pellet was added. The pellet and beads were mixed to expel any air 
before any remaining space within the chamber was filled with lysis buffer. Lysis was 
carried out at 4°C with 5 cycles (30 seconds on, 30 seconds off) and the cell debris removed 
by centrifugation (11,000 rpm, 20 minutes, 40C). 
4.2.4.5 Solubilisation of the Microsomal Fraction 
A S. cerevisiae cell free extract was centrifuged (15,000 rpm, 25 minutes, 4°C) to remove the 
mitochondrial fraction and the supernatant subsequently centrifuged (30,000 rpm, 
45 minutes, 4°C,) to obtain the microsomal fraction. The microsomal pellet was resuspended 
in solubihisatioii buffer and agitated slowly for 90 minutes at 4°C. The insoluble fraction was 
removed by centrifugation (30,000 rpm, 4°C, 45 minutes) and the supernatant aliquoted and 
stored immediately at -80°C until required. 
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4.2.5 PROTEIN PURIFICATION 
4.2.5.1 Ni-NTA Agarose 
On average, each purification using a HiPrepTM column yielded approximately 10 rrig of 
protein per litre of cell culture. Although this yield is sufficient for biochemical and 
structural analyses, purification was optirnised further to give a higher yield of protein. The 
prepacked HiPrepTM column (GE Healthcare) was replaced with Ni-NTA agarose 
(Invitrogen). This method was subsequently used routinely, in the purification of 
pET28aSPT for crystallisation. 
The cell free extract (approximately 40 mL) was incubated with pre-equilibrated Ni-NTA 
agarose (2 mL, 5-10 mg protein/mL beads) at 4°C for 1 hour prior to packing the beads into 
an empty polyprep column (5 mL, QIAGEN) by gentle suction. This method allowed longer 
contact between the cell free extract and the chromatography media thus allowing more time 
for the 6-histidine tag of the protein to interact with the Ni-NTA of the agarose. The beads 
were packed and washed with 10 column volumes of Ni-NTA binding buffer, under gentle 
suction, and the protein eluted with 5 column volumes of Ni-NTA elution buffer. The protein 
was eluted with 100 mM imidazole in comparison to the HiprepTM method which required 
200 mM. 
It appeared that the Ni-NTA agarose beads were being over loaded with protein, as a large 
amount of recombinant SPT was observed by SDS PAGE analysis of the flow through. To 
prevent over loading, half the volume (20 mL of cell free extract) was used per 2 mL of 
agarose. This modification yielded a two-fold increase in protein production (approximately 
20 nig of protein per Litre of cell culture). 
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4.2.5.2 Size Exclusion Chromatography 
A HiPrepTM 26/60 SephacrylTM S-200 (3 18 ml) size exclusion column was pre-equilibrated 
with I column volume of gel filtration buffer. Before loading, the protein sample was 
0.45 jim filtered and concentrated to 3-5% of the total column volume. It was eluted over I 
isocratic column volume and 10 mL fractions were collected. The approximate molecular 
mass of purified protein was calculated using a calibration curve obtained from known 
molecular weight standards (GE Healthcare). 
4.2.5.3 lgG "Pull Down" 
An initial "pull-down" purification of AURJ-CSTEVZZ was attempted using lgG 
Sepharose6 (fast flow) resin (GE Healthcare). The cell free extract (40 mL) was incubated 
with lgG resin (1 00 jiL) for 2 hours at 4°C. The beads were harvested by centrifugation and 
washed with lysis buffer containing one protease inhibitor cocktail tablet. The beads were 
incubated in the presence of TEV protease (1 00 units) at 4°C overnight to remove the ZZ-
domain and release Aurl p from the resin. 
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4.2.6 PROTEIN ANALYSIS 
42.6.1 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
An average gel (10 mL) consisted of a 12% running gel (1-120,30% acrylamide, 1.5 M Tris 
pH 8.8, 10 % SDS, 50 rng/mL anirnonium persulfate and 15 p1. TEMED) and a 4 % stacking 
gel (H10, 30% acrylamide, 0.5 M Tris pH 6.8, 10% SIDS, 50 mg/mL ammonium persulfate 
and 15 p1. TEMED). All protein samples were denatured by the addition of SDS-loading 
buffer (1.5 M TrisHCl pH 6.8, 5 % v/v glycerol, 10% w/v SIDS, 0.4 mL f3-niercaptoethanol 
and 0.05% w/v bromophenol blue) and boiled for 10 minutes. The mixture was centrifuged 
(13.000 rpm, 5 minutes) prior to loading the gel. 
The gel was run for approximately 50 minutes at a constant voltage of 180 volts. 
Subsequently, it was immersed in Coomassie stain (H20, 0.1% w/v Coomassie brilliant blue 
R250, 40% v/v methanol and 10% v/v acetic acid) and incubated for 20 minutes at 37°C. The 
gel was destained (H0, 40% v/v methanol and 10% v/v acetic acid) until all excess stain 
had been removed. 
An approximate protein molecular mass was obtained using the pre-stained protein 
molecular weight markers SeeBlue PIus2 (Invitrogen) or Low Molecular Weight Marker 
(GE Healthcare). 
4.2.6.2 Non-Denaturing (Native) Gel 
A pre-cast Tris-Glycine gel (10%, Invitrogen) was used for the detection of non-denatured 
protein. Native loading buffer (25 p1., Invitrogen) was added to each protein sample (25 p1.) 
which was loaded onto the gel without boiling. The gel was run for 90 minutes at a constant 
voltage of 100 volts and was stained as mentioned in section 4.2.6. 1. 
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4.2.6.3 Semi-Dry Western Blot 
After SDS-PAGE (section 4.2.6.1), HybondTM ECL nitrocelluose membrane (GE Healthcare) 
was cut to fit the gel. Both the gel and the membrane were equilibrated in transfer buffer (25 
mM Tris, 150 mM glycine, 10% methanol) for 15 minutes at room temperature. Three pieces 
of Whatman filter paper slightly larger than the membrane were soaked in transfer buffer 
before being transferred onto a Trans-blot SD semi-dry transfer cell (Biorad). The membrane 
was placed onto the filter paper followed by the gel and finally another three sheets of filter 
paper, pre-soaked in transfer buffer. At each stage, care was taken to ensure that no air 
bubbles were present between each layer. The protein was transferred for 1 hour at a 
constant voltage of 1 5 volts. 
The membrane was blocked for 90 minutes at room temperature (or overnight at 4°C) in 
blocking solution (5% w/v skimmed dried milk powder in PBS-Tween) with gentle agitation 
and then washed with PBS-Tween for 2 x 5 minutes, 2 x 10 minutes, I x 20 minutes. It was 
subsequently incubated with antibody solution (blocking solution containing antibody to 
desired dilution) at room temperature for 90 minutes before being washed as described 
above. The ECL pJ115TM  (GE Healthcare) reaction was carried out according to manufacturers 
instructions and the membrane was exposed to Kodak® X-Omat AR film, XAR-5, 18 cm x 
24 cm for the amount of time required for adequate detection of protein. The film was 
developed using Konica SRX- 101 A. 
Exposure time is protein dependent and optimisation is often required for each individual 
protein detected. 
4.2.6.4 BCATm Protein Assay (PIERCE) 
This method utilises bicinchoninic acid for the colourimetric detection and quantitation of 
total protein in solution. The assay relies on the proteinaceous reduction of Cu2 to Cu in an 
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alkaline medium. The CuH  is consequently detected by the bicinchoninic acid in a ratio of 
1:2, thus producing a colour change from green to purple which can be detected 
spectrophotometrically at 562 nm. 
2 rnL of working reagent (50:1 v/v. solution A: solution B) was added to a clean, dry test 
tube, containing the protein sample (100 L) and incubated for 30 minutes at 37 °C. A 
standard curve was produced from serial dilutions (table 6) of a known stock concentration 
of BSA (2 mg/mL) and the concentration of protein calculated according to this standard 












Table 6: Standard Curve Concentrations 
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4.2.7 PROTEIN AND SMALL MOLECULE 
CHARACTERISATION 
4.2.7.1 Liquid Chromatography-Mass Spectrometry of Proteins 
Mass spectrometry was performed oil a Micromass Platform equipped with an electrospray 
ion source. The spectrometer cone voltage was ramped from 40 to 70 volts and source 
temperature set to 140°C. Protein samples were separated with a Waters HPLC 2690 with a 
Jupiter CS reverse phase column (5trn, 250 x 4.6mm, Phenomenex) directly connected to the 
spectrophotometer. Proteins were eluted from the column with a 5-95% acetonitrile gradient 
using an acetonitrile/water/TFA (0.01%v/v) solvent system (flow rate 0.4ml/min). The total 
ion count in the range 500 to 2000 m/z was scanned at 0.1s intervals. The scans were 
accumulated, the spectra combined and the molecular mass was determined by the MaxEnt 
and Transform algorithms of the Mass Lynx software (MicroMass). 
4.2.7.2 Liquid Chromatography-Mass Spectrometry of Small Molecules 
Mass spectrometry was performed on a Micromass Platform equipped with an electrospray 
ion source. The spectrometer cone voltage was ramped from 40 to 70 volts and source 
temperature set to 140°C. Protein samples were separated with a Waters HPLC 2690 with 
Phenomenex C18  reverse phase column directly connected to the spectrometer. The small 
molecules were eluted from the column with a 30-60% acetonitrile gradient using an 
acetonitrile/ water/ TFA (0.01%v/v) solvent system (flow rate 0.1rnl/min). The total ion 
count in the range 200 to 800 m/z was scanned at 0.1s intervals. The scans were 
accumulated, the spectra combined and masses were determined by the MaxEnt and 
Transform algorithms of the Mass Lynx software (MicroMass). 
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4.2.8 PROTEIN CHEMISTRY 
All assays in this section refer to pET28aSPT unless otherwise stated. All UV-visible spectra 
were recorded on a single-beam Hewlett-Packard 8452A diode array spectrophotometer and 
analysed using UV-Visible ChemStation software (Agilent). All assays were carried out on a 
500 iL scale at 25 °C unless otherwise stated. 
4.2.8.1 Spectroscopic Measurements 
To convert apo-SPT to holo-SPT, the enzyme was dialysed for I hour at 4°C against 20 mM 
potassium phosphate pH 7.5 containing 150 mM NaCl, 25 1.uM PLP and 1 mM EDTA. 
Excess PLP was removed using a PD-10 (Sephadex G-25M) desalting column (GE 
Healthcare) before any spectrophotometric measurements were taken. The concentration of 
recombinant SPT was 20[LM in all assays unless otherwise stated and the spectrophotometer 
was blanked with 20 mM potassium phosphate pH 7.5, 150 mM NaC1 and 1 mM EDTA. 
For measurements involving L-serine or L-cycloserine fresh stock solutions (I Ox) were made 
prior to use by dissolving the required mass of substrate in sterile water. 
4.2.8.2 Stopped Flow Measurements of L-serine Binding 
Data were obtained using a SX. I 5MV stopped-flow spectrophotometer (Applied 
Photophysics) at 25 + I T. Data were analysed with Origin 7 (Microcal) and average traces 
from four or more measurements were used for analysis. The buffer used for all stopped-
flow experiments was 20 mM Khos pH 7.5, 150 mM NaCl. A 2x solution of protein and 
substrate were loaded into separate chambers and the protein mixed in a 1:1 ratio with 
substrate within the reaction vessel to give a final concentration of 20 LM. The reaction was 
monitored by the increase in absorbance (428 nm) at various L-serine concentrations (0.1 to 
50 mM). 
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4.2.8.3 Detection of 3-ketosphinganine 
A radioactivity assay, which monitors the incorporation of 14C-serine into ' 4C-labelled 3-
ketodihydrosphingosine, was used for the detection of 3-ketodihydrosphingosine produced 
by recombinant SPT. 
A typical assay contained 20 tM SPT (iii 20mM KPhos pH 7.5, 150 mM NaCl and I mM 
EDTA), 20 mM L-[U- 4C] serine (9250 Bq/0.250 .tCi) and 1.6 mM palmitoyl-CoA. The 
reaction was incubated at 37°C for 20 minutes and terminated by the addition of 0.4 M 
Nl-140H. The lipid portion was extracted with an equal volume of CHCI3:CH30H (2:1 v/v) 
and the sample centrifuged. The aqueous layer was removed and the organic solvent 
evaporated overnight. The lipid residue was resuspended in 15 VLL of CHCI3:CH30H (2:1 
v/v) and spotted onto a Silica Gel 60 TLC plate. The lipids were separated with 
CHCI3:CH30H:NFI40H (40: 10:1 v/v) and the TLC was incubated with a Storage Phosphor 
Screen (GE Healthcare) for 5 days at room temperature. The screen was developed using a 
Storm Phosphor Imager (GE Healthcare) and the image visualised using lmageJ software. 
For comparison, a reference sample of 3-ketodihydrosphingosine (Matreya) was analysed on 
a Silica Gel 60 TLC plate as above and detected using ninhydrin. 
For incubation with S. paucimobilis cell free extract, the assay described above was 
incubated for 1 hour at 37 °C before addition of a concentrated S. paucimobilis cell free 
extract. This mixture was incubated for a further hour at 37 °C and extracted as above. 
4.2.8.4 L-cycloserine Inhibition of Recombinant SPT 
Inhibition of recombinant SPT by L-cycloserine was monitored using the method previously 
described (section 4.2.8.3) with the following modifications: 20 jiM SPT (in 20 mM KPhos 
pH 7.5, 150 mM NaCl), 1.6mM palmitoyl-CoA and 1mM L-cycloserine were incubated for 
1 hour at 37 °C, before 10mM L-[U-'4C] serine (9250 Bq/0.250 j.tCi) was added. This was 
incubated for a further hour at 37 T. 
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4.2.8.5 Denaturation with Urea 
SPT (20uM) was incubated with L-cycloserine (I mM) and the protein denatured with Urea 
(final concentration 4 M) at time points 15, 30, 40, 60, 120 and 240 minutes. The UV-visible 
spectra were recorded before after denaturation. 
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4.2.9 STRUCTURAL BIOLOGY 
4.2.9.1 Apo-SPT 
pET28aSPT was screened for suitable crystallisation conditions using the high throughput 
facilities at the Scottish Structural Proteomics Facility (SSPF), University of St. Andrews. 
The crystallisation conditions were screened using a nano-drop crystallisation robot 
(Cartesian Honeybee, Genornic Solutions) as part of the l-lamilton-Thermo Rhombix system. 
Over 700 conditions were tested from commercially available sparse-matrix screens, using 
sitting-drop vapour-diffusion, with a well volume of 100[LL in 96 well plates (Griener 3-
square) at 293 K. Drops containing 0.2 tL of protein and 0. 1 iL of well solution were used. 
Several conditions produced initial crystals and these were optimised using the Rhombix 
system. Small (< 0.05mm x 0.05 x 0.2mm) colourless, cubic crystals were produced by 
adding 0.1 1iL of SPT (24 mg/mL in 10mM Tris pH 7.5, 150 n1 NaCl, 25 LM PLP) and 
5 jsL myriocin to 0.1 jtL of well solution (100 ruM Tris pH 6.5, 10% PEG 8K, 170 mM 
MgC 1 2). 
The crystals were mounted in cryoloops (Hampton Research) and cryoprotected by passing 
them through a mixture of 20% glycerol and well solution. Crystals were then frozen by 
rapid immersion in liquid nitrogen, and transferred to sample changer baskets (Molecular 
Dimensions). Multiple crystals were screened at Beam Line BMI4, Grenoble, ESRF using 
the sample changer, and a low-resolution dataset (3.0 A) was collected from the highest 
diffraction resolution, single crystal at lOOK. Data were indexed and scaled with DENZO 
and SCALEPACK as implemented in the CCP4 suite (2). Initial phases were determined 
using molecular replacement, with a homology model generated from the KBL (PDB code: 
I FC4) monomer structure and confirmed a dinner. The molecular replacement model was 
built using the CASPR server (3). 
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4.2.9.2 Holo-SPT 
The initial hits were further optimized with screens generated using the Crystools server (3). 
The protein was dialysed in the presence of excess PLP to ensure complete reloading. 
Contrary to preparation of the apo-SPT, excess PLP was not removed by size exclusion 
chromatography prior to crystallisation. Sitting drop plates (EasyXtal DG-CrystalSupport; 
QIAGEN) were used for trials in which, a large yellow crystal ('-0.8mm x 0.2 x 0.2mm) 
grew in a 2[LL drop, consisting of 1 jiL SPT (20 mg/mL in 10 mM Tris pH 7.5, 150 mM 
NaCl and 25 LM PLP) and I ltL of well solution (100 mM l-IEPES p1-1 6.5, 230 mM MgCl-), 
and 25% PEG 3350). The crystal was mounted in a cryoloop and cryoprotected in 22% 
PEG3350, 100 mM HEPES p1-I 6.5, 120 mM MgCl-,, 20% PEG400. 
The crystal was subsequently frozen and shipped to the ESRF where a 1.3 A dataset was 
collected on BM 14 at 100 K. Data were processed with MOSFLM and SCALA. Phases were 
calculated with Phaser (4, 5) using the partially refined apo- structure as a starting model. 
Automated model building in ArpWarp successfully built 391 residues out of 427, and 
produced an initial model with an R-factor of 19.5% and a Rfree of 23.2% (6). Both apo- and 
holo- models were refined using Refrnac5 (7) and manually adlusted by Coot (8). The apo-
structure was refined using isotropic B factors, with tight non-crystallographic restraints 
applied between the two monomers for the whole of the refinement process. The holo-
structure was refined with anisotropic B factors, with TLS refinement used in the later 
rounds of refinement. Waters were added and checked using Coot. Structure quality was 
checked using the tools with Molprobity (9). The final model statistics are shown in table 1, 
section 2.4.1. 
4.2.9.3 L-serine External Aldimine 
Crystallisation trials were set up in sitting drop plates (EasyXtal DG-CrystalSupport, 
Qiagen). Holo-SPT crystals grew in a 2 jil drop, consisting of I tl of 20 mg/mI SPT (in 10 
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mM Tris pH 7.5, 150 mM NaCl and 25 iM PLP and I pA of well solution (22% PEG 3350, 
100 mM HEPES pH 6.5, 120 mM MgCl-,). A single holo-SPT crystal was soaked for 10 
minutes at room temperature in 22% PEG3350, 120 mM MgCl,, 100 mM HEPES p1-16.5 
containing 5mM serine before being mounted in a cryo-loop and cryo-protected in 22% 
PEG3350, 120 niM MgCl-,, 100 mM HEPES pH6.5, 20% PEG400. The crystal was frozen 
and shipped to the ESRF where a 1.5 A dataset was collected on beamline 1D23-2 
(wave length=0.873A) at 100 K. 
4.2.9.4 SPT and L-cycloserine 
A 10 mM stock solution of L-cycloserine was prepared. This was added to holo-SPT (20 
1-tM) to a final concentration of I mM. After incubation overnight at 4 °C, the protein was 
concentrated to 20 mg/ml and this solution was used in co-crystallisation experiments. SPT-
L-cycloserine crystals grew from a 2 1-tI  drop, consisting of I pA of 20 mg/m1 SPT/L-
cycloserine (in 10 mM Tris pH 7.5, 150 mM NaCl and 25 jiM PLP) and I pA of well solution 
(100 mM HEPES p1-I 6.5, 110 mM MgCl,,, 21.5% PEG 3350). A single, colourless crystal 
was mounted in a cryo-loop and cryo-protected in 22% PEG3350, 120 mM MgCl", 100 mM 
HEPES pH6.5, 20% PEG400. The crystal was frozen and shipped to the ESRF where a 1.45 
A dataset was collected on beamline ID 14-1 (wave length0.934 A) at 100 K. 
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Chapter 5: Conclusions and Future Work 
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The high-resolution structural information produced from these studies will facilitate a more 
detailed investigation into the mechanism and inhibition of SPT. 
The holo-SPT and L-serine external aldimine structures, presented in this thesis, are the first 
to be solved of a SPT from any organism. In addition to the crystal structures, bioinformatic 
analysis of bacterial and human SPT have not only provided insights into enzyme function 
but have also shown how mutations may affect enzyme behaviour e.g. mutations associated 
with hereditary sensory and autonomic neuropathy type I (HSAN 1). 
Mutations of human SPT (C133W, C133Y and V144D) have been shown to directly affect 
enzyme activity and cause a range of neuropathological defects leading to the condition 
1-ISAN 1. Since S. paucirnobilis SPT shows sufficient sequence conservation with human 
SPT, it has allowed us, in collaboration with the SSPF St. Andrews, to generate homology 
models of the human SPTI/SPT2 heterodimer. This has facilitated the analysis of how 
mutations of SPT may be involved in the pathology ofHSAN1 (see section 2.5) (4). 
Two S. pauciinobilis SPT N 100W and N I OOY mutants were obtained shortly after 
conclusion of these studies. The high-resolution crystal structures of both mutants have been 
determined, in collaboration with the SSPF, St. Andrews (Dr K Johnson and Marine Raman) 
and both appear to have impaired L-serine binding efficiencies. However, further kinetic and 
structural analyses are essential in order to provide details of how these mutations affect SPT 
activity. 
In addition to holo-SPT and the L-serine external aldimine, the crystal structure of L-
cycloserine inhibited SPT provides a basis for the further analysis of inhibition. To date, 
although mechanisms for the cycloserine inhibition of PLP-dependent enzymes are 
hypothesised in many publications, no specific mechanism has been determined (13-16, 22, 
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23). The results shown in this thesis appear to agree with the mechanism proposed by 
Ikushiro et al. (3). However, mass spectrometry analysis is required to determine the 
intermediates formed during the L-cycloserine inhibition of SPT and, together with further 
biochemical and crystallographic experiments, should provide a detailed mechanism of 
inhibition. 
After numerous attempts to obtain soluble Aurip, insertion of the AURI gene into the 
expression vector pYES2/CT (Invitrogen) was successful. The pYES2/CT/AURJ-C construct 
allowed the (galactose induced) over-expression of a C-terminal histidiiie tagged AurI-C-
1-Iis, protein which could be purified in one step, by Ni-NTA chromatography. 
Unfortunately, time did not permit further optimisation of the purification protocol for Aurl - 
C-His6. As the yield of protein from 10 litres of S. cerevisiae cell culture was significantly 
low (could not be detected by colloidal coomassie staining), production of a higher cell 
mass, by fermentation, would have been advantageous at this point. It is hoped that 
purification of Aurl-C-I-lis6 from a larger volume of S. cerevisiae cell culture would provide 
sufficient protein for identification by Coornassie staining and mass spectrometry. 
Alternatively, future work focusing on the screening of a range of detergents, in order to 
increase the amount of soluble material isolated would also be beneficial. 
Biochemical and kinetic analysis of substrate binding are also important considerations. The 
availability of fluorescently labelled ceramide substrates, such as C6NBD and C1 NBD-
ceramide, will enable the production of fluorescently labelled inositol phosphorylceramide to 
be monitored. 
The successful cloning, over-expression, purification and detection procedures from these 
studies (section 3.3) may now be applied to the AUR] gene from the fungal pathogen B. 
cinerea in order to isolate and characterise this important target enzyme. 
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To date, there is no data to suggest that the over-production of a soluble, histidine tagged 
Aurlp has been achieved. In addition, no biochemical analysis can be found on recombinant 
Aurip-Hiso Therefore, the results reported in this thesis, may facilitate the progression of 
this field toward obtaining biochemical, and possibly structural, information about this 
important fungicidal target. 
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Sphingolipids are essential components of eukar-
yotic cells where they play important roles in in-
tracellular signalling and in membrane structure.11  
All sphingolipids are composed of a long-chain base 
(LCB), a fatty acid and a polar head group. The 
sphingoid bases (containing 1 ,3-dihydroxy-2-amino-
alkane and its derivatives) were first isolated by 
Thudichum who characterised the brain alkaloid 
"sphingosin" over a century ago.5 The chemical 
structure of the family of sphingolipids was subse-
quently characterised by Carter and colleagues 
over five decades later.6 Serine palmitoyltransferase 
(SPT; EC 2.3.1.50) catalyses the first and rate-limiting 
step of the sphingolipid biosynthetic pathway in 
all organisms studied to date. This reaction is a 
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Figure 1. The reaction catalysed by serine palmitoyltransferase (SPT). 
pyridoxal 5'-phosphate (PLP)-dependent, decarbox-
ylative, Claisen condensation of the amino acid 
L-serine and the long-chain (C16) fatty acid palmi-
toyl-CoA, which produces the sphingolipid precur-
sor, 3-ketodihydrosphingosine (KDS; Figure 1). 
SPT belongs to the small family of enzymes called 
the a-oxoamine synthases (AOS) which catalyse the 
condensation of specific amino acid and acyl-CoA 
thioester suhstrates.h  This family is classified under 
the larger a-division, fold type I enzymes within the 
PLP-dependent enzyme superfamily.U)  Other 
members of this family include; 8-amino-7-oxono-
nanoate synthase (AONS)' 1,12  from the biotin 
biosynthetic pathway, 5-aminolevulinate synthase 
(ALAS)C 3  15 which catalyses the first step in tetra-
pyrrole biosynthesis and 2-a mino-3-ketobutyrate 
CoA ligase (KBL)1 involved in threonine metabo-
lism. A consensus catalytic mechanism has emerged 
for those enzymes catalysing the decarboxylation of 
an amino acid substrate (SPT, AONS and ALAS) 
(Figure 2).7,12,171 20 Briefly, the catalytic pathway is 
comprised of the following steps: formation of an 
external aldimine via displacement of the lysine-PLP 
internal aldimine (holo-SPT) by the incoming amino 
acid substrate; formation of a quinonoid intermedi-
ate by abstraction of the a-proton from the PLP-
amino acid external aldimine; a Claisen condensa-
tion with the fatty acid-CoA substrate followed by 
displacement of the CoA to form a 	-ketoacid; 
decarhoxylation of this species to form a product 
quinonoid; protonation of this quinonoid to form 
the product external aldimine and finally release of 
the ct-oxoa mine product and regeneration of the 
enzyme PLP-internal aldimine. The factors govern-
ing differences in substrate specificity that distin-
guish each member within the family have still to 
be resolved. 
Early studies of sphingolipid biosynthesis in 
eukaryotes revealed serine palmitoyltransferase 
activity in rat liver and yeast extracts. 	Eukar- 
yotic SPT is located in the endoplasmic reticulum 
(ER) and consists of at least two heterologous mono-
mer subunits, long chain base I and 2 (LCBI/LCB2, 
also known as SPT1 and SPT2, respectively), enco- 
ded by separate genes (/cbl and lcb2).21 ' 25 25 
Sequence analysis of the encoded Saccharonyces 
cerevisiae SPT1 and SPT2 subunits revealed that 
SPT2 contains an active site lysine residue required 
for PLP-binding which is conserved amongst other 
members of the AOS family. In contrast, SPT1 lacks 
this lysine (and other key residues) and it has been 
suggested that it plays a regulatory role in the SPT 
dimer.'2 ' Both of these subunits are essential to 
produce the functionally active, heterodimeric SPT; 
however, both are membrane-associated and this 
has made their isolation and characterisation parti-
cularly challenging. Nevertheless, small amounts of 
active SPT have been isolated from yeast and 
mammalian cells. ° Curiously, a small protein, 
of unknown activity (Tsc3p) has been shown to be 
required for optimal SPT activity in S. cercvisiac; 
however, a homologous protein has yet to be 
identified in other species.31  
Despite the apparent non-catalytic role of SPT1 
within the mammalian heterodirner, it has been 
shown that single amino acid mutations within a 
highly conserved region of this subunit down-
regulate SPT activity leading to the condition 
known as hereditary sensory and autonomic rieuro-
pathy type I (HSANI).32'33 Analysis of HSAN1 
patients has revealed two mutational hotspots in 
SPT1 at Cys133 (C133W or C133Y) and Val144 
(V144D). Corresponding mutations in the SPT1 
subunit of S. CereviSint' cause reduced SPT activity, 
though they do not affect the ability of the SPT1 
mutant to dimerise with SPT2. _26 
Topological studies of the eukaryotic SPT1 sub-
unit from Chinese hamster ovary (CHO) cells 
identified a single non-essential, membrane-span-
ning, N-terminal domain. In comparison, SPT1 from 
S. cerevisine has two additional membrane-spanning 
domains near to the predicted PLP-binding region 
of the protein which, when deleted, affected 
membrane binding and SPT activity.-" - In order 
to overcome the solubility problems encountered 
with membrane-associated SPTs, Ikushiro et al. 
isolated a water soluble, homodimeric form of the 
enzyme from the Gram-negative, aerobic bacteria 
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Figure 2. Proposed reaction mechanism of SPT. (a) Transaldimination of internal aldimine (holo-SPT), I with L-serine 
to form external aldimine, II; (b) deprotonation of C by base to form quinonoid, III; (c) Claisen condensation to form 
putative -ketoacid-aldimine complex, IV; (d) decarboxylation to form product quinonoid, V; (e) reprotonation of 
quinonoid to form product external aldimine, VI (f) release of product 3-ketodihydrosphingosine (KIDS) and regeneration 
of I. 
Sphingoinonas pauciniobilis EY2395. 	This organ- 
ism possesses an unusual feature, its outer mem-
brane is composed solely of glycosphingolipids 
(GSLs) whereas most other Gram-negative bacteria 
have lipopolysaccharides (LPS, also known as 
endotoxins) in their outer leaflets. Currently, there 
is no high-resolution structural information available 
for a SF!' from any organism. Here, we present the 
crystal structure the holo-form of S. pauciinobilis SPT. 
The holo-SPT structure reported here is the first 
high-resolution structure of an enzyme from the 
sphingolipid biosynthetic pathway. 
Results and Discussion 
Purification and characterisation 
S. paucimobilis SPT was expressed in Escijerichia calF 
from plasmid pET-28a as a six-histidine, C-terminal 
fusion (a corresponding N-terminal, six-histidine 
fusion was unsuitable for structural studies; data not 
shown). A rapid, two-step purification procedure 
using immobilised nickel affinity and size-exclusion 
chromatography was carried out. This enabled the 
isolation of milligram amounts of both the apo and  
holo-forms of the enzyme. Increased amounts of the 
holo-form were obtained by incubation of the 
predominantly apo-form with excess PLP. The 
purified holo-enzyme was dimeric in solution 
(based on size-exclusion chromatography and 
native gel electrophoresis; data not shown) and its 
UV-visible spectrum showed characteristic peaks at 
336 rim and 425 nm which correspond to the 
enolimine and ketoenamine forms of the PLP-
bound enzyme, respectively (Figure 3(a))!' The 
recombinant holo-SPT was active in the conversion 
of scrine and palmitoyl-00A to form KIDS (Figure 
3(b)) and displayed similar catalytic properties to 
those reported previously (data not shown). 36 
Electrospray ionisation mass spectrometry (ESI-
MS) analysis gave a molecular mass consistent 
with the predicted mass of recombinant S. paucinlo-
bilis SF1' from the gene sequence. This takes into 
account loss of the N-terminal methionine residue 
and the addition of the C-terminal histidine affinity 
tag. 
Structures of S. paucimobilis SPT 
Our discussion focuses on the higher-resolution 
holo-enzyme structure. The first 20 N-terminal 
amino acids and the last nine C-terminal residues, 
0' 
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Figure 3. (a) UV-visible spec-
trum of SPT used in this study. 
Purified SPY (20 iM) shows the 
characteristic peaks for the PLP-
bound (holo-) internal aldimine 
form of the enzyme with absor-
bance maxima at 336 nm and 
425 nm. (b) Autoradiograph show-
ing SPT is active in the conversion 
of L-serine and palmitoyl-CoA to 3-
ketodihydrosphingosine (KDS). 
Recombinant holo-SPT was incu-
bated with (U-14C)- labelled L-
serine and palmitoyl-00A for 
20 inin at 37 °C and the assay was 
extracted with an equal volume of 
chloroform/ methanol (2:1, v/v). 
The aqueous (1) and organic (2) 
phases were analysed by TLC and 
compared with authentic stan-
dards. The arrow marks the posi-
tion of the product KIDS. 
including the histidine tag, are not visible and 
therefore our final model contains 391 of the 427 
amino acids from Arg22 to 11e419 inclusive. The 
1.3 A map is of a high quality and the cofactor is 
clearly defined (Supplementary Data). The mono-
mer of the holo-SPT form consists of three domains 
(N-terminal, central catalytic and C-terminal) and is 
shown in Figure 4. The overall topology of SPT 
Figure 4. Overall structure of the holo SPT homodimer. One monomer is coloured with the N-terminal domain shown 
in red, the central catalytic domain in green, and the C-terminal domain in yellow. The second subunit is shown in blue 
and the N and C terminii are labelled. The PLP in each monomer is shown as a purple space-fill and magnesium ions are 
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closely resembles that observed for structures of the 
other members of the -oxoarnine synthase (AOS) 
family; ALAS (PDB code 2BWN), KBL (PDB code 
1FC4) and AONS (PDB code 1DJE) (Figure 5). The 
C RMSD values for SPT relative to these structures 
are 1.5 A over 372 residues with ALAS, 1.4 A over 
364 residues with KBL and 1.6 A over 357 residues 
with AONS. All of the structures have the same 
relative orientation of domains, the most obvious 
differences are in the orientation of the NJ-terminal 
helix and the position of loops connecting secondary 
structural elements remote from the active site. The 
N-terminal domain of 80 residues comprises an 
a-helix followed by a three-stranded, antiparallel 
(s-sheet. This is linked to a larger central catalytic 
domain composed of a seven-stranded, mainly 
parallel, -sheet domain of -200 residues where the 
active site lysine (Lys265) resides. The C-terminal 
domain comprises -100 amino acid residues which 
make many interactions with residues of the N-
terminal domain. 
In common with the other members of the PLP-
dependent superfamily, bacterial SPT is an intimate, 
interlocked, dimer (Figure 4). In the holo-SPT 
structure the dimer is produced by applying -X,Y,-
Z+1/2 crystallographic symmetry of the C2221  
space group to the monomer in the asymmetric 
unit. The buried interface area (composed of 
residues from the central domain of one monomer 
and the N-terminal domain of the other) is 3880 A 
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Figure 5. Structural alignment of the members of the AOS family. (a) Overlay of key conserved residues involved in 
cofactor binding: His234, His159, A1a160, Ser161, and Lys265 (SPT numbering). The SPT (2JG2) structure is shown in 
green, the AONS (IDJE) is shown in orange, the ALAS (2BWN) structure is shown in purple, and the KBL (1 FC4) structure 
is shown in blue. (b) An overall alignment of the monomers (same colouring scheme as in (a)). (c) The structure-based 
sequence alignment of these four enzymes. The conserved (His, Ala, Ser) motif is shown in pink, the conserved residue 
Asp231 which interacts with NI of PLP in turquoise, the conserved His involved in PLP binding is highlighted in green, 
and the conserved active site Lys residue is shown in red. 
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per monomer, which is approximately 22% of the 
monomer surface area. 
The active site 
In the holo-SPT structure the PLP cofactor is 
bound to Lys265 as an internal aldimine (Schiff 
base). Although all PLP-dependent enzymes require 
formation of an imine via a conserved lysine, the PLP 
binding sites are varied with respect to the 
surrounding protein environment. ' In SF1, the 
PLP makes polar contacts with the side-chains of 
Asn138, Asp231, His234 and Thr262 and with the 
main-chain of Gly134 and Tyr135 (Figure 6). We also 
observe His159 stacking above one face of the 
pyridinium ring of PLP (Figure 7). This residue is 
located at the beginning of a three-residue motif 
(His159, AlaI60, Serl6l) that is strictly conserved 
throughout the AOS family (Figure 5(c)). The 
cofactor binding site is composed of residues from 
both monomers. Importantly, the side-chain of 
AsnIOO from monomer B is in close proximity to 
the backbone of Lys265 from monomer A (Figure 7). 
This provides an example of the inherent dimeric 
nature of the functional enzyme and also gives 
insight into how mutations in the human "non-
catalytic" SF11 subunit may influence the activity of 
the heterodimer. 
Other residues which interact with the cofactor 
are clearly observed; the pyridinium nitrogen atom  
(NI) and the oxygen atom of Asp231 are 2.8 A apart, 
suggesting that this carboxylic acid group may 
stabilise a protonated pyridinium form of the PLP 
by salt bridge formation .39 This acidic residue is 
conserved throughout the family (Figure 5(c)) and a 
similar salt bridge has been observed between the 
Ni of PLP and the Asp204 residue of E. coli AONS, 
the Asp214 of Rhodobacter capsulatus ALAS and the 
Asp2I0 of E. co/i KBL. 516 
Since we were unable to obtain a complex of SPT 
with palmitoyl-00A, we used the structure of the 
R. capsulatus ALAS/PLP-external aldimine/succi-
nyl-00A complex to predict potential binding sites 
(PDB code 2BWO).15 In the ALAS structure the 
density corresponding to the adenine part of the 
succinyl-CoA is well defined, and the base is hound 
within a hydrophobic pocket formed by a group of 
isoleucine residues on the surface of the enzyme. 
The adenine also makes a number of H-bond 
contacts with serine side-chains and the 3'-phos-
phoribose moiety interacts with a lysine residue. 
Density for the phosphopantethene arm of CoA was 
not observed in the ALAS structure but the 
carboxylate of the succinate makes contact with 
Arg2l. A similar salt-bridge interaction was pre-
viously observed in the AONS/AON external 
aldimine structure where the AON carboxylate 
interacts directl,y with the Arg2I residue of the 
product AON.' - We used this information to super-
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Figure 7. Stereo view showing the proximity of the AsnIDO residue of monomer B to the PLP cofactor of monomer A 
in the S. paucimobilis SPT homodimer. Monomer A is drawn in green and monomer B is drawn in blue. AsnlOO of 
monomer B is shown in CPK. Using the sequence alignment in Figure Y, the S. paucinobilis SPT AsnlOO residue maps to 
residue Cys133 on the SPT1 subunit of human Sf9'. Mutations at this residue C133W and C133Y are known to cause the 
autosomal disease hereditary sensory and autonomic neuropathy type I (HSANI). The conserved residues His159 and 
His234 which interact directly with the PLP cofactor are also highlighted. 
structure in an attempt to define a palmitoyl-00A 
binding site. Two long hydrophobic channels where 
the C16 palmitic acid chain could reside are 
illustrated in Figure 8. Since palmitoyl-CoA lacks a 
terminal carboxylate, SPT is devoid of a salt-bridge 
anchor, which would delineate the end of either 
channel. 
The cofactor binding site 
The high resolution of the holo-SPT structure has 
provided an insight into the relative juxtaposition of 
the planar PLP ring with the imine bond which links it 
to Lys265 (see Supplementary Data). PLP-dependent 
enzymes ca ta lyse a variety of reactions and the stereo-
electronic control of the reactivity of the cofactor was 
proposed by Dunathan. te This "Dunathan hypoth-
esis" requires the imine and PLP ring to be co-planar 
and suggests that rotation about the ct-carbon to 
nitrogen bond in the external aldimine form of the 
enzyme controls which bond is activated towards 
cleavage. The bond to be broken is therefore placed 
perpendicular to the PLP ring. In the SPT mechanism, 
this would be the C°-H of the serine-PLP external 
aldimine (intermediate II; Figure 2). The nature of the 
protonation state of the imine nitrogen (NZ) and PLP 
oxygen are also thought to influence the rate of 
catalysis.S 3S In the crystal structure of holo-SPT 
reported here, we note that the PLP ring is not co-
planar with the imine (offset by 47°, around C3-C4-
C4'-NZ), suggesting that the oxygen of the PLP is 
protonated (intermediate I; Figure 2). Further evi-
dence for this comes from the observation of 
additional density at this oxygen. We attribute this 
to a water molecule H-bonded to the 0-H. This water 
molecule is surrounded by a network of others and 
may he displaced upon binding of serine and 
formation of the external aldimine. This phenomenon 
was also observed in the structure of the alanine 
racemase from Mycobacterium tuberculosis .41 It is  
known that large conformational changes occur 
during the catalytic cycle of the enzymes from the 
AOS family thus enabling them to control the bond 
breaking and forming steps. 11,12,15 
Structural impact of human HSANI mutations 
A number of human diseases have been discov-
ered that are caused by defects in sphingolipid 
catabolism. The hereditary sensory and autonomic 
neuropathies (HSAN) are a clinically and genetically 
heterogeneous group of disorders, which are cur-
rently classified into five types. '2 HSAN type I 
(HSAN1) is an autosomal dominant (AD) neuro-
pathy characterised by marked sensory impairment 
and degeneration of peripheral nerves. The HSANI 
locus was mapped using genetic linkage analysis to 
human chromosome 9 (9q22.1-.q22.3), specifically to 
missense mutations in the lcbl gene of SPT.3 Analysis 
of a number of HSANI patients has revealed several 
mutations of the SPT1 subunit: C133W, C133Y, 
V144D and G387A. These mutations confer dominant 
negative effects on SPT activity, resulting in down- 
43,11 regulation of sphingolipid synthesis. 
A recent study used a transgenic mouse model 
containing the SPT1 C133W mutation to investigate 
its impact on SPT activity and resulting molecular 
pathophysiology. Mice expressing the 033W muta-
tion had impaired activity confirming that this 
mutation dominantly inhibits the SPT enzyme in 
vivo. These mice developed mild sensory and motor 
deficiency by ten months of age and also displayed 
myelin thinning and morphological changes of the 
root ganglia. Surprisingly, the authors noted that 
although the composition of the ceramide pool was 
altered, the total ceramide levels in these mice were 
unaffected. This suggests a compensatory mechan-
ism may be present which regulates cellular cer-
amide production. The role played by these SPT1 
mutations in HSANI remain unclear; however, they 







Figure 8. Analysis of coenzyme A thioester binding. (a) In yellow a space-fill of the structure of the S. paucimobilis SPT 
structure aligned to the ALAS structure (PDB code 2BWO; RMSD 2.2 A), and with the ALAS succinyl-CoA substrate 
shown in ball and stick. Above the SPT structure the true substrate palmitoyl-CoA is shown, with the fatty acid thioester 
bond of CoA highlighted. The two putative channels where the additional carbons of the SPT substrate palmitoyl-CoA 
may bind are labelled I and 2. (b) The ALAS structure and the location of succinyl-CoA binding site (succinyl-CoA is also 
shown above the structure, allowing the relative lengths of the two CoA substrates to be appreciated). The positions of the 
channels, which are absent in ALAS are highlighted with crosses. (c) A stereo view of the alignment of the ALAS and SPT 
structures as wireframes, displaying how channel 2 is foreshortened in the ALAS structure, by a rearrangement of the first 
helix (circled), possibly leading to specificity for the shorter succinyl-CoA substrate. 
may lead to toxic accumulation of misfolded 
proteins which is a mechanism commonly associated 
with neurodegenerative diseases. 
To examine the possible structural impacts of 
human SPT1 mutations we have used our S. 
paucirnobilis SPT structure to model the human 
SPTI /SPT2 dimer. BLAST alignment 45 of S. pauci-
mobilis SPT to human SPT1 and SF12 finds pairwise 
percentage identities of 28% and 32%, respectively. 
The alignment of SPT1 and S. paucimobilis SPT maps 
SF11 residues Cys133, Val144, and Gly387 to S. 
paucimobilis SPT residues AsnlOO, Aspill and 
Thr342, respectively (Figure 9). Mapping of the 
SPT active site residues to SPT1 and SF12 is shown 
in Table I. It is notable that many of the SPT1 active 
site residues are markedly different to the bacterial  
and SPT2 residues, indicating substantial degrada-
tion of the ancestral active site formed within the 
SF11 subunit. Homology models for the human 
SPT1 /SPT2 heterodimer "wild-type" (WT) and 
incorporating the mutated S11T1 residues Cl 33W, 
V144D and G387A were built using the structure of 
the S. pauciniobilis holo-SPT as a template. The WT 
model is generally similar to the bacterial holoen-
zyme structure; STAMF16 alignment of the bacterial 
monomer to SPT1 of the WT model finds a mean C' 
RMSD of 0.52 A over 352 residues. 
Figure 10 shows modelled snapshots of the 
molecular mechanisms by which the mutations 
C133W and V144D may affect the SPTI/SPT2 
structure and provide insights into how mutations 
in the "inactive" SPT1 subunit have a dominant 
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Figure 9. Alignment of S. paucitnobilis SPT (Pubmed accession number: AB055142) to human SPTI and SP1'2 (UniProt 
Primary accession numbers: 015269, LCBI_Human and 015270, 1,CB2 Human, respectively). Residues are coloured to 
indicate conservation, numbering refers to the S. paucimol7ilis SPT sequence; + symbols denote important active site 
residues identified by examination of the SPT structure (also see Table 1). The secondary structure elements were 
identified with STRIDE using the bacterial SF1' structure. In general, SF1' can be aligned relatively well to the human 
sequences. However, a region at the N terminus is more difficult to align, including the putative transmembrane sections 
of SPTT1 and SPT2 (residues 16-36 and 67-87, respectively), as well as the first x-helix and the first two 13-strands in the 
bacterial structure; this difficult alignment region is shown in smaller, italicised font. Regions considered to he relatively - 
' well-aligned are boxed. This Figure was produced using Aiscript: 
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Table 1. Active site residues identified by Ligplot and 
analyses in Chimera of the S. paucimobilis holo-SPT (SPT) 
structure as well as the homology model for the wild-type 
human SFI'l /SPT2 heterodimer 
SPT 	SPTI 	SVI'2 	Suggested function 
Y73 F106 Y176 (496) 1 lydrophohic interactions 
with Lys265 
G134 G167 G238 (558) Interacts with phosphate of PLP 
Y135 P168 1,7239 (559) Interacts with phosphate of PL,P 
H159 C192 H263 (583) Stacks above pyridinium ring 
of P1,1' 
S161 A194 S265(585) Part of strictly conserved 
HAS motif 
D231 E274 1)344 (664) Makes polar contacts to Ni of 
pyridinium ring 
A233 S276 A346 (666) Hydrophobic interactions with 
PLP 
H234 L277 11347 (667) Hydrogen bond to oxygen of 
pyridinium ring 
1262 N306 1376 (696) Interacts with phosphate of PLP 
S264 E308 1378 (698) Unknown 
K265 N309 K379 (699) Forms an internal aldirnine with 
1'I.l' 
S266 A310 S380 (700) Unknown 
V267 L311 P381 (701) Unknown 
G268 A312 G382 (702) Hydrogen bond to backbone 
oxygen of Lys265 
1294 S338(296) A408 Interacts with phosphate of PLP 
A295 A339 (297) A409 interacts with phosphate of PLP 
Numbers given in parentheses refer to the numbering in the 
homology model and also serve to distinguish residues that are 
thought to participate in the active site. 
effect on the "active" SPT2 subunit, and on SPT 
activity as a whole. Residue AsnlOO in the bacterial 
sequence maps to human SPT1 Cys133, and is 
located in the S. paucimobilis holo-SPT structure at 
the dimer interface and more importantly close to 
the active site (Figure 7). The amino group of the 
side-chain of AsnlOO from monomer B is within 
hydrogen bonding distance of the backbone oxygen 
from the active site residue (Lys265) of monomer A. 
Thus, substitution by Trp or Tyr would he expected 
to affect the enzyme activity. The homology model 
for the HSANI C133W mutant shows a steric clash 
between Trp133 and the backbone carbonyl oxygen 
of the active site lysine residue which anchors the 
PLP cofactor (Figure 10(b)), suggesting that this 
mutation exerts direct perturbations to the geometry 
of the active site and consequently affects the 
enzyme activity. Indeed, in the WT model Cys133 
does not contact the cofactor (Figure 10(a)). Addi-
tionally, the mutant model suggests that Trp133 
contacts SPT2 active site residue Thr378, as well as 
being likely to affect SPT2 active site residue Tyr176 
via contact with residue Asn177. 
The WT model reveals V144 in a-helix3 (H3), 
packing with several hydrophobic residues in a-
helix9 (H9) (Figure 10(c)). We postulate that V144 
could be important in stabilising the packing of 
these two helices. Indeed, the models predict the N-
terminal half of H9 to be composed of hydrophobic 
residues; interpretation of the V144D mutant model 
suggest that alterations to the H3-H9 packing may  
cause shifts in the neighbouring structure (Figure 
10(d)). The opposite face of H9 is seen to contact the 
C-terminal portion of a-helix 2 (H2), which is 
predicted to he adjacent in space to the region of 
the active site containing SPT2 residues Ser380 and 
G1y382. Furthermore, the loop between H2 and H3 
(SPT1 residues 129-149) appears close to the 
cofactor and is the location of the pathogenic 
Cys133 mutations. Therefore movement of the C 
terminus of H2 is likely to disturb the H2—H3 loop 
and he communicated to the active site. Thus, the 
V144D mutation may conceivably disturb the active 
site geometry by inducing rearrangements of H9, 
H3, H2, and the H2-H3 loop. Indeed, in the V144D 
mutant model the active site geometry is altered, 
and we suggest that the cofactor encounters steric 
clashes, causing disruption of hydrogen bonding 
when compared to the WT model. Therefore, 
analysis of the models suggests that the HSANI 
V144D mutation, despite being remote from the 
cofactor, can still influence the active site geometry 
and lead to a reduction in enzyme activity. 
Conclusion 
The high-resolution structure presented here is not 
only the first structure of a SPT, but is also the first 
crystal structure reported for any enzyme involved 
in sphingolipid biosynthesis. SPT catalyses the first 
and rate-limiting step of this pathway and our work 
now allows an in-depth analysis of the structure and 
mechanism of this important enzyme. Mutations of 
human SPT have been shown to directly affect 
enzyme activity and cause a range of neuropatholo-
gical defects leading to the condition known as 
hereditary sensory and autonomic neuropathy 
(HSAN). The homodirneric, bacterial enzyme 
shows sufficient sequence conservation with the 
human SPT1 /SPT2 heterodimer to allow generation 
of models and our study provides some insight into 
the molecular mechanisms of the human disease 
HSANII. 
Materials and Methods 
Plasmids and competent E. coil cells were purchased 
from Novagen, all chromatography columns were from 
GE Healthcare, restriction endonucleases and DNA 
ligase were purchased from New England Biolabs. All 
buffers and reagents were from Sigma unless stated 
otherwise. Palmitoyl-CoA was from Roche, [U-14C]serine 
(specific activity 1.85 MBq/ml) was from GE Healthcare. 
The S. paucimobilis strain 13.361 was from the National 
Collection of Industrial and Marine Bacteria (NCIMB), 
Aberdeen, and is also known as strain DSMI098 (NCTC 
11030). 
Cloning and expression of S. paucimobilis SPT in 
E. coli 
The full length spt gene was amplified by PCR from S. 
paucimobilis strain 13361 using chromosomal DNA as a 
template and PCR forward and reverse primers based on 
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the spt sequence deposited by Ikushiro et al. in the NCBI 
database with the accession number AB0551 42. ' Primers 
were designed to incorporate BspHl and Xhol restriction 
enzyme sites at the 5' and 3' end of the gene, respectively 
(SPT BspHl forward: 5' GGACACCGTCATGACC-
GAAGCC 3', SPT Xhol reverse: 5' GATCCTCGAGGCC-
GATGACGCCGACCGCGCGGCCC 3'). The BspHl site 
spanned the start codon and the Xhol site removed the 
stop codon and allowed the gene to he cloned as a C-
terminal six-histidine tagged fusion. The PCR product of 
1263 hp was cloned into pCR2.1 (Invitrogen) and positive 
clones were isolated and sequenced to confirm the identity 
of the spt gene and the incorporation of the restriction 
enzyme sites. A positive pCR2.1 /SPT clone was digested 
with BspHl and Xhol and the isolated spt gene ligated into 
pET-28a cut with the restriction enzymes Ncol and Xhol. 
Positive clones were isolated and identified by restriction 
enzyme analysis, sequenced to confirm the fidelity of the 
clone and consequently named pET-28a SPT. The sequence 
of the SPT used in our study from S. paucimobilis strain 
13361 is 100% identical to that isolated from S. paucimobilis 
strain EY2395.' 
Plasmid pET-28a SPT was used to transform E. co/i HMS 
174 (DE3) competent cells and selection was carried out on 
LB agar containing 30 pg/nil of kanamycin. A single 
colony was used to innoculate 500 ml of 2YT broth (16 g/l 
Bacto-tryptone, 10 g/l Bacto-yeast extract, 5 g/l sodium 
chloride (pH 7.5)) which was shaken at 250 rpm overnight 
at 37 °C. The overnight culture was added to 4 1 of 2YT 
broth supplemented with kanamycin and grown at 37 °C 
to an A600  of 0.6. Protein expression was induced by the 
addition of IPTG to give a final concentration of 0.1 mM 
and growth was continued for 6 h at 30 °C. The cells were 
harvested (Sorvall RC5-13 centrifuge) by centrifugation at 
3500 rpm for 20 min at 4 °C. 
Purification of pET-28a SPT 
All purification steps were carried out at 4 °C. The cell 
pellet (-10 g) was resuspended in Ni-NTA binding buffer 
4:1 (r/w) (20 mM potassium phosphate (pH 7.5), 25 1&M 
PLP, 150 mM NaCl, 10 mM imidazole and one EDTA-free 
protease tablet (Roche)) before being disrupted by sonica-
tion (Soniprep 150) for 15 cycles (30 s on, 30 s of f on ice. 
The cell debris was harvested by centrifugation at 
16,000 rpm for 30 mm. The cell-free extract was filtered 
(0.45 mtm syringe filter) before being loaded onto a 5 mL 
HisTrapTM column at 0.5 ml/min. The column was 
washed with binding buffer until all unbound proteins 
had been eluted and then a linear gradient of 10 mM-
500 mM imidazole gradient was applied over 20 column 
volumes (100 ml). Fractions containing the SF1' protein 
were analysed by SDS—PAGE before being combined for 
dialysis against three changes of buffer (20 mM potassium 
phosphate (pH 7.5), 150 mM NaCl, 25 1,tM PLP, 2 mM 
EDTA). This sample was then loaded onto a previously 
calibrated HiPrepTh1 26/60 SephacryP"° S-200 size exclu-
sion column. Recombinant SF1' was eluted at a flow rate of 
I ml/min in buffer (10 mM Tris (pH 7.5), 150 mM NaCl, 
25 gM PLP, 1 mM EDTA). The presence of a SF1' dimer 
was calculated using the calibration curve of known 
molecular mass standards (GE Healthcare). 
The purity of the SPT from the size exclusion column 
was analysed by SDS—PAGE and the protein concentration 
was measured using the BCATM  protein assay kit (Pierce) 
giving a yield of -10 mg protein per litre of initial F. co/i 
cell culture. The enzyme was dialysed against 10 mM Tris 
(pH 7.5), 150 mM NaCl, 25 LM PLP at 4 °C in preparation  
for crystallisation. Initially, excess PLP was removed using 
a PD1O column (GE Healthcare) before being concen-
trated, routinely to 20 mg/ml, using a VivaSpin 10 kDa 
cut-off concentration filter. 
Structural biology 
The protein was screened for suitable crystallisation 
conditions using the high-throughput facilities at the 
Scottish Structural Proteomics Facility (SSPF). The crystal-
lisation conditions were screened using a nano-drop 
crystallisation robot (Cartesian Honeybee, Genomic Solu-
tions) as part of the Hamilton-Thermo Rhombix system. 
Over 700 conditions were tested from commercially 
available sparse-matrix screens, using sitting-drop 
vapour-diffusion with a well volume of 100 jil in 96 well 
plates (Griener; 3-square) at 20 "C. Drop sizes of 0.2 pA 
(containing 0.1 pl of protein and 0.1 p1 well solution) and 
0.3 pA (containing 0.2 uI of protein and 0.1 pA well solution) 
were used. Several conditions produced initial crystals 
and these were optimised using the Rhombix system. 
Small (<0.05 mm x 0.05 x  0.2 mm) colourless cubic crystals 
were produced by adding 0.1 p1 of 24 mg/ml SF1' in 
10 mM Iris (pH 7.5), 150 mM NaCl, 25 pM PLP, 5 p1 of 
myriocin, to 0.1 iii of 10% PEG 8000, 0.17 M MgCl2, 0.1 M 
Tris (pH 6.5) well solution. These crystals were mounted in 
cryo-loops (Hampton Research) and then cryo-protected 
by passing the crystals through a mixture of 20% (v/v) 
glycerol and well solution. Crystals were then frozen by 
rapid immersion in liquid nitrogen, and transferred to 
sample changer baskets (Molecular Dimensions). Multiple 
crystals were screened at Beam Line BMI4, Grenoble, 
ESRF using the sample changer, and a low-resolution 
dataset (3.0 A) was collected from the "best" (highest 
diffraction resolution) single crystal at 100 K. 
Data were indexed and scaled with DENZO and 
SCALEPACK as implemented in the CCP4 suite 47 
(statistics are shown in Table 2). Analysis of the solvent 
content suggested that there were two molecules in the 
asymmetric unit (509% solvent; Matthew's coefficient48  2.5). 
Initial phases were determined using molecular replace-
ment, with a homology model generated from the KBL 
(PDB code IFC4) monomer structure and confirmed a 
dimer. The molecular replacement model was built using 
the CASPR server .411  Initial analysis of the density showed 
that this crystal did not have PLP bound in either subunit; 
in one subunit a water molecule was observed in the active 
site. This indicated we had crystallized the apo-form of the 
enzyme from the solution (or at least predominantly apo-
form), despite the presence of PLP in the crystallisation 
solution. There was also no observable density for 
myriocin. 
The initial hits were further optimized using screens 
generated using the Crystools server." The protein was 
dialysed in the presence of excess PLP to ensure complete 
reloading prior to crytallisation. Contrary to preparation of 
the apo-SPT, excess PLP was not removed by size exclusion 
using a PDIO column. Crystallisation trials were set up in 
sitting drop plates (EasyXtal DG-CrystalSupport; Qiagen). 
A large yellow crystal ('-0.8 nun x0.2x0.2 mm) grew in a 
2 0 drop, consisting of 1 pA 20 mg/ml SF1' in 10 mM Tris 
(pH 7.5),150 mM NaCl and 25 pM PLP and I pl of the well 
solution (0.I1M MgC1.,, 21% (w/v) PEG3350, 0.I0M Hepes 
(pH 6.5)). The crystal was mounted in a cryo-loop and 
cryo-protected in a solution containing 22% PEG 3350, 
100 mM Hepes (pH 6.5), 120 mM MgCl2, 209% PEG 400. 
The crystal was then frozen and shipped to the ESRF 
where a 1.3 Adataset was collected at BMI4 at 100 K. Data 
were processed with MOSFLM and SCALA and are 
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shown in Table 2. Analysis of the solvent content 
suggested that there was one molecule in the asymmetric 
unit (33% solvent; Matthew's coefficient, 1.9 Da A). 
Phases were calculated with Phaser, 2 using the 
partially refined apo structure as a starting model. 
Automated model building in ArpWarp'3 successfully 
built 391 residues out of 427, and produced an initial 
model with an R-factor of 19.5% and a Rt r of 23.2%. 
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Figure 10. Homology modelling insights into the molecular pathogenesis of human SPTI C133W and V144D 
mutations found in HSANI. In all panels the PLP cofactor is shown in orange, a-helix 2 (H2) in purple, a-helix 3 (H3) in 
cyan, and the H2—H3 loop in magenta. Unless otherwise specified, residue numberings refer to SPTI. All panels are 
rendered in stereo view. (a) The wild-type (WI) model with C133 (red) close to, but not contacting the cofactor. ,The 57 
atom of the C133 side-chain is closest to the phosphate oxygen of the PLP cofactor (van der Waals distance of 0.73 A to the 
PLP 02P). (b) The C133W mutant model, the W133 (red) C6 and N atoms clash with the backbone carbonyl oxygen of 
Lys265 which binds the PLP cofactor. The W133 C5 has 0.65 A van der Waals overlap with the Lys265 carbonyl oxygen. (c) 
The WT model, with Val144 (red) packing with lle350, Ala346 and A1a347 (all shown in yellow). These residues form part 
of a-helix 9 (H9)1  shown in blue. The C3 atom of the V144 side-chain is the closest to the PLP cofactor (van der Waals 
distance of 13.6 A from the PLP 02P). (d) The V144D mutant model, the Asp144 mutation appears to destabilise the H3-
H9 packing and is likely to cause shifts in the neighbouring structure. We highlight Pro343 (blue) at the N terminus of H9, 
disturbance of this and other residues by perturbations of the H3—H9-H2 interactions is postulated to affect the H2—H3 
loop (magenta). For example, Va1130 (magenta) on the H2—H3 loop contacts SPT2 residues associated with the active site 
A1a383 and Gly382 (green); SPT2 Ser380 (green) is also likely disturbed by movements in these residues. Moreover, the 
H2—H3 loop is the site of the C133W mutation, thus perturbations in the H2-H3 structure are likely to disturb the active 
A site geometry. The CO atom of the D144 side-chain is closest to the PLP cofactor (van der Waals distance of 14.1 from the 
PLP 02P). This Figure was produced using Chimera,"' GIMP thttp://www.gimp.org/1  and Adobe Illustrator [http:// 
www.adohe.com/products/ illustrator!]. 
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Figure 10 (legend on previous page) 
Analysis of the density revealed that the PLP was 
covalently bound to Lys265, confirming we had obtained 
the holo-form of the protein. Both apo and holo models 
were refined using Refmac5 4 and manually adjusted by 
Coot.' The apo structure was refined using isotropic B 
factors, with tight non-crystallographic restraints applied 
between the two monomers for the whole of the 
refinement process. 
The process of completing the apo structure was 
greatly helped by using the 1.3 A holo-SPT structure as a 
guide. The holo structure was refined with anisotropic B 
factors, with TLS refinement used in the later rounds of 
the refinement process. Waters were added and checked 
using Coot. Structure quality was checked using tools 
within Molprohity. 	The final model statistics are 
shown in Table 2. In the holo-SPT structure the first 21 
residues and the C-terminal tag are disordered. Super-
positions were carried out using the SSM algorithm 
implemented in CCP4.47 The root-mean-square deviation 
(RMSD) between chain A of the apo and holo structures 
is 1.0 A over 355 C' atoms. The largest differences occur 
in a number of flexible loops, which are poorly ordered 
in the apo structure. There is no evidence of large 
domain movements between the apo and holo struc-
tures. There is a slight rigid body movement of the 
monomers with respect to each other in the apo 
compared to holo-SPT dimer. Whether this affect is 
caused by PLP binding or is a result of crystal packing is 
unclear. 
Spectroscopic measurements 
All UV-visible spectra were recorded on a single-beam 
Hewlett-Packard 8452A diode array spectrophotometer 
and analysed using UV-Visible ChemStation software 
(Agilent). To convert the apo-SPT to holo-SPT the 
enzyme was dialysed for I h at 4 °C against 20 mM 
potassium phosphate (pH 7.5) containing 150 mM NaCl, 
25 iM PLP and 2.0 mM EDTA. Excess PLP was removed 
by passing the protein through a PD-10 (Sephadex G-
25M) desalting column (GE Healthcare) before any 
spectrophotometric measurements were taken (Figure 
3(a)). The concentration of recombinant SVT was 20 iM 
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Table 2. X-ray crystallographic data 
Data details apo-SPT holo-SPT 
Integration software Denzo Mosflni 
Scaling software Scalepack Scala 
Space group C2221 C2221  
Unit cell parameters (A) a = 93.87, a = 74.2, 
b=i09.54, b=107.6, 
c=187 c=90.32 
Matthew's coefficient 2.6 1.9 
Solvent content (%) 53 35 
Monomers in 2 
asymmetric unit 
Wavelength (A) 0.976 0.9785 
Observations 152,432 692,849 
Resolution range (A) 50-3.0 30-1.3 
(3.11-3.0) (1.37-1.3) 
Number of reflections 19,635 (1927) 88,217 (12,783) 
Completeness (%) 99.5 (99.9) 99.7 (100.0) 
Mean 1/>(I) 21(5) 19.7 (2.9) 
0.08 (0.49) 0.07 (0.50) 
Redundancy 7.8 (8.2) 7.9 (5.2) 
Refinement statistics 
Resolution range (A) 20-3.0 18.8-1.3 
(3.07-3.00) (1.33-1.30) 
Number of reflections 18,544 (1325) 83,750 (6020) 
(working) 
Number of reflections (test) 996(-57) 4422 (355) 
Completeness (% total) 99.6 (99.42) 99.57 (98) 
Rwrki,g 	(%) 25 (31) 15 (27) 
(%) 28 (38) 18 (32) 
Mean B Factor (A) 85 13.65 
Stereochemical parameters 
Bond length 0.008 0.002 
(RMS observed) (A) 
Bond angle 1.3 1.2 
(RMS observed) (deg.) 
Protein residues 720 397 
Water molecules 39 415 
Magnesium molecules 0 1 
Total atoms 5563 3470 
Ramachandran plot Favoured/ 99.3/94/0.6 97.8/100/0 
allowed/outliers (%) 
PDB code 2jgt 2jg2 
Rmerge>ssi L fIhC, i(lhkl) I / 	ss, (1;,), where 1, i is the 
intensity of the ith measurement and (I,,,,) is the weighted mean of 
all measurements of I,. 
b 
Rss.,,r ,1. (and 	 F. f- F,. / Z F. 1, where F. 
and F, are the observed and calculated structure factors. 
and the spectrophotometer was blanked with 20 mM 
potassium phosphate (pH 7.5) containing 2.0 mM EDTA 
and 150 mM NaCI. 
Mass spectrometry 
Protein masses were determined by high-pressure 
liquid chromatography electrospray mass spectrometry 
(HPLC ESI-MS). These were carried out on a MicroMass 
Platform II quadrupole mass spectrometer equipped with 
an electrospray ion source. Protein samples were sepa-
rated with a Waters HPLC 2690 fitted with a Phenomenex 
C5 reverse phase column. Data were acquired and ana-
lysed using MassLynx software (V4.0). The experimentally 
determined mass of recombinant S. paucimobilis SPT 
(45,969.64 (±4.93) Da) is in good agreement with the 
expected mass of 46,104 Da for apo-SPT (428 amino acids, 
which includes the C-terminal LEHHHHHH fusion 
affinity tag). The mass obtained represents SPT having  
lost the N-terminal methionine residue (expected mass 
without N-terminal methionine is 45,973 Da). 
Assay of recombinant SPT activity 
The activity of the purified SF1' enzyme was based on a 
published radioactive assay which monitors the conden-
sation of 1.-[U-14C]serine and palmitoyl-00A to produce 
the 4C-labelled 3-ketodthydrosphingosine (KDS) pro-
duct. A typical assay was carried out on a 500 fLi scale 
and contained 20 jiM SPT in 50 mM Hepes (pH 7.5), 
150 mM KCI, 0.1 mM EDTA, 20 mM 1-[U-14C]serine (9250 
Bq/0.250 tCi; GE Healthcare) and 1.6 mM palmitoyl-CoA. 
The reaction was incubated at 37 'C for 20 min and 
terminated by the addition of 2.0 M NH40H to a final 
concentration of 0.4 M. The lipid portion was extracted 
with an equal volume of CHC13 /CH3OH (2:1, v/v). The 
sample was centrifuged and the aqueous layer was 
removed before the organic solvent was allowed to 
evaporate in air. The lipid residue was resuspended in 
15 .tl of CHCI3/CH3OH (2:1, v/v) and spotted onto a 
Silica Gel 60 TLC plate. The lipids were separated with 
CHCI3/CH30H/NftOH (40:10:1, by vol.) and the TLC 
was exposed to a Storage Phosphor Screen (GE Health-
care) for five days at room temperature. The screen was 
developed using a Storm Phosphor Imager (GE Health-
care) and the image visualised using lmagej software 
(Figure 3(b)). For comparison, a reference sample of 
3-ketodihydrosphingosine (KDS; Avanti Polar Lipids) 
was analysed on a Silica Gel 60 TLC plate as described 
above. The KDS was detected using a ninhydrin spray and 
its Rf value agrees with published values. 
Multiple sequence alignments for homology 
modelling 
Multiple sequence alignment (MSA) can be more 
accurate when more related sequences are aligned.' 
Additionally, an MSA of many related sequences is useful 
for identifying core, relatively reliable, alignment regions. 
Evaluation of the alignment quality is a key factor in 
assessing the reliability of analysis based on the associated 
homology models. The S. paucimobilis SPT sequence 
(Pubmed accession number A13055142) formed the basis 
to search for sequences to include in the first MSA. The 
BLASTP' top hit from a search of the COG" database 
identified C0G0156, thus the 78 sequences from this COG 
were included. Also included were 347 sequences found 
via PSIBLAST searching (five iterations, default settings) 
the SEG and Helixfilt (D. Jones, unpublished results) 
filtered UniRef100' database. Additionally the Ensembl51  
human SF11 (UniProt Primary accession number 015269; 
LCBI_Human) and human SPT2 (UniProt Primary acces-
sion number 015270; LCB2._Human) isoforms were 
included. Magicmatch52 was used to filter out identical 
sequences leaving a total of 411 sequences for the first of 
several rounds of MSA using Mafft6.234' with the "linsi" 
setting (iterative refinement for maximum accuracy). 
Jalview 4 was employed to examine this alignment 
annotated with the STRIDE" secondary structure assign-
ments and Chimera'" assigned inter-monomer contacts of 
the S. pauciinobilis SPT holo-enzyme homodimer, as well as 
the jnetl'7  predicted secondary structure for the human 
SPT1 and SF12 sequences. Visual inspection drawing on 
this information as well as the Swissprot' annotation for 
http: / /align.hmr.kvushu-uac.jp/ Mafft/software/ 
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human SPTII and SF12 then allowed the exclusion of 
divergent sequences for the next round of MSA using 
Mafft Two further rounds of MSA and visual inspection 
were conducted, leading to the exclusion of 23 sequences 
Then the PfamOO155 seed alignment (48 sequences)"" was 
aligned to this alignment using Mafft; this Pfam family 
provides substantial coverage of the sequences of interest 
(residues 98-464 and 168-528 of the human SF11 and SF12 
sequences, respectively). A further round of visual inspec-
tion excluded a further two sequences leaving a final set of 
434 sequences; this final alignment was then edited with 
consideration of the alignment of the S. paucinobilis SPT 
structure/sequence to the human SF11 and SF12 
sequences. Figure Q shows the final alignment of these 
three sequences, which was used as the starting point for 
homology modelling. Structural visualisation was per-
formed with both Chimera and RASMOL.'°  
Homology modelling 
Several rounds of homology modelling were performed 
using Modeller,'' with selective removal of restraints 
according to inspection of the Modeller probability 
densities (temperature factor estimates) and the MSA. 
The S. paucimobilis SF1 homodimer holo structure was 
used as a template for modelling the human S11T1 and 
SF12 sequences as a heterodimer with the cofactor 
included as a block residue. Modeller parameters for the 
final rounds of modelling were set to obtain high-quality 
models (model at level 3 and refine at level 5), with a 
total of 15 models attempted per Modeller run (three 
models, each with five loop models). The model with the 
lowest value of the Modeller objective function was 
selected and then side-chain rebuilding was performed 
using SCWRL.72 
Protein Data Bank accession number 
The coordinates can be downloaded from the RCSB 
PDB using accession codes 2JGT for apo-SPT and 2JG2 for 
holo-SPT. 
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